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ABSTRACT
Synthesis and Evaluation of Tetrahydroprotoberberines as
Dopamine Receptor Ligands
By
Satishkumar Gadhiya

Advisor: Dr. Wayne Harding

Dopamine (DA) receptors belong to the G-protein coupled receptors (GPCRs) family,
divided in to two groups based on their high homology transmembrane domains; D1-like DA
receptors (D1, D5) and D2-like DA receptors (D2-D4). DA receptor specific ligands have been
exploited as a means for studying the prognosis and curing several CNS disorders. Though several
efforts have been devoted to discover selective and potent DA receptor ligands, complete
selectivity within the DA receptor subtypes remains a challenge.
Tetrahydroprotoberberines (THPBs) are a group of naturally occurring tetracyclic
alkaloids that belong to the tetrahydroisoquinoline family. A wide range of biological activities
are associated with the THPB scaffold. Noted examples of THPB alkaloids, (-)-stepholidine 2.1
(SPD), (-)-tetrahydropalmatine 2.2 (THP), (-)-isocorypalmine 2.3 (ICP), and (-)-canadine 2.4, are
known to possess high affinity for DA receptors and have been studied widely for their utility in
various CNS disorders. (-)-Stepholidine is endowed with DA D1 agonist and D3 antagonist dual
pharmacological profile, which makes it a potential candidate for the treatment of schizophrenia
and psychostimulant drug abuse. Limitations on the unavailability of efficient synthetic methods,
scarcity of structure-activity relationship (SAR) data at DA receptors and metabolic instability
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need to be addressed to make (-)-SPD 2.1 an ideal drug candidate for schizophrenia and
psychostimulant drug addiction.
In our work we have addressed prominent issues and missing gaps towards the synthesis
and SAR studies of THPBs at dopamine D1, D2 and D3 receptors. A novel route to synthesize
(±)-SPD (2.1) was developed over eight synthetic steps with 30% overall yield via the
intermediacy of easily obtainable diester 3.7. In addition to the superior yield, this approach is
advantageous in terms of conciseness and ease of synthetic manipulations. This route was
deployed to produce C10 THPB analogues for SAR studies at DA receptors. Employing vital
intermediate lactone 2.102, the enantioselective synthesis of (-)-SPD (2.1) was accomplished in
23% overall yield from commercially available starting materials in a fourteen step sequence. The
crystal structure of (-)-SPD (2.1) was determined by single crystal X-ray diffraction. Synthesis of
lactone 2.102 was straightforward, scalable and high yielding. This synthetic pathway was applied
to generate C3 chiral THPB analogues of THPB for bioactivity studies.
In order to understand the structural tolerance of the THPB core required for selective
D1/D3 receptor binding, a thorough SAR study was designed. Consequently, a diverse library of
C3 and C10 THPB analogues was synthesized and evaluated for affinity at DA D1, D2 and D3
receptors. Results from the SAR studies demonstrate that the C10 THPB analogues exhibit a
general preference for the D1 receptor. Binding affinity evaluation at D3 receptor indicates that
larger alkoxy groups are not tolerated at C10 position. In general, small alkoxy substituents are
well tolerated at C10 position of THPB scaffold for D1 and D3 receptor affinity. Novel enantiopure
C3 analogues of THPB were designed and synthesized to assess the optimum size of the alkoxy
group at this position required for DA D1 and D3 receptor affinity. The results for binding affinity
data suggest that C3 alkoxy substitution, decreases D1 and D3 receptor affinity while improving
v

selectivity at D3 versus D2 receptor when compared with parent compound (-)-SPD (2.1). Reduced
affinity at D2 receptor for these analogues signifies the importance of the C3 alkoxy group to
suppress affinity at the D2 receptor. These compounds will further expand our understanding of
the tolerance of the THPB core required for DA D1 and D3 receptor activity.
In order to rationalize the affinity of ligands, molecular docking studies were conducted at the D3
receptor. The ligand binding energies from the D3 receptor docking studies show some similarities
and minor discrepancies compared to the experimentally derived affinities. These docking studies
have revealed key receptor–ligand interactions, including the critical protonated tertiary N—
Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic interactions to Phe106
and Phe345.
Novel series of conformationally flexible analogues of (-)-SPD (2.1) were synthesized and
evaluated in order to identify potent and selective DA D1 and D3 receptor ligands. Two groups of
analogues were synthesized and assayed for binding affinity at DA receptors, one group having
truncated THPB scaffold while the other featured a tetrahydroisoquinoline (THIQ)/arylamide
hybridized pharmacophore core. Results of this study indicate that de-rigidification of the THPB
scaffold nullifies the DA receptor activity and the intact THPB scaffold of (-)-SPD is necessary
for the DA receptor activity. On the other hand, THIQ/arylamide hybrid analogues have
demonstrated high potency and selectivity for D3 receptor.
Representative compounds were studied in order to test the metabolic stability of
synthesized THPB analogues. The results of this metabolic study indicate that having phenolic
hydroxyl group at C2 and/or C10 on THPB scaffold engenders susceptibility to hepatic
metabolism.
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Chapter 1: Dopamine receptor: subtypes, selective ligands and therapeutic
relevance
1.1

Introduction
Dopamine (DA) is a vital catecholamine neurotransmitter in the mammalian brain that

controls important functions including motor co-ordination, cognition, working memory, learning,
neuroendocrine regulation and positive reinforcement. Moreover, it contributes to the regulation
of several autonomic and peripheral functions including cardiovascular, renal and hormone
secretion. 1-4
Much research over the last 50 years has been directed towards understanding the role of
the dopaminergic system in several pathological conditions such as Parkinson’s disease,
schizophrenia, psychostimulant drug abuse, restless leg syndrome, attention deficit hyperactivity
disorder, hyperprolactinemia, and Tourrete’s syndrome.5-8
Efforts have been made to modulate the dopamine activity in these ailments through
different dopamine receptor agonist and antagonist agents, but adverse drug effects have stymied
positive clinical outcome due to lack of selectivity of the drugs. The etiology of neurological
disorders has not been clearly resolved, but the study of dopaminergic systems with various
dopamine receptor ligands has enabled a greater understanding of the dopaminergic system.9
A new momentum to the exploration in the DA field came from gene-cloning procedures
to receptor biology brought into play three decades ago, which discovered more complicated
structure of DA receptors than previously thought. 2, 10

1

1.2

Dopamine receptors
Dopamine receptors belong to the G-protein coupled receptors (GPCRs) family, which are

prime targets for >25% of marketed drugs.11 One prominent physiological response of dopamine
is to increase the synthesis of cAMP by activating the adenylyl cyclase enzyme. 12 Various
compounds have also been demonstrated to mimic this effect of dopamine to increase adenylyl
cyclase activity.13 On the other hand, there are physiological responses of dopamine not associated
with stimulation of adenylyl cyclase or elevation of intracellular cAMP. An example here is
dopamine induced inhibition of prolactin release from mammotrophs. The biochemical,
physiological and pharmacological evidence have shown the presence of dopamine receptors on
the mammotrophs and work as endogenous hypothalamic factor to inhibit prolactin release while
there is no evidence found that dopamine mediated inhibition of prolactin release is associated
with increased cAMP level.14 Amongst various other examples of studies where dopamine
receptors have shown discrepancy in physiological response, one includes a considerable range of
potency at DA receptors from micromolar to nanomolar in different tissues by dopamine itself. 15,
16

In 1978, Kebanian and Calne concluded this diversity into the classification of two different DA

receptor populations, one positively coupled to adenylyl cyclase is the D1 receptor and one
independent of this factor is D2 receptor.17
The original classification of DA receptors served as the base for the study of DA receptors
for a decade. However, molecular cloning and recombinant DNA techniques revealed the
existence of five DA receptor subtypes (D1-D5).18-20 Structural, pharmacological and biochemical
studies of the cloned receptors put them into two families based on their high homology in
transmembrane domains; D1-like DA receptors (D1, D5) and D2-like DA receptors (D2-D4).2, 3,
21-24

2

1.2.1

Structures of dopamine receptor subtypes
The structural analysis of the cloned DA receptors revealed that they are members of the

seven transmembrane (TM) domain G protein-coupled receptor families and share most of their
structural characteristics. In their TM segment, the D1 and D5 receptors share 78% homology,
while D3 receptor and D4 receptor have respectively 75% and 53% identity with the parent D2
receptor.21, 25
The NH2-terminal stretch has a similar number of amino acids in all the receptor subtypes
while having a variable number of N-glycosylation sites. The D1 and D5 receptors possess two
such sites, the D2 receptor has four, the D3 has three, and the D4 possesses only one Nglycosylation site.22, 23, 26 The COOH terminal is about seven times longer for the D1-like receptors
than for the D2-like receptors and is rich in serine, threonine, and cysteine residues. In the D1-like
receptors, this cysteine residue is located near the beginning of the COOH terminus, whereas in
the D2-like receptors it is located in end of the terminus. As in all G protein-coupled receptors,
DA receptors possess two cysteine residues in extracellular loops 2 and 3, which have been
suggested to form an intramolecular disulfide bridge to stabilize the receptor structure. 27, 28 The
D2-like receptors have a long third intracellular loop, which is common to receptors inhibiting
adenylyl cyclase, whereas the D1-like receptors have a short third loop. The D1 and D5 receptor
third intracellular loop and the COOH terminus are similar in size but divergent in their sequence.
The external loop between TM4 and TM5 is considerably different in the two receptor subtypes,
shorter (27 amino acids) in the D1 receptor than in the D5 receptor (41 amino acids). 22, 23, 26 Highly
conserved residues are present in the core of the protein and define a binding pocket that is most
likely the agonist binding site.29

3

The D2 receptor exists as two alternatively spliced isoforms D2S and D2L. 30, 31 In spite of several
efforts, no obvious differences have emerged so far between the two isoforms. Both variants share
the same distribution pattern, both isoforms inhibited adenylyl cyclase and revealed the same
pharmacological profile.30-32
Splice variants of the D3 receptor have also been identified wherein one transcript carries
a 113-bp deletion in TM3 and the second variant derives from a deletion of 54 bp between TM5
and TM6 of the D3 receptor.33, 34

1.2.2

Distribution of brain dopamine receptors
In situ hybridization techniques and immunohistochemical analysis have been employed

to study the distribution of DA receptor mRNAs in the brain. The dopaminergic neurons in
substantia nigra pars compacta, ventral tegmental area, and hypothalamus give rise to three major
dopaminergic pathways in the brain, the nigrostriatal, the mesolimbocortical, and the
tuberoinfundibular.
The DA D1 receptors are more widespread than any other receptors. Using in situ
hybridization and receptor autoradiography, expression and distribution of dopamine D1 receptor
in the brain was examined. The mRNA for D1 receptor is most abundant in cortical, limbic, and
hypothalamic brain regions as well as caudate, nucleus accumbens and olfactory tubercule .35

36

This indicates its important role in cognitive, affective and neuroendocrine functions of the brain.37
In contrast, no mRNA has been detected in the substantia nigra pars reticulata even though D1
receptor protein is highly expressed in this region, suggesting that D1 receptors in this area are on
terminals of the striatonigral pathway neurons.36, 38
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In contrast to DA D1 receptors, DA D5 receptors are poorly expressed in rat brain. mRNAs
of this receptor are expressed restrictively to the hippocampus, parafascicular nucleus of thalamus
and the lateral mamillary nucleus.39, 40 Further studies have discovered the distribution of DA D5
receptors in various forebrain regions including striatum, cerebral cortex, lateral thalamus, and
diagonal band area.41-43 Progress in finding the DA D1 and D5 receptor specific antibodies have
led to better insight about cellular and subcellular localization of these receptors. 44
In the neostriatum, both DA D1 and D5 receptor antibodies tagged the medium spiny
neurons, on the other hand D5 receptor antibodies labeled the large spiny neurons only. In the
caudate nucleus, D5 antibodies mostly labeled the shafts, and rarely, the spines of these cells,
whereas D1 receptor labeling was more intense in the spines and shafts of projection neurons.

44

Within the same pyramidal neuron cells, D1 receptors are located on dendritic spines and D5
receptors are on dendritic shafts.44, 45 The D1 receptors have been distributed into the pars reticulate
of the substantia nigra, but D5 receptors are not detected in this structure.

46

These dissimilarities

between D1 and D5 receptors at subcellular localization suggest that even though having
analogous pharmacology, functionally they are different.
In the rat brain, the highest concentration of D2 receptor mRNA was found in substantia
nigra, nucleus accumbens, olfactory tubercle, neostriatum and ventral tegmental area. 47 D2
receptor is also distributed in granule cells of hippocampal formation, in the septal region, in
cingulate, prefrontal, enthorinal and temporal cortex. 23 In ventral tegmental area, substantia nigra,
and hypothalamus regions, D2 receptor is expressed by dopaminergic neurons. 47, 48

Immunohistochemical analysis study has suggested that D2 receptors are more concentrated in
spine heads and dendrices than in somata in the spiny neurons of striatum. 46,
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49

The

immunoreactivity of D2 receptor with specific monoclonal antibodies is also found in the central
nucleus of amygdala and internal plexiform layers.49
In situ hybridization histochemistry revealed the localization of DA D3 mRNAs in the
islands of Calleja and in the nucleus accumbens, as well as low level of D3 mRNAs was spotted
in putamen and in anterior caudate.50 In the rat brain, D3 receptor mRNAs, mainly detected in the
islands of Calleja, hippocampus, nucleus accumbens, and stria terminalis. 48 The granule cells of
islands of Calleja are enriched with both D3 receptor binding RNAs and mRNAs, while in nucleus
accumbens, they are mainly expressed in neurons of the ventromedial shell subdivisions and rostral
pole.51
The D4 receptor mRNAs shows a limited expression in the central nervous system. The
hypothalamus, olfactory bulb, thalamus and frontal cortex are the main areas where mRNAs for
D4 receptors are significantly expressed.52 Subtype specific antibodies binding study for these
receptors revealed the presence of GABAergic interneuron modulator D4 receptors in cerebral
cortex and in hippocampus as well as in globus pallidus and reticular nucleus of thalamus. 53
The D5 receptor mRNA is most abundant in hippocampal subfields, in discrete cortical areas
(layers II, IV and VI), and in the dentate gyrus.54 in the rat brain, this receptor mRNAs are found
to localized in parafascicular nucleus of the thalamus and in hippocampus. 39

1.2.3

Functions of brain dopamine receptors
The importance of DA in the control of movements is well demonstrated in pathological

conditions such as Parkinson’s disease. The role of DA receptors in motor functions, such as
forward locomotion, grooming, catalepsy, rearing, and sniffing has been studied. 55 D1, D2 and D3
receptors in ventral striatum are primarily involved in forward locomotion. Decreased locomotor
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activity is associated with decreased DA release triggered by activation of D2 autoreceptors.23
Individual D1 receptor activation has barely or no effect on producing locomotor activity. 56
However, pharmacological studies have shown that the simultaneous stimulation of D1 receptor
is crucial to produce maximal locomotor effect by D2 agonists, which indicates forward
locomotion involves synergistic interaction between D1 and D2 receptors. 57, 58 Targeted gene
inactivation of D1 receptor in the mouse has confirmed these observations as well. 59
The D3 receptors present in nucleus accumbens have an inhibitory role on locomotor
activity. In fact, supported by physiological actions of selective agents, DA D3 agonists inhibit
while, DA D3 antagonists induce the locomotion.24, 60 The opposite roles of DA D2 and D3
receptors on neurotensin gene expression in nucleus accumbens may have some correlation with
their differing effect on locomotion.61
Although some biases are present in literature, the mesolimbocortical DA is considered as
an important neurological system responsible for cognition and memory. In the monkey, DA
neurons in the area A10 have been reported to be involved in the cognitive behavior and learning
process via transient changes in impulsive activity.62 Dopaminergic neurons in the prefrontal
cortex are known to play an important role in working memory. The activation of DA D1 and D2
receptors in the hippocampus by post training administration of agonists has improved the working
memory tasks in animal models, suggesting important role of hippocampus DA receptors in the
retention of working memory.63, 64 The stimulation of DA D1 and D2 receptors in prefrontal cortex
has been shown to enhance performance in working memory in the monkey. 37, 65
Increased DA transmission in mesolimbic areas after administration of drugs of abuse and
psychostimulants and decreased level of DA after withdrawal of these drugs implies that
mesolimbic DA is primarily involved in reward and reinforcement mechanisms. 66-69 Amongst
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various models developed for the study of drug abuse and dopamine release, drug self
administration and intracranial self stimulation are commonly used in this area. In the case of drug
self administration, both DA D1 and D2 receptors are associated with reinforcing effect of drugs,
with D1 receptor playing an acquiescent role while D2 receptor mediates drug reinforcement.70, 71
D1 and D2 receptors are mainly involved in this behavior as agonists and antagonists increase and
decrease self administration of drug of abuse respectively.72, 73 Previous studies suggest that D1
receptors in the nucleus accumbens are important for the reinforcing properties of cocaine. 71 The
opposite role of DA D1 receptor and DA D2 receptor was observed while studying the effects of
agonists on cocaine seeking behavior. D1 agonists inhibited the cocaine seeking behavior, while
D2 receptor agonists promoted this behavior.74 D3 receptors are also involved in modulating
reward and reinforcement. Recently, D3 receptor partial agonists and antagonists have shown to
inhibit cocaine self administration in animal models for cocaine addiction study. 75, 76 Several
additional behaviors, including yawning, hypothermia, ejaculatory behavior, alcohol consumption,
and inhibition of sniffing are associated with nucleus accumbens D3 receptor.77
The role of D4 and D5 receptors in the physiology of dopaminergic system is still mostly
unknown. Studies have found pharmacological evidences to establish possible links between mood
disorders and DA D4 gene polymorphism, however the findings are not consistent and need to be
reevaluated.78-80 Because of a lack of selective agents that can differentiate the D1 receptor from
D5 receptor, scarce data is available to decide the physiological role of D5 receptors in the CNS.
Currently, gene knockout techniques are being used to study the involvement of D5 receptors in
attention deficit hyperactivity syndrome (ADHD) and in the locomotor stimulant effect of
cocaine.81, 82 Very recently, it has been revealed that DA D5 receptor is linked to the activation of
brain-derived neurotrophic factor (BDNF) and protein kinase B signaling which indicates a
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possible association with mood stabilizers and antidepressant effect.83 Further research into the
role of DA D5 receptor in prefrontal cortex as a therapeutic target in neurological disorders is
required, with the development of selective DA D5 receptor therapeutic agents.

1.2.4

Regulation of dopaminergic system in schizophrenia and drug abuse

1.2.4.1 Role of dopamine receptors in schizophrenia
Schizophrenia is a psychological disorder characterized by disturbed thought process, poor
emotional flow, auditory hallucinations, delusion and disorganized speech and thinking. 84, 85 It is
a heterogeneous mental disorder, prevailing in about 0.85% of the population worldwide. 86
Schizophrenia syndromes can be classified into positive symptoms and negative symptoms.
Positive symptoms reflect excessive expression of normal functions, exemplified by hallucination,
bizarre behavior and delusions. Loss of normal functions or decreased intensity of normal
functions is associated with negative symptoms, characterized by defect in attention, social
withdrawal and cognitive impairment, lack of interest, flattened affect and poverty of speech. 87, 88
The initial hypothesis of schizophrenia was based on the consideration that psychological
outcomes in this ailment are due to a hyperdopaminergic state of the CNS. 89 During the 1970s, a
direct relation between the therapeutic effectiveness of neuroleptics and their affinity for DA
receptors, further solidified this hypothesis.90,

91

At that time, the spotlight was on

hyperdopaminergia and halting the transmission at dopaminergic neurons to treat schizophrenia.
The study of various DA agonists and antagonists on schizophrenia provided indirect evidences to
this hypothesis. However, inconsistent results obtained during the treatment as well as in different
studies have turned this hypothesis inaccurate. Resistance in the treatment, no induction of
schizophrenia even after augmentation of dopaminergic system in nonschizophrenic individual
9

and partial effectiveness of neuroleptics in alleviating negative symptoms are some examples to
support this fact. In 1991, Davis et al revised this concept, calling it “a modified dopamine
hypothesis of schizophrenia”, wherein they explained multiple facets of the hypothesis based on a
subcortical hyperdopaminergia and prefrontal specific hypodopaminergia. 92 Elevated levels of DA
and its metabolite, homovanillic acid was observed in the striatum after lesions in prefrontal cortex,
while decreased DA metabolite level in striatum by presence of DA agonists in prefrontal areas
has provided more precise definition of schizophrenia i.e. prefrontal hypodopaminergia resulting
in striatal hyperdopaminergia.93, 94
Further evidence in schizophrenia in this line comes from PET imaging of DA receptors
using different radiotracers. Numerous studies have confirmed the elevated DA D2 and D3
receptor density in striatum because of intrinsic abnormalities in schizophrenia but not due to
rebound effects of antipsychotics.95-98

Figure 1.1: Mesolimbic dopamine hypothesis for positive and negative symptoms of
schizophrenia (Source: Stahl’s Essential Psychopharmacology, 4th Edition)

DA D1 receptors are rich in prefrontal cortex and mediate major dopaminergic
transmission in this region, and D1 hypofunction is found to be connected to negative symptoms
10

and cognitive impairment in schizophrenia.99, 100 That concludes, impaired activity of dopamine
D1 receptors in the medial prefrontal cortex is an important factor in producing the negative
symptoms and cognitive disorders of schizophrenia, whereas D2 receptor hyperactivity might lead
to the positive symptoms of the disorder (Schematic diagram shown in Figure 1.1).

1.2.4.2 Abnormal dopamine transmission in drug abuse
Psychostimulant drug abuse is understood as a special case of operant attitude bolstered by
the positive reinforcing properties of the abused drugs. 101-103 Among the neural pathways that
contribute in incentive the ones that operate dopamine emerge as that most diffusely involved in
the action of drugs of abuse. As examined by brain microdialysis in rats, most drugs of abuse of
various pharmacological classes increase extracellular DA in different areas of the brain,
preferentially in nucleus accumbens and ventral tegmental area. 104 This is explained in cocaine
(1.1) like, amphetamine (1.2) like, nicotine (1.3), narcotic analgesics and phencyclidine (1.4) drug
abuse and their reward enhancing properties.105-110
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Figure 1.3: Schematic representation of mechanism of action of a) cocaine b) methamphetamine
and c) nicotine (Source: NIH Curriculum Supplement Series, The Brain: Understanding
Neurobiology through the Study of Addiction)

Different drugs of abuse have varied mechanism of action by which they stimulate DA
transmission directly or indirectly (shown in Figure 1.3). Amphetamine operates through carrier
mediated non-exocytotic release of newly synthesized DA, while phencyclidine increase synaptic
DA concentration by blocking the reuptake process.111 Nicotine activates the firing activity of DA
units by directly stimulating excitatory nicotine receptors localized on the somato-dendritic region
of DA neurons.112 Hyperpolarization of the interneurons by narcotic analgesic acting on opioid
receptors attenuate the GABA mediated synaptic input to the DA cells, which lead to excitation of
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the dopamine cells by disinhibition.113 Cocaine binds to the presynaptic DA transporters and
inhibits its reuptake mechanism.114

1.3

Dopamine receptor ligands
The development of selective DA receptor agents has provided necessary tools to assess

the role of these receptors in the nervous system. Over the several decades, DA receptor specific
ligands have been exploited as the means for studying the prognosis and curing several CNS
disorders. Agents possessing selectivity at one type of receptor may demonstrate distinct type of
clinical actions in the neurological disorders. Though some sort of selectivity is achieved between
main classes of receptors i.e. D1 versus D2 types, complete selectivity within the DA receptor
subtypes remains a challenge.

1.3.1

Clinical significance of dopamine receptor ligands

1.3.1.1 Therapeutic significance of D1 receptor selective ligands
The insufficient D1 receptor signaling in prefrontal region results in cognitive deficits in
psychosis. Low doses of selective D1 receptor agonists, such as dihydrexidine (1.5), A77636 (1.6)
and SKF81297 (1.7), have been reported to have cognitive-enhancing actions in nonhuman
primates.115-117 The finding that full D1 receptor agonists can elevate working memory suggests
that such type of agents can be a newer approach to treat negative and cognitive symptoms of
schizophrenia.118, 119 Animal laboratory data indicate that D1 receptor agonists may have possible
applicability for the treatment of cocaine abuse. D1 agonists, such as, SKF81297 (1.7) and
dihydrexidine (1.5) have been shown to decrease cocaine craving in humans and motivation to
seek cocaine, and masks the reinforcing effects of cocaine during self-administration.120, 121 These
D1 agonists could serve as “methadone like” compound for their capacity to therapeutically
13

substitute psychomotor stimulant drugs.122 However, considering the addiction potential,
development of tolerance and severe adverse effects limits their therapeutic liability as
antipsychostimulant drug.

The alternate approach along with this line is of using partial D1 agonist agents to avert the
addiction potential of psychomotor stimulants. D1 partial agonists would be expected to act
primarily as antagonists in the presence of cocaine, whereas in the absence of cocaine they would
be expected to function as weak agonists.123 Various pharmacological studies have exhibited the
antidrug abuse potential of D1 partial agonist agents like SKF 83959 (1.8), SKF 77434 (1.9) and
SKF 38393 (1.10) (shown in Figure 1.4b). 123-125
Based on preclinical studies, D1 antagonists are not found much effective as
antipsychotics, but they are developed for the treatment of self-harming behavioral disturbances
arise in Lesch−Nyhan Disease, as well as for the treatment of Tourette syndrome in children and
for obesity.126-128
14

1.3.1.2 Therapeutic significance of D2 receptor selective ligands
Since the discovery of chlorpromazine (1.11), D2 antagonism is considered a fundamental
necessity to positively modulate psychosis.129,

130

Since then, without exception, currently

available antipsychotics all have some degree of D2 receptor antagonist property.131, 132 As shown
in Figure 1.5, other examples of antipsychotics having D2 antagonist effect include fluphenazine
(1.12), haloperidol (1.13), thiothixene (1.14), risperidone (1.15), clozapine (1.16), and quetiapine
(1.17).
Brain imaging studies including positron emission tomography (PET) indicate that the
blocking of at least 65% of D2 receptors is necessary to achieve antipsychotic effects, at the same
time, passing the threshold of 72%-78% blockade of D2 receptors, increases the risk of
extrapyramidal motor symptoms (EPS) and hyperprolactinemia.130, 133
A second approach to treat schizophrenia is to prevent the excessive D2 receptor activity
using D2 partial agonists. D2 receptor antagonists block the action of endogenous DA, while
partial agonists like aripiprazole (1.18), diminish the hyperactivity of the receptor by competing
with endogenous DA to produce lower degree of action at DA receptors. 134 D2 agonist compounds
(shown in Figure 1.6) like bromocriptine (1.19), cabergoline (1.20), and quinagolide (1.21) are
being used for the management of hyperprolactinaemic disorders and combination therapy with
levodopa (1.21) for Parkinson’s disease.135, 136
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The enhanced reinforcing effect and self administration of cocaine was observed after the
administration of D2 agonist as well as, clinical and pharmacological studies indicate that D2
agonist agents are not effective against cocaine addiction because of the abuse potential in
humans.74, 137, 138
16

1.3.1.3 Therapeutic significance of D3 receptor selective ligands
Cocaine and methamphetamine overdose fatalities have been associated with upregulation
of D3 receptors in the ventral striatum and other D3 receptor rich regions in brain.139, 140 D3
receptor antagonists SB277011A (1.23), have shown promise in reversing acquisition and
expression of drug-seeking and cue-induced relapse in animals.141, 142 Rewarding effects of cocaine
and cocaine-induced reinstatement of drug-seeking behavior was shown to be inhibited by D3
receptor antagonist NGB 2904 (1.24).143 As shown in Figure 1.7, other examples of D3 receptor
antagonists include SR21502 (1.25), PG01037 (1.26), and YQA14 (1.27) that have demonstrated
to inhibit cocaine seeking behavior and cocaine self administration in animal models. 144-146
Moreover, it has been demonstrated that the D3 selective partial agonist BP 897 (1.28) inhibits
cocaine seeking behavior caused by the presentation of drug-associated cues.76

Elevated expression of D3 receptor was observed in a postmortem study of untreated
schizophrenic patients, whereas D3 receptor level was normal in subjects having antipsychotic
drugs treatment.147 There is increasingly strong evidence that D3 receptor antagonists will be
effective antipsychotic agents. In this regard, refinement of the cognitive and negative symptoms
17

of schizophrenia holds the most promise for D3 receptor antagonists.148 Studies have shown that
the D3 receptor antagonism can inhibit extrapyramidal symptoms and can positively affect the
social behavior in schizophrenia.149

1.3.1.4 Therapeutic significance of D4 receptor selective ligands
Considerable work has been progressed to find selective D4 receptor binding compounds
based on the hypothesis that the D4 receptors are likely involved in a psychosis, ADHD and
erectile dysfunction. There are many studies suggesting that the selective D4 receptor antagonists
might be a novel strategy towards schizophrenia.150, 151 Various D4 receptor selective antagonists
(Figure 1.8) have reached clinical trials, for instance, sonepiprazole (1.29), NGD-94-1 (1.30), and
L-745, 870 (1.31) but none of them have successfully demonstrated antipsychotic activity in
schizophrenic patients.152-154 The effect of stimulating the D4 receptor using selective agonist
agents in erectile dysfunction is under investigation.155
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1.3.1.5 Therapeutic significance of D5 receptor selective ligands
A few studies have implicated the D5 receptor in the pathophysiology of hypertension and
drug abuse, making it of pharmacological interest.156-158 It was shown in D5 knockout mice that
the D5 receptor seems to be involved in the locomotor-stimulant effects of cocaine, whereas there
is only little involvement in the discriminative stimulus effects of cocaine suggesting therapeutic
relevance of D5 receptor in cocaine addiction.81 However, discrimination between D1 and D5
receptors remains largely unexplored due to lack of highly selective ligands and of specific
methods of biological characterization. There are some examples of selective D5 receptor
antagonists (compounds 1.32 and 1.33 shown in Figure 1.9) under investigation for their antiaddiction potential against cocaine.159

Potential clinical importance of selective dopamine receptor ligands for different CNS disorders is
summarized in Table 1.1.
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Table 1.1: Potential therapeutic applications of dopamine receptor ligands
DA receptor ligand
D1 receptor

agonist

partial agonist

D2 receptor

agonist

-

Tourette syndrome
self-harming behavioral disturbances in
Lesch−Nyhan Disease
Hyperprolactinaemic disorders
Parkinson’s disease
Prolactinoma
Restless legs syndrome
Parkinson’s disease
Restless legs syndrome
Schizophrenia
Bipolar disorders
Depression
Schizophrenia

-

Hyperprolactinaemic disorders
Parkinson’s disease
Psychostimulant drug abuse

-

Psychostimulant drug abuse
Schizophrenia
Cognitive disorders
Erectile dysfunction
Schizophrenia
ADHD
-

-

Psychostimulant drug abuse

agonist
partial agonist
antagonist
agonist
antagonist

D5 receptor

-

Parkinson’s disease
Cognitive and working memory deficits in
schizophrenia
Psychostimulant drug abuse
Psychostimulant drug abuse

-

antagonist

D4 receptor

-

antagonist

partial agonist

D3 receptor

Therapeutic significance

agonist
Antagonist
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1.3.2

Selective D1 receptor ligands

1.3.2.1 Arylbenzazepines
1.3.2.1.1 Simple arylbenzazepines
Initial findings of D1 antagonists like SCH-23390 (1.34), followed by a number of selective
D1 receptor ligands were developed in 1980s.160 All of these D1 receptor ligands (1.7, 1.8, 1.10,
and 1.34-1.36) share a common template of phenyl tetrahydrobenzazepine (shown in Figure 1.10).
Many useful D1 receptor selective compounds having agonist or antagonist activity with high D1
affinity, for example SCH and SKF series (Figure 1.10), were acquired from this class. More
diverse D1 receptor ligands were developed to enhance binding affinity and selectivity at D1
receptor as well as to improve intrinsic efficacy and metabolic stability. In these compounds, βcatechol-substituted ethylamine moiety, which resembles the catecholamine neurotransmitter DA,
is associated with D1 receptor affinity. The chiral center at C1 position should be in the R
configuration to be active at DA receptors.161 Variant substitutions on C1 phenyl ring, C6 or N3
can modify the binding affinity and selectivity between D1 and D2 receptors. Usually, catecholbenzazepines are D1 agonists, while C7 substituent can govern the functional activity from
agonism to antagonism predominantly. As demonstrated by benzazepine analogues 1.34 and 1.35,
replacing the catecholic 7-OH group with halogen produces D1 antagonist activity. 160, 162 SKF
83959 (1.8) is one of the primary D1 receptor agonist with high binding affinity and selectivity.
To overcome the limitations of having low intrinsic activity and poor metabolic stability, various
analogues of SKF 83959 (compounds 1.37-1.44) were synthesized and studied for their affinity at
DA receptors.163, 164 These SAR studies have revealed that 3’ or 2’ CH3 substitution on 1-phenyl
ring and H, CH3 or allyl N-substituents as well as C6 halogens are important for the D1 receptor
activity.163 Most of these
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Table 1.2: Structure modification and binding affinities of catechol containing arylbenzazepines
at DA D1 and D2 receptors

Comp.

Isomer

R1

R2

R3

(±)-1.8
(+)-1.8
1.37
1.38
1.39
1.40
1.41
1.42
1.43
1.44
1.45
1.46
1.47
1.48

RS-(±)
R-(+)
R-(+)
RS-(±)
RS-(±)
RS-(±)
RS-(±)
RS-(±)
RS-(±)
RS-(±)
RS-(±)
RS-(±)
RS-(±)
RS-(±)

Cl
Cl
Br
Cl
Cl
Br
Br
Br
Cl
Br
3-toluyl
2-naphthyl
3-toluyl
2-naphthyl

CH3
CH3
CH2CH=CH2
CH3
H
CH3
CH3
H
CH2CH=CH2
CH2CH=CH2
H
H
H
H

3’-CH3
3’-CH3
H
2’-CH3
3’-CH3
3’-CH3
2’-CH3
2’-CH3
3’-CH3
3’-CH3
H
H
3’-CH3
3’-CH3

agents exhibited higher D1 receptor

Ki (nM)
D1
1.18
0.49
2.29
0.46
0.60
0.19
1.10
1.81
0.52
0.11
39
56
6.81
4.88

D2
920
515
2.09
226
≥5000
440
409
19.5
119
83.8
>10000
>10000
>10000
>10000

selectivity over D2 receptor with subnanomolar binding

affinity (Table 1.2). For the same molecule (1.8), another series of analogues (1.45-1.48, Table
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1.2) having an aryl group at 6 position, has been synthesized. The tolerance of larger aryl group at
this position indicate a large hydrophobic pocket on D1 receptor around the C6 position of
phenylbenzazepine.164 In the parent molecule SCH 23390 (1.34), various substituents were
introduced at para position of pendant phenyl ring to generate novel D1 antagonists (1.49a-1.49f,
Table 1.3).165 Most of these analogues have shown higher preference for D1 over D2 receptors
with subnanomolar (0.5-0.9 nM) binding affinity (Table 1.3).
Table 1.3: Structure modification and binding affinities of arylbenzazepines at DA D1 and D2
receptors

Comp. Isomer

R1

R2

1.49a

R-(+)

H

1.49b
1.49c
1.49d
1.49e
1.49f

R-(+)
R-(+)
R-(+)
R-(+)
R-(+)

Ac
SO2CH3
SO2CH3
SO2Ph
Bn

Ki (nM)
D1

D2

n-Bu

0.9

2000

n-Bu
n-Bu
CH3
CH3
2,4-F2C6H3

0.2
0.5
0.5
0.6
0.7

159
2000
6000
331
552

1.3.2.1.2 Conformationally constrained arylbenzazepines
Arylbenzazepines retain a noticeable mobility, and the proposed position of the aryl moiety
in the binding pocket of D1 receptor is postulated to be equatorial. 166, 167 One of the binding
intercations of phenylbenzazepines with the D1 receptor was believed to be π-π interaction
between C1 aryl group and Tyr, Phe or Trp terminals in the receptor active site. 168 In the parent
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compound SCH23390 (1.34), introducing an ethylene bridge between C2 and C2’ results in
conformationally restrained benzazepine compound 1.50 (Figure 1.11).166 Binding study at D1
receptor reveals that (R)-trans isomer has the highest affinity (Ki 1.9 nM) amongst all four isomers,
supporting the fact that the pharmacologically active arylbenzazepine possesses R- configuration
at C1 chiral center.166 Compound 1.50a (SCH 39166), also known as ecopipam, was studied
extensively for the treatment of obesity, but it faces limitations of poor oral bioavailability.127

To further explore this scaffold, novel D1 antagonist analogues (1.51a-1.51j, 1.52a-1.52c, Table
1.4) having variant ring D substitutions at 3’ and 4’ positions in SCH 39166 were synthesized and
their activity at D1 receptor was studied.165,

169

These compounds have shown nanomolar to

subnanomolar D1 affinity (0.2-3.1 nM, Table 1.4) with better selectivity at D1 versus D2 receptor
and improved pharmacokinetic properties as compared to parent compound 1.50a. Highest binding
affinity was demonstrated by 4’ phenyl analogue 1.51g (0.2 nM) while compound 1.51c has shown
>3000-fold selectivity at D1 (3.1 nM) versus D2 receptor (>10000 nM). 3’-sulfonyl derivative
1.52b, showed to improved pharmacokinetics and oral bioavailability (F oral = 29% for 1.52b versus
0.6% for 1.50a).165
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Table 1.4: Structure modification and binding affinities of conformationally constrained
arylbenzazepines at DA D1 and D2 receptors

Comp.

R

1.50a
1.51a
1.51b
1.51c
1.51d
1.51e
1.51f
1.51g
1.51h
1.51i
1.51j
1.52a
1.52b
1.52c

H
CH2OH
OH
2-oxopurrolidine-1-yl
NH2
NHCONHEt
NHCO2Et
Ph
4-OMePh
Thien-2-yl
1H-indol-5-yl
H
SO2Me
CONH(2,6-Cl2Ph)

Ki (nM)
D1
1.2
2.0
0.6
3.1
2.8
2.4
2.3
0.2
0.7
0.9
0.6
7.0
0.5
0.7

D2
980
1647
440
>10000
2100
900
500
79
550
93
51
5400
3000
1093

1.3.2.1.3 Bioisosteres of benzazepines
The metabolic susceptibility of arylbenzazepines arises because of O-glucuronidation of
the catechol hydroxyl group and N-dealkylation of N-methyl functionality. The main approach to
tackle this drawback is to replace catechol with its bioisosteres, which can mimic the hydrogen
bond complement of phenol at the receptor binding site.170 Wu et al. developed heterocycle-fused
phenol isostere compounds (Figure 1.12) as DA D1 receptor ligands having triazole (1.53, 1.54),
indole (1.55), imidazole (1.56), imidazolone (1.57a, 1.57b) and thiazolone (1.58a, 1.58b).171
Considerably poor binding affinity (Table 1.5) was displayed by the benzotriazole (1.53, 1.54) and
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benzimidazole (1.56) analogues with Ki values of 583, 146, and 248 nM respectively. Remarkable
higher binding affinity (Table 1.5 Ki = 2.1 to 16.5 nM) shown by benzimidazolone and
benzthiozolone compounds (1.57a-b, 1.58a-b) signifies the importance of orientation and acidity
of the NH moiety in these heterocycles. Based on this observation they conclude that, suitably
aligned heterocycle with an NH group would be able to serve as surrogates for the phenolic OH
group. As expected, these D1 receptor antagonists exhibited better pharmacokinetic profiles as
compared to parent benzazepines.

Table 1.5: Binding affinities of bioisosteres of arylbenzazepines at DA D1 and D2 receptors
Comp.

Ki (nM)

1.53

D1
583

D2
3000

1.54

146

1530

1.55

24.7

232

1.56

248

984

1.57a
1.57b

7
16.5

1023
3270

1.58a

2.1

257

1.58b

6.5

661
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1.3.2.2 Dihydrexidine derivatives
Compound 1.59 represents a class of 4-phenyl substituted tetrahydroisoquinolines which
has moderate, but selective DA D1 receptor affinity. 172, 173 As shown in Figure 1.13, introduction
of ethylene-bridge has rigidified this scaffold to give novel D1 receptor ligands 1.5, 1.5a, and
1.5b.174 The trans configured compound 1.5, also known as dihydrexidine, is a highly selective
and potent D1 receptor ligand. More significantly, compound 1.5 is a full DA D1 agonist with
EC50 of 70 nM to activate adenylate cyclase. The cis isomer (1.60) of 1.5 is found inactive at DA
receptors. The N-Me (1.5a) and N-Pr (1.1.5b) analogues demonstrated much lower binding
affinity of 91 nM and 651 nM, respectively, with the reduction of intrinsic activity at the same
time. Switching the substitution from 10, 11 dihydroxy in ring D of 1.60 to 9, 10 dihydroxy
(compound 1.61) results in vanished D1 receptor activity.
Applying the original idea of rigidifying compound 1.59 to develop dihydrexidine, similar
D1 ligands (1.62a-1.62d) were designed wherein, two phenyl rings were connected through
methylene-bridge and ethylene-bridge was removed in dihydrexidine. Binding affinity of
compound 1.62a (also known as dinapsoline) was found to be 5.9 nM, comparable to 1.5, and it
displayed D1 full agonistic profile.175 The C6-methyl (1.62b) and C6-ethyl (1.62c) compounds
have nearly equal affinity to the D1 receptor with K i of 11 and 14 nM, respectively, while C6fluoro analogue (1.62d) has biological activity consistent with dinapsoline. 176
Replacing methylene bridge with ether linkage to tether phenyl rings in dinapsoline
produced compound 1.63a, also known as dinoxyline.177 This novel ligand was found to possess
remarkable affinity (3.9 nm) for D1 receptor and greater selectivity (22-fold) for D1 versus D2
receptor. It also retained full agonistic profile (EC50 87 nM) at D1 receptor similar to dinapsoline.
It has shown high binding affinity at D5 receptor with K i value of 1.0 nM as well as at D3 receptor
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(Ki 6.5 nm). Reduction in affinity was observed after N-alkyl insertion (compound 1.63b and
1.63c) in the dinoxyline template. Compound 1.63a serves as the key example of ligands with
improved affinity for all DA receptors and also endowed with the functional aspects akin to
dopamine itself. Dinoxyline is under investigation for the treatment of Parkinson’s disease. 178

D1 agonists have been investigated as potential treatments for Parkinson’s disease and
hypertension, and D1 antagonists have been tested in the treatment of psychotic disorders,
including schizophrenia, though both efforts have yielded only limited success. Fenoldopam
(Figure 1.13, 1.64), a benzazepine analog, remains the only D1-selective compound to reach the
pharmaceutical market in the US for short-term management of severe hypertension.179
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1.3.3

Selective D2 receptor ligands

1.3.3.1 Dihydroindenes and oxime analogues
To develop metabolically stable DA receptor ligands, trans-2-amino, 1-phenyl-2,3dihydroindene derivatives were designed. Compounds 1.65-1.67 (Figure 1.14) belong to this class
of DA receptor ligands, having C2-amino group and C1-phenyl moiety in trans configuration to
attain the receptor activity. Amino group substitution affects the activity at D2 receptors, as
demonstrated by N,N di-alkyl substituted indenes having greater affinity and selectivity at D2
receptors. Indene analogues 1.65, 1.66, and 1.67 have D2 affinity 650, 270, and 170 nM
respectively and they possess D2 agonist effect.180, 181

Aminotetralin compound 1.68 and its derivatives are known mixed DA D1/D2 agonists
explored for the potential utility in the treatment of Parkinson’s disease.

182-184

To combat against

the metabolic instability, series of oxime analogues (1.69-1.71, Figure 1.14) were developed as
prodrug of 60.185 These compounds exhibited apparent and extended dopaminergic effects in
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Parkinson’s disease behavioral model. Novel compounds 1.72 and 1.73 developed as DA agonists,
since the thienylethylamine moiety can act as bioisosteres of DA. 186 Though these compounds
have moderate DA D2 receptor affinity (K i 27 nM for 1.72 and Ki 20 nM for 1.73), they have
improved oral bioavailability. The benzoquinoline compound 1.74, is a potent DA D1 and D2
receptor agonist with EC50 value of 25 nM (D1 receptor) and 0.64 nM (D2 receptor). The enone
compound 1.75 is the prodrug of 1.74, which is an interesting lead compound for potential
development of anti-Parkinson agents.187, 188

1.3.3.2 Aporphine analogues
Based on the fact that 1,2,3,4-tetrahydroisoquinoline compounds maintain the integrity of
the phenethylamine portion of dopamine, several naturally occurring as well as synthetic
tetrahydroisoquinoline derivatives have been screened for dopamine receptor activity. 1-benzyl1,2,3,4-tetrahydroisoquinoline alkaloids, for example, nor-roefractine (1.76, Figure 1.15) and nor
armepavine (1.77, Figure 1.15) have affinity for both DA D1 and D2 receptors.189, 190 Among the
tetrahydroisoquinolines and congeners, the conformationally rigid aporphines have been
extensively studied with regard to their dopamine receptor activity. 191 Apomorphine and some of
its derivatives were among the earliest pharmacological tools used to characterize DA receptors.192
Clinically, R-(-)-apomorphine (1.78) is being used as anti-Parkinson drug and for the treatment of
male erectile dysfunction as D1 and D2 agonist.
To resolve the drawback of poor bioavailability and short duration of action, diverse
synthetic analogues (1.80-1.91, Figure 1.15) were developed and studied at DA receptors.193-195
The optimum activity at D2 receptor was found with n-propyl alkyl chain on tertiary nitrogen of
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aporphines, for example (R)-(-)-N-n-propylnorapomorphine (NPA, 1.79 Ki = 4.80 nM). For DA
receptor activity, apart from the structural requirements of tertiary nitrogen and 6a-R configuration,
C-2 substitution is also considered a significant factor in aporphines. Differences in affinity (Table
1.6) was observed between alkyloxy and 4-hydroxyphenyl substitutions at C-2 position. When
compared to the parent compound APO (1.78), C2 alkoxy analogues (1.80, 1.81) were 4 to 8-fold
less potent, while, hydrophilic substituent 4-hydroxyophenyl analogues (1.82, 1.83) were 5-fold
more potent.196, 197 Insertion of alkylthio moiety at C2 position in aporphine scaffold yielded novel
compounds 1.84-1.86 (Table 1.6). Methylthio analogue (1.84) was found to have improved
potency (Ki 3.73 nM), while ethyl and propyl analogues have shown reduced affinity (K i 7.8 and
15.6 nM respectively) compared to NPA (1.79 Ki 4.80 nM) at DA D2 receptors.198
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Table 1.6: Binding affinities of aporphine analogues at DA D1 and D2 receptors
Comp.
1.78
1.79
1.80
1.81
1.82
1.83
1.84
1.85
1.86
1.87
1.88
1.89
1.90
1.91

Ki (nM)
D1
214
733
2900
3500
124
94
>10000
>10000
>10000
130
1690

D2
13.2
4.8
44
75
1.5
2.0
3.73
7.8
15.6
>10000
>10000
97
28.0
44.0

To improve the in vivo metabolic stability profile of aporphines, exclusion of one or both
catecholic hydroxyl group or replacing them with bioisosteres was envisaged. Switching the
catechol component with its aminothiazole bioisosteres, results in complete loss of activity at D2
receptor (1.87, 1.88), while mono hydroxyl analogues (1.89-1.91) have shown to reduce the
potency 3 to 8-fold as corresponds to their lead compounds 1.78 or 1.79.199

1.3.3.3 Arylpiperazine/piperidine analogues
Arylpiperazines or arylpiperidines belong to one of the largest groups of chemical structure
with dopaminergic activities. Most of the recent widely used antipsychotics which have D2
antagonistic activity (for example haloperidol, risperidone, olanzapine and clozapine) fall into this
category. Current attempts to develop D2 ligands as superior antipsychotics with limited EPS, have
targeted agents bearing moderate D2 antagonism or D2 partial agonistic effects, combined with
interactions at other DA receptors as well as serotonin receptors.
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Various analogues (1.92-1.104, Figure 1.16) were generated by modification of haloperidol
(1.13) scaffold. The nitrogen/silicon exchange at the C-4 position of the piperidinyl ring, has
produced sila-haloperidol (1.92) and sila-trifluperidol (1.93). Switching the chloro group of
haloperidol with trifluoro moiety produces novel the compound 1.94. Binding affinity at D2
receptor for compound 1.92 and 1.93 is comparable to haloperidol, while compound 1.94 is 15fold less potent than haloperidol (Table 1.7).200 The role of hydroxyl group and other features in
haloperidol were assessed through probing the D2 receptor activity of analogues 1.95-1.98.201 In
this series, conformationally constrained tropane agents 1.95 and 1.96 have shown high D2 affinity
(Ki = 0.31nM and 2.3 nM, respectively) while having low selectivity between D2 and D3 receptors.
Removal of hydroxyl group has substantial effect on DA receptor activity as demonstrated by
analogues 1.97 and 1.98 which have reduced affinities for all DA receptors as shown in Table 1.7.
Another library of analogues (1.99-1.104, Figure 1.16) was generated by replacing the
butyrophenone portion of haloperidol with 3-methylindole and 3-methylbenzofuran
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heterocycles. Compounds 1.99 and 1.100 bind at D2 receptors with high affinity (Ki = 2.3 and 5.5
nM) with more than 50-fold (1.99) and 100-fold (1.100) D2/D3 selectivity, and were found to be
D2 antagonists.202, 203 Compounds 1.101-1.104 possess binding affinities ranging from 6.9 to 23.9
nM and 10- to 28-fold selectivity for D2 versus D3 receptors.203

Table 1.7: Binding affinities of haloperidol analogues at DA D2, D3 and D4 receptors

1.13, haloperidol

D2
1.1

Ki (nM)
D3
5.5

D4
12.7

1.92
1.93
1.94
1.95

3.0
15.0
1.5
0.31

0.81

12.1

1.96
1.97
1.98
1.99
1.100

2.3
16.3
254
2.3
5.5

3.2
46.0
403
190
580

19.1
25.9
17.5
840
567

1.101
1.102
1.103

10
23.9
6.9

104
638
111

449
319
1100

1.104

21.0

28.0

167

Comp.

Because the “pure D2 antagonism” engenders extrapyramidal side effects, researchers tried
to bring about molecules having weaker D2 antagonist profile mixed with other receptor activity,
for instance 5-HT2A, to avoid the risk of EPS.204 Some compounds with phenylpiperazine
connected to benzotriazole have exhibited antipsychotic effects, for example, analogue 1.105 have
low D2 receptor affinity (Ki = 52 nM) and high 5-HT2A receptor affinity (Ki = 5.1 nM). Other
examples include, compounds 1.106-1.109 (Figure 1.17) which having benzoisoxazole and
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benzoisothiazole attached to piperazine ring have similar profile as atypical antipsychotics i.e.
moderate D2 and high 5-HT2A affinity (Table 1.8).205

Table 1.8: Binding affinities of arylpiperazine analogues at DA D2 and 5-HT2A receptors
Comp.

Ki (nM)

1.105
1.106

D2
51
25.2

5-HT2A
5.1
0.73

1.107
1.108

27.7
15

0.12
0.17

1.109
1.18
1.110
1.111

4.0
8.0
2.6
5.0

1.07
40
7.4
16

1.112

0.14

0.81

Enlarging the piperazine ring in aripiprazole (1.18) provided novel analogues 1.110 and
1.111. With improved affinity for D2 receptor (K i = 2.6 and 5.0 nM) and moderate affinity for
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other DA as well as serotonin receptors (Table 1.8), these compounds possess potent antipsychotic
activity.206 Structurally distinct from traditional antipsychotics, novel compound 1.112
(blonanserin) has a dual D2/5HT2A receptor activity (Ki = 0.14 and 0.81 nM), but has similar risk
of EPS as haloperidol.207

1.3.3.4 Dibenzazepine analogues
Dibenzazepines are another class, different from arylpiperazines or piperidines, found in
several antipsychotics including clozapine (1.16), olanzapine (1.113), and sertindole (1.114).
Considerable amount efforts have been made to enhance the antipsychotic activity of this class by
optimizing the structural requirements of dibenzazepine core.208

Clozapine analogues (Figure 1.18) 1.115, 1.116, 1.17 (quetiapine), and 1.117 were
developed as D2 antagonists for the treatment of schizophrenia. Most of these compounds except
1.117, exert EPS and prolactin elevating effects.209 A novel series of pyrrolobenzazepines and
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pyrrolobenzothiazepine analogues (1.118a-1.118d, 1.119a-1.119c) have been developed.210 All
these analogues demonstrated moderate to low affinity (Ki = 3.1 nM to 79 nM) at DA D2 receptors.

1.3.4

Selective D3 receptor ligands

1.3.4.1 2-Aminotetralin derived D3 ligands
The concept of rigidifying the free aminoethyl side chain of dopamine led to development
of 2-aminotetralin class of DA ligands. As shown in Figure 1.19, α- and β-rotamers (1.120a,
1.120b) of dopamine were advanced to conformationally restrained 5-hydroxy and 7-hydroxy
analogues 1.123 and 1.124. 2-aminotetralin derivative 7-OH-DPAT (1.122) was recognized as
selective D3 agonist and suitable radioligand ([3H] 7-OH-DPAT) to analyze the pharmacological
characteristics and brain distribution of DA D3 receptors.211 Later on, it was found out that, R-(+)7-OH-DPAT binds with 74-fold higher affinity to DA D3 receptors (Ki = 0.57 nM) than the
corresponding S-(−)-enantiomer (42.1 nM), while 5-OH derivative resulted in the opposite trend,
wherein the S-(−)-enantiomer was 140-fold more active than the R-(−)-enantiomer.212, 213 The S-()-5-OH-DPAT analogue S-(−)-N-0437 (1.123, rotigotine) is known for its potent agonistic activity
at DA D2 and D3 receptors and exhibited similar efficacy in Parkinson’s disease symptoms and
restless leg syndrome.214, 215 In a similar way, the iodinated analogue (1.124) of (+)-7-OH-DPAT
(1.122) was developed to have improved selectivity (143-fold) at D3 over D2 receptors as
compared to 1.122 (60-fold).216
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Table 1.9: Structure modification and binding affinities of aminotetralin derivatives at DA D2 and
D3 receptors

Comp.

Isomer

X

R

R1

1.125a
1.125b
1.125c
1.125d
1.125e
1.126a
1.126b
1.126c
1.126d
1.126e

RS
RS
S
RS
RS
RS
RS
R
RS
RS

5-OH
5-OH
5-OH
5-OH
5-OH
7-OH
7-OH
7-OH
7-OH
7-OH

H
H
n-Pr
n-Pr
n-Pr
H
H
n-Pr
n-Pr
n-Pr

H
n-Pr
n-Pr
2-thienylethyl
phenylethyl
H
n-Pr
n-Pr
2-thienylethyl
phenylethyl
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Ki (nM)
D2
ND
0.50
14
0.06
0.5
3.3
3.8
34
0.76
ND

D3
340
0.75
0.54
4.0
3.4
5.1
0.66
0.57
0.75
2.0

D2/D3
ND
0.67
26
0.015
0.15
0.64
5.8
60
1.0
ND

SAR studies of 2-aminotetralins at DA receptors suggest that meta OH (5 or 7 position) is
significant for DA receptor activity.162, 182, 217 Moreover, n-propyl group is most favorable in size
as N-alkyl substituents to increase the activity at D3 receptors. The affinity of the 5-OH derivative
at D3 receptors has greatly increased by having mono substitution on nitrogen with n-propyl (Ki
340 nM for compound 1.125a to 0.75 nM for compound 1.125b). As shown in Table 1.9, adding
a second n-propyl group to the nitrogen significantly improved selectivity for D3 over D2 receptors
in both the 5-OH (1.125c, 26-fold) and 7-OH derivatives (1.126c, 60-fold).213 Replacement of one
n-propyl group with a sterically more demanding 2-thienylethyl or phenylethyl substituent results
in minor to moderate decreases in D3 affinity (1.125d, 1.125e, 1.126d, 1.126e), but also in a loss
of the D3 selectivity relative to the D2 receptor.
Further development of 2-amonitetralins as D3 ligands turned to replacing the phenolic
OH group with metabolically stable isosteres. An exemplary prototype for this transformation is
pramipexole (1.127), wherein an aminothiazole component replaces the catechol of
aminotetralin.218, 219 Advancement in this direction lead to development of potent mixed D2-D3
agonists like 1.128, ropinirole (1.129), quinelorane (1.130), quinpirole (1.131), and pergolide
(1.132) (shown in Figure 1.20).220-223
Replacing the catechol OH group with enyne or endiyne functionalities produced novel
nonaromatic tetralin analogues 1.133 and 1.134 (Figure 1.21).224, 225 These compounds have high
affinity and selectivity at D3 receptor with K i value of 9.1 nM and 3.2 nM for 1.133 and 1.134
respectively. Another modification, having pyrazole and pyrazolopyridine element as isostere of
phenol, results in compounds 1.135-1.138.226, 227 The fact that S-enantiomer of these analogues
have demonstrated higher binding affinity (6.0 nM to 0.54 nM, Table 1.10) as well as higher
selectivity (15 to 157-fold) at D3 receptor over D2 receptor, suggests that the sp 2 nitrogen of
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pyrazole 1.136 and thiazole of pramipexole (1.127) have significant role as pharmacophoric
element. Introducing the enyne component in to the hybrids of arylpiperazine and aminotetralin
produced new D3 receptor ligands. Representative compounds 1.139 and 1.140 have very high
affinity and selectivity at D3 receptor (Table 1.10).
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Table 1.10: Binding affinities of pramipexole analogues at DA D2 and D3 receptors

1.127, pramipexole

D2
2.07

Ki (nM)
D3
0.49

1.133

110

9.1

12

1.134

54

3.2

17

1.135

90

6.0

15

1.136

180

4.0

45

1.137

85

0.54

157

1.138

230

16

14

1.139

40

0.21

190

1.140

610

1.3

469

Comp.

D2/D3
4

1.3.4.2 4-Phenylpiperazines and analogues
In last 20 years, 4-phenylpiperazines have been thoroughly studied regarding their usage
as potent and selective D3 ligands. Structural congener of DA antagonist nafadotride (1.141),
1.142 has been developed, in which basic 4-phenylpiperazine is linked to naphthamide through
ethyl chain.228 Even though having only two carbon alkyl linker, compound 1.142 has good
binding affinity (Ki 8 nM) and 1250-fold selectivity at D3 receptor (Table 1.11). In this chemical
class, numerous analogues having diverse arylamide group and alkyl linker with 2,3dichlorophenylpiperazine or 2-methoxyphenylpiperazine moiety have been designed and studied
for D3 receptor activity. Extending the alkyl chain and modifying the arylamide group to
dichlorinated phenyl ring led to identification of novel tricyclic D3 receptor antagonists 1.24 (NGB
2904) and 1.143 (NGB 2849) with a remarkable binding profile (1.24 Ki = 1.4 nM, 1.143 Ki = 0.9
nM) with more than 160 to 290-fold selectivity for D3 receptor (Table 1.11).229 SAR examinations
relating fluorene and oxo-fluorene derivatives 1.144 and 1.145 show modest and nonselective
binding profile (Ki = 19 nM at D3 and Ki = 10 nM at D2) for 1.144, while 1.145 has nanomolar
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affinity (1.4 nM) and 64-fold selectivity at D3 receptor.230 In this chemical class, the naphthamide
derivative 1.28, (BP 897) is a high affinity D3 receptor ligand (Ki 0.92 nM) with 66-fold selectivity
over D2 receptor having partial agonistic effect at D3 receptors. 231 Though results are not
promising, it is one of the most studied D3 partial agonist that had entered clinical trials for the
treatment of drug addiction.232
Following the parent compounds 1.28 (BP 897) and 1.24 (NGB 2904), other new selective
D3 partial agonists and antagonist have been identified (Table 1.11). Replacing the naphthamide
aryl ring system in BP 897 with benzofuran (1.146, 1.147) or benzothiophene (1.148, 1.149) results
in a rise in D3 binding affinity (Ki 0.23–1.5 nM). More importantly, thiophene compound 1.149,
is found to be one of the most selective D3 antagonists (7200-fold over D2 receptor) with greater
potency (Ki 0.5 nM) while compound 1.148 is even more potent (Ki 0.23 nM) than 1.149 and
having D3 partial agonist activity.233 With similar approach, two new compounds (1.150, 1.151)
were discovered having indolcarboxamide as isostere of benzamide. Both of these compounds
were recognized as highly potent and selective D3 receptor ligands (1.150 Ki = 0.56 nM, 5500fold vs D2, 1.151 Ki = 0.25 nM, 640-fold vs D2).234 Other remarkable compounds acquired by
variation of arylamide portion are 1-methoxynaphthamide analogue (1.152) and 7methoxybenzofuran analogue (1.153), which have subnanomolar D3 affinities (1.152 Ki = 0.60
nM and 1.153 Ki = 0.13 nM) and significant selectivities over D2 receptors (1400-fold for 1.152
and 2800-fold for 1.153).235 Apart from modification at phenylpiperazine moiety, replacing the
flexible alkyl spacer moiety with rigid cyclic structures has been studied towards the identification
of novel D3 ligands.
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Table 1.11: Structure modification and binding affinities of 4-phenylpiperazine analogues at DA
D2 and D3 receptors

Comp.
1.141
1.142
1.24
NGB 2904

R
-

R1

R2

X

Ki (nM)
D2
D3
3.0
0.3
>10000
8.0

D2/D3
10
>1250

-

-

-

Cl

Cl

-

220

1.4

160

1.143
NGB 2849

Cl

Cl

-

260

0.9

290

1.144

Cl

Cl

-

10

19

0.53

1.145

Cl

Cl

-

89

1.4

64

1.28
BP 897

OMe

H

-

61

0.92

66

1.146
1.147
1.148
1.149
1.150

OMe
Cl
OMe
Cl
Cl

H
Cl
H
Cl
Cl

O
O
S
S
H

110
320
87
3600
3100

1.1
1.5
0.23
0.50
0.56

100
210
380
7200
5500

1.151

OMe

H

CN

160

0.25

640

1.152

Cl

Cl

-

830

0.60

1400

1.153

Cl

Cl

-

370

0.13

2800
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Introduction of the cyclohexylethyl linker in place of simple alkyl chain generated
compounds such as 1.154 and 1.155 (Figure 1.22).236 The 2-thienylcarboxamide analogue (1.154)
has shown noticeable D3 affinity (Ki 0.02 nM), however D3 receptor selectivity is only 30-fold
over D2 receptor. It has antagonist functional activity at D3 receptor.

Stereochemical

conformation change in cyclohexyl ring has prominent impact on D3 receptor activity. Cis isomer
of 1.155 has 90-fold reduced (1.8 nM) D3 affinity compared to trans isomer.
Tetrahydroisoquinoline derivative 1.156 has somewhat low D3 affinity, while, 1.23 (SB-277011)
is a potent and selective D3 receptor antagonist (K i = 4.0 nM, >60-fold selective over other DA
receptors).237,

238

Novel

D3

antagonists

having

pyrazolyl

substituted

thiopropyltetrahydrobenzazepine (1.157) and its congener (1.158) having fused tricyclic
benzazepine have been developed, possessing binding affinities 1.0 nM (1.157) and 2.1 nM (1.158)
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with improved bioavailability profile.239, 240 The similar series of “C-linked” analogues were found
to preserve high activity and preference at D3 receptor. The representative compounds 1.159 and
1.160 have D3 Ki values of 3.2 nM and 2.5 nM and better selectivity (>100-fold) versus D2
receptors. In addition both compounds displayed high oral bioavailability (84%) and longer half
life (> 6h), which make them attractive lead compounds for further assessment. 241
Having discussed broadly, variant dopaminergic receptor activities present in several core
molecular structures can be summarized as shown in Table 1.12.

Table 1.12: Summary of dopaminergic properties displayed by different chemical scaffold
Molecular Scaffold
Arylbenzazepine

D1 receptor ligand
Ag. Ant. P. Ag.
√
√
√

Conformationally
constrained
arylbenzazepine

D2 receptor ligand
Ag. Ant. P. Ag.

D3 receptor ligand
Ag.
Ant. P. Ag.

√

Dihydrexidine,
dinapsoline

√

√

Aporphine

√

√

Arylpiperazine/
piperidine

√
√

Dibenzazepine
√
√
Aminotetralin
√
√
4-phenylpiperazine
√
√
√
Ag. = agonist, Ant. = antagonist, P. Ag. = partial agonist
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√

√

√

√
√
√

√

√
√

1.4

Limitations with dopaminergic agents related to their clinical use
With respect to the clinical use of D1 dopamine agonists, poor pharmacokinetic profiles

and adverse effects of the agent are likely to limit its clinical value. Hypotension was the major
reason for the early termination of the pilot human trial on intravenous dihydrexidine (1.5).
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Several compounds, with high binding affinity and selectivity for the D1 receptor had even entered
clinical trials as anti-parkinson or anti-psychotic drugs, but were discontinued later. These ligands
include, for example, SKF-81297 (1.7), SKF-83959 (1.8), SKF-77434 (1.9), and SKF-38393
(1.10).243-245 A-77636 (1.6) has rewarding and antiparkinson effects in animal studies, but its high
potency and long duration of action causes D1 receptor downregulation and tachyphylaxis.246 In
addition to their low intrinsic partial agonist activity, the failure of these compounds was largely
due to poor oral bioavailability and rapid tolerance. The catechol moiety, that seems a necessary
component of D1 agonist activity, causes major problems related to low bioavailability. Ecopipam
(1.50a) was studied extensively for the treatment of obesity, but it faces limitations of poor oral
bioavailability. Moreover, it lacks apparent antipsychotic effect and fails to attenuate the subjective
effects of cocaine.247, 248 Apomorphine (1.78) is one of the clinically available dopamine agonist
that has been shown to be markedly efficacious for patients with advanced PD. Its oral use is
limited by both pharmacokinetics and drug-related azotemia. Parenteral use has been limited by
side effects including severe nausea, vomiting, orthostatic hypotension, local skin irritation, plus
the inconvenience of the pump required for drug administration.249, 250
In terms of D2 receptor binding, for pure D2 antagonists, there is a narrow window between
the threshold for antipsychotic efficacy and that for side effects like EPS and hyperprolactinemia.
To avoid these adverse effects, atypical antipsychotics are endowed with mixed receptor binding
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profile. However, some of these agents (especially clozapine 1.16, olanzapine 1.113, and
quetiapine 1.17) strongly promote weight gain and result in adverse metabolic effects, including
type 2 diabetes mellitus, hyperlipidemia, and hypertension. 251
Apart from the mixed D2 and D3 agonists, pramipexole (1.127), ropinirole (1.129), and
rotigotine (1.123), selective high-potency D3 ligands (especially D3 partial agonists and
antagonists) entering clinical trials are rare. SB-277011A (1.23) is a highly selective D3 receptor
antagonist with good oral availability and significant effects in many models of drug seeking and
reinstatement. However, this compound was not studied clinically due to in vitro metabolism
studies in liver microsomes that demonstrated rapid metabolism by aldehyde oxidase, predicting
low bioavailability in humans.252 In a similar way, NGB2904 (1.24), could not enter in clinical
trials because of its limited bioavailability and poor pharmacokinetics owing to its high
lipophilicity.75 The most studied D3 partial agonist BP-897 (1.28) had entered clinical trials for
the treatment of drug addiction, but the results are not promising. Nevertheless, its intrinsic
efficacy at D3 receptors has been disputed, depending on what functional assay is used for
assessment.253, 254
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Chapter 2: Tetrahydroprotoberberine alkaloids and derivatives

2.1

Introduction
Tetrahydroprotoberberines (THPBs) are a class of naturally occurring tetracyclic alkaloids

that contain an isoquinoline core, and are a subclass of the protoberberine alkaloids. The general
structure (Figure 2.1) contains two isoquinoline rings fused in [3,2-a] fashion to generate a
stereocenter at C14 position. More commonly ring A and ring D are substituted with oxygen
functionalities at C2, C3, C9 and C10 positions in THP natural products, for example, (-)stepholidine ((-)-SPD, 2.1), (-)-tetrahydropalmatine ((-)-THP, 2.2), (-)-isocorypalmine ((-)-ICP,
2.3), (-)-canadine or (-)-tetrahydroberberine ((-)-THB, 2.4), (-)-scoulerine ((-)-SCL, 2.5), (-)stylopine (2.6), (-)-sinactine (2.7), and (-)-cheilanthifoline (2.8). While, less common is the class
of “pseudo-THPBs” wherein the oxygen substitutions are on C2, C3, C10 and C11 positions, for
example, (-)-corytenchine (2.9), (-)-xylopinine (2.10), and (-)-govadine (2.11).

48

2.2

Occurrence
The tetrahydroprotoberberines, occur in at least seven plant families including

Menispermaceae, Papaveraceae, Annonaceae, and Euphorbiaceae.255-258 THPB alkaloids are
widely distributed in various species of genus Stephania (Menispermaceae) and genus Corydalis
(Papaveraceae). The genus Stephania is a large family of about 350 species, distributed in warmer
parts of the world. The members of this family are mostly slender herbs or shrubs but rarely trees
with peltate leaves and umbelliform flowers. In traditional medicine, these plants have been used
for the treatment of

tuberculosis, dysentery, asthma, inflammation fever, and intestinal

complaints.259-261 Over the last 50 years, an ample amount of work has been done on several of
these plants because of their medicinal importance. More than 200 alkaloids including
tetrahydroprotoberberines along with other minor constituents have been isolated from these
plants. Different THPB alkaloids isolated from different species of genus Stephania are listed in
Table 2.1 and their structures are shown in Figure 2.2.
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Table 2.1: THPB alkaloids from genus Stephania
Stephania species

THPB alkaloid/s

Stephania bancroftii262

(-)-THP (2.2), (-)-corydalmine (2.12)

Stephania elegans263

(-)-N-methylcorydalmine (2.13), (-)-cyclanoline(2.14)

Stephania glabra264, 265

Stephania pierrei266
Stephania rotunda267

(-)-ICP (2.3), (-)-capaurine (2.15),
(-)-corydalmine (2.12), (-)-SPD (2.1),
(-)-corynoxidine (2.16), (-)-tetrahydrojatrorrhizine (2.17), (-)tetrahydropalmatrubine (2.18)
(-)-N-methyltetrahydropalmatine (2.19), (-)-xylopinine (2.10), (-)capaurine (2.15),
(-)-THP (2.2)
(-)-SPD (2.1), (-)-THP (2.2)
(-)-corynoxidine (2.16), (-)-xylopinine (2.10)
(-)-corydalmine (2.12)

The genus Corydalis contains about 350 species such as C. melifolia, C. ambigua, C.
decumbens, C. ternate, C. impatiens and C. yanhusuo in the family Papaveraceae. It is most diverse
in China, which has over 290 species, mainly distributed in the southwest regions. Up to now,
different classes of isoquinoline alkaloids have been found in Corydalis species including
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aporphine,

protopine,

protoberberine,

tetrahydroprotoberberine,

benzo[c]phenanthridine,

benzylisoquinoline, and morphinan. THPB alkaloids derived from Corydalis species as well as
from other plants are listed in detail in Table 2.2 and the structures of these alkaloids are shown in
Figure 2.3.
Table 2.2: THPB alkaloids found in Corydalis species and other plants
Plant source

Corydalis impatiens268

Corydalis yanhusuo269

Corydzlis meifolia270
Corydalis turtschaninovii 271

THPB alkaloid/s
(-)-cavidine (2.20), (-)-stylopine (2.6)
(-)-tetrahydrocorysamine (2.21), (-)-apocavidine (2.22), (-)tetrahydroepiberbeine (2.23)
(-)-cheilanthifoline (2.24), (-)-isoapocavidine (2.25)
(-)-corydaline (2.26), (-)-THP (2.2), (-)-stylopine (2.6), (-)canadine (2.4)
(-)-ICP (2.3), (-)-corypalmine or tetrahydrojatrorrhizine
(2.17)
(+)-sinactine ((+)-2.7), (-)-apocavidine (2.22)
(-)-stylopine (2.6), (+)-cavidine (2.20)
(-)-cheilanthifoline (2.24)
(+)-stylopine (2.6), (+)-corydaline (2.26)
(-)-demethylcorydalmine (2.27), (-)-ICP (2.3)

Corydalis clarkei272

caseanidine (2.28), clarkeanidine (2.29)

Corydalis remota273

corymotine (2.30)

Arcangelisia gusanlung
(Menispermaceae)274

(-)-gusanlung E (2.31), (-)- THP (2.2)
oxotetrahydroplamatine (2.32), gusanlung B (2.33),
corydaline (2.26), tetrahydrothalifendine (2.34)

Annona spinescens
(Annonaceae)275

(-)-pessoine (2.35), (-)-spinosine (2.36)

Annona cherimolia Mill.
(Annonaceae)276

(-)-corytenchine (2.9)

Croton hemiargyreus.
(Euphorbiaceae) 277

hemiargyrine (2.37)
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2.3

Synthesis of THPBs
Several approaches have been adopted to synthesize tetrahydroprotoberberines. Significant

challenges that still persist in the synthesis of the THPB scaffold, are introducing the four
substituents ortho to each other on the future ring D and introduction of the stereocenter at C14
position. While building the THPB scaffold, based on which ring closure takes place last as shown
in Figure 2.4, currently available synthetic methods can be categorized as below;
2.3.1

Via late stage closure of ring B
2.3.1.1 Ring B closure via bond formation between ring A and C14 carbon
2.3.1.2 Ring B closure via bond formation between ring A and C5 carbon
2.3.1.3 Ring B closure by bond formation between C6 carbon and nitrogen

2. 3.2

Via late stage closure of ring C
2.3.2.1 Ring C closure via adding C8 carbon between ring D and nitrogen
2.3.2.2 C-N bond formation between nitrogen and C8 carbon pre-established on ring D
2.3.2.3 Ring C closure via bond formation between ring D and C13 carbon
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2.3.1

Via late stage closure of ring B

2.3.1.1 Ring B closure via bond formation between ring A and C14 carbon
One strategy for late stage construction of ring B of the THPB core structure, involves
synthesizing the benzylisoquinoline portion in the end with the formation of a bond between the
C14 carbon and aromatic ring A.278 According to this method (shown in Scheme 2.1), o-vanillin
(2.54) was transformed to tosyl protected aminoacid (2.55) and this acid, after chlorination
underwent Friedel-Craft condensation to get tetrahydroisoquinoline (2.56). In compound 2.56,
deprotection and reduction was achieved in same step using sodium bis-methoxyethoxyaluminum
dihydride (red Al) to furnish 2.57. Linkage with phenylethyl iodide (2.58) followed by ring closure
with concentrated HCl produced THPB scaffold in compound (2.60). The final cyclization step
was quite low yielding (30 %) in this synthetic method.

Amongst several approaches, one of the most commonly used to form the ring A/ring B
tetrahydroisoquinoline motif of the THPB scaffold, is via using an appropriate Bischler
Napieralski cyclization condition.279-281 Yasuda et al. designed and synthesized (±)-THP (2.2)
using a similar synthetic strategy wherein, the ring B was formed towards the end of synthesis via
Bischler Napieralski condition in the cyclic amide 2.64.282 As shown in Scheme 2.2, secondary
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amine 2.62 derived after reductive amination of primary amine 2.61 and aldehyde 2.54, was
acylated with α-chloro-α-(methylthio)acetyl chloride and subjected to intramolecular FriedelCrafts cyclization in presence of stannic chloride to yield isoquinoline compound 2.64. A
secondary amine similar to 2.62 but

without the bromine atom on ring A, proved unsuccessful due to providing a mixture of desired
isoquinoline compound and the seven-membered lactam benzazepinone 2.65 having cyclization
on ring A. Blocking the para position of methoxy group in ring A prevented this undesirable
cyclization and produced product 2.64 solely. The Bischler-Napieralski cyclization of 2.64
followed by reduction of intermediate iminium ion produced (±)-THP (2.2).
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2.3.1.2 Ring B closure via bond formation between ring A and C5 carbon

Another connectivity that has been utilized to form ring B, is through a bond formation
between C-5 carbon and C-5α carbon; the Pomeranz-Fritsch reaction remained the prominent one
to serve this purpose. Using this strategy (shown in Scheme 2.3), (-)-THP (2.2) was synthesized
from (R)-1-amino-2-methoxymethylpyrrolidine (RAMP) hydrazone 2.66 and 2,3-dimethoxy-6methylbenzamide 2.67.283 In this synthesis, deprotonation of 2.67 was achieved by using the
mixture of tetramethylethylenediamine (TMEDA) and sec-butyllithium. Nucleophilic addition of
lithiated 2-methylbenzamide to the CN double bond of hydrazone (R)-2.66 from less hindered face
followed by cyclization produced (S,R)-2.68. Chiral auxiliary on nitrogen was removed by using
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BH3·THF followed by HCl with concomitant reduction of carbonyl group to prepare isoquinoline
compound (S)-2.69. Pomeranz-Fritsch precursor 2.70 was obtained by addition of two carbon
chain of bromoacetaldehyde diethyl acetal using S N2 condition. Pomeranz-Fritsch cyclization was
carried out using the mixture of conc. HCl and acetone to render intermediate 2.71 as a
diastereomeric mixture which was subjected to dehydration to afford (-)-THP (2.2) with 98% ee.
Transformation from (S)-2.69 to (-)-THP (2.2) was also effected via the Pummerer reaction using
2.72 (Figure 2.5), but after the cyclization, reductive desulfurization of the intermediate was a low
yielding (30%) step. On the other hand, Friedel-Crafts cyclization conditions were not effective to
induce the cyclization in compound 2.73 (Figure 2.5) to provide (-)-THP (2.2).283

2.3.1.3 Ring B closure by bond formation between C6 carbon and nitrogen
An alternate plan to construct ring B of the THPB scaffold is via forming the C-N bond in
the final stage of the synthesis as demonstrated by Yang et al to synthesize (-)-SPD (Scheme
2.2).284 This method to synthesize (-)-SPD (2.1) exploits a similar approach to install the chiral
center as adopted by Enders to synthesize (-)-THP (2.2) (Scheme 2.3), i.e. chiral auxiliary aided
nucleophilic addition of a tetrasubstituted future ring D moiety to an appropriate imine (2.66 in the
case of (-)-THP and 2.79 in the case of (-)-SPD). As shown in Scheme 2.4, primary alcohol 2.75
derived from substituted phenylacetic acid, was brominated and protected to grant 2.76. Lithiumhalogen exchange followed by reaction with DMF introduced the aldehyde group in compound
2.77. After condensation with chiral sulfinylamide 2.65, aldehyde 2.77 was transformed to
sulfinimine 2.79. Nucleophilic addition of lithiated tetrasubstituted benzonitrile 2.80 to sulfinimine
2.79 followed by sequential steps of concomitant removal of silyl group and N-sulfinyl auxiliary,
and hydrolysis of nitrile group produced 2.83. In final steps, tosylation of hydroxyl group rendered
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cyclization of ring B which was followed by reduction and deprotection to procure (-)-SPD (2.1).
Apart from having a lengthy procedure to synthesize 2.66 (5 steps) and 2.80 (6 steps) as well as
their further transformation to (-)-SPD (2.1) (6 steps), the nucleophilic addition step was low
yielding because of self condensation of 2.80.
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2.3.2

Via late stage closure of ring C

2.3.2.1 Ring C closure via adding C8 carbon between ring D and nitrogen
The most commonly used approach to synthesize the THPB scaffold is via an
intramolecular

Mannich

cyclization

of

a

relevant

benzyltetrahydroisoquinoline

with

formaldehyde. The major complication in this method is regiochemical control in the closure of
ring C and getting a mixture of para and ortho cyclized products or exclusively giving the former
product. This approach is the most widely utilized route to synthesize “pseudo-THPBs” in a
racemic and enantioselective manner.279, 280, 285 Using this approach, Battersby et al. synthesized ()-SCL (2.5) and coreximine (2.85) (Scheme 2.5) wherein, benzyltetrahydroisoquinoline (2.84)
bearing 3-hydroxy substituted benzyl group underwent Mannich condensation to produce a 2:1
mixture of THPBs scoulerine (2.5) and coreximine (2.85).286 Varying the pH gave a higher yield
of the desired 9,10 substituted product; however tedious chromatographic separation remained
necessary.287
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To tackle this problem, a strategy was used wherein compound 2.84 was brominated to
block the para position (2.86) for Pictet-Spengler cyclization to afford the single product 2.87 and
it was transformed to (-)-SCL (2.5) by debromination. The disadvantage in this method apart from
adding two more steps in the synthesis, was that the cyclization step was low yielding, most likely
due to ring deactivation by halogen atom.288
Another similar approach in the synthesis of 9,10 substituted THPBs is to use an
preestablished ipso directing group in ring D. Schore et al. synthesized five different THPB alkoids
using a trimethylsilyl moiety as an ipso-directing ring closure functionality.289 As shown in
Scheme 2.6, aryl silyl agent 2.90, which mimics the substitution patern of ring D of THPB, was
synthesized from tertiary amine 2.89 by introducing a TMS group into the benzene ring with the
aid of n-BuLi. Subsequent synthetic transformation lead to benzyltetrahydroisoquinoline 2.92 with
ipso-directing silyl substituted benzyl moiety. The Pictet-Spengler cyclization was accomplished
using formaldehyde in acidic condition to produce (-)-THP (2.2) in 46% overall yield and 55% ee.
In the case of (-)-sinactine (2.7) synthesis, the final cyclization no longer displayed regioselectivity
and the product obtained was almost a 1:1 mixture of both (-)-sinactine (2.7) and 2.94. That
indicates the ineffectiveness of this method when having strongly activating substituent like
methylenedioxy group on ring D.
In a similar manner, Pictet-Spengler cyclization involving the participation of the sulfinyl
group as an ipso-director in the electrophilic aromatic substitution reaction, opened new synthesis
of THPBs (shown in Scheme 2.7).290 Using this method, the synthesis of optically pure (-)-THP
(2.2) and (-)-canadine (2.4) was performed with overall isolated yields of 33% and 34%,
respectively. This synthesis was commenced by reaction of ortho-sulfinyl benzyl carbanion
derived from 2.95 and N-sulfinylimines 2.96 and 2.97 to cater intermediates 2.98 and 2.99.
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Subsequent sulfinyl- directed microwave assisted Pictet-Spengler cyclization produced (-)-THP
(2.2) and (-)-canadine (2.4).
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Kroutil and group members came up with a unique approach in the synthesis of THPBs.
As shown in Scheme 2.8, the biocatalytic property of berberine bridge enzyme (BBE) for oxidative
C-C bond formation was employed to synthesize steroselectively (-)-SCL (2.5) from
benzylisoquinoline (2.100).291 This transformation takes place via oxidative C-H activation of the
substrate’s N-methyl group at the expense of molecular oxygen, a reaction unparalleled in organic
synthesis.292

2.3.2.2 C-N bond formation between nitrogen and C8 carbon pre-established on ring D
To construct the continuously tetrasubstituted ring D is the most eminent problem towards
the synthesis of a 9,10 substituted THPB scaffold. Having a tetrasubstituted pattern on ring D and
closure of ring C during the late stage of synthesis is a common approach taken up in many
synthesis of THPB scaffold, especially for (-)-SPD (2.1).293-295 Several examples of
tetrasubstituted intermediates (shown in Figure 2.6) have been employed as a surrogate to ring D
in the synthesis of the THPB core.
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By executing a similar strategy, Yang and group members reported the first
enantioselective synthesis of (-)-SPD (2.1) (Scheme 2.9).293 The key intermediate lactone (2.102)
was synthesized from the substituted phenylacetic acid (2.101) through hydroxymethylation
directed by phenylboronic acid in the presence of paraformaldehyde. Aminolysis of the lactone
with substituted phenylethylamine produced amide (2.103). It was eventually transformed to (-)SPD (2.1) employing the key steps of Bischler-Napieralski cyclization, Noyori’s asymmetric
reduction followed by ring C closure via chlorination of primary alcohol. This route seemed
promising to apply further for the synthesis of diverse THPB compounds to study their biological
activities. However, transformation from phenylacetic acid (2.101) to lactone (2.102) was
inefficient and troublesome and it was the bottleneck for this synthetic route.
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Recently, the same group synthesized (-)-SPD (2.1) using bromo compound 2.109 which
was derived from chiral auxiliary protected amine 2.108 and bromo substituted phenylacetic acid
2.107 (Scheme 2.10).294 Serving as an alternate of lactone 2.102, tetrasubstituted phenylacetic

acid 2.107 was employed in this synthesis to construct the ring D of (-)-SPD (2.1). Dihydroxy
benzaldehyde 2.104 was selectively protected with an isopropyl group, which was followed by
ortho bromination to produce tetrasubstituted benzaldehyde 2.105. Sequential steps of reduction
of aldehyde, chlorination of alcohol, cyanation, and hydrolysis of intermediate nitrile compound
produced acid 2.107 from aldehyde 2.105. Acid 2.107 was coupled with chiral auxiliary protected
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secondary amine 2.108 to afford amide 2.109. A sequence of reactions including BischlerNapieralski cyclization and reduction installed the chiral center in compound 2.110. The C-8
carbon of ring D was introduced in compound 2.110 via lithium-halogen exchange followed by
treatment with methyl chloroformate to provide compound 2.111. Removal of the chiral auxiliary
proceeded with simultaneous closure of ring C to present the tetracyclic scaffold of compound
2.112 which was further transformed to (-)-SPD (2.1) via reduction of the carbonyl group and
deprotection of the phenolic hydroxyl groups.

Engaging a similar strategy to synthesize (-)-THP (2.2) (as shown in Scheme 2.11), to
furnish ring D, Meyers et al. employed carboethoxy compound 2.114 derived from tertiary amine
2.113.295 Transformation from 2.113 to 2.114 was carried out via metalation followed by addition
of a formyl group to afford intermediate alcohol which was protected with TBS group. Chiral
formamidine 2.117 was synthesized from isoquinoline 2.115 by transamination with a valine
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derivative 2.116. In this route, the crucial step involves addition of the carbanion of 2.114

to

chiral formamidine 2.117 to furnish intermediate 2.118, which was advanced to compound 2.119
via removal of the formamidine auxiliary. Deprotection of the silyl group was accompanied by
ring closure to yield (-)-THP (2.2). Carbanions having an ortho carbonyl substituent in place of a
methyl silyl ether in compound 2.114 were tried first, but owing to an unexplainable problem of
racemization of the chiral center, this was switched to compound 2.114.

2.3.2.3 Ring C closure via bond formation between ring D and C13 carbon
Having stereocenter established in isoquinoline moiety and addition of ring D part followed
by closing the ring C at C13 carbon is an interesting way to construct THPB core. Pyane employed
chiral β-amino sulfoxide (2.120), conveniently prepared by conjugate addition of amine to chiral
vinyl sulfoxide296, 297, to synthesize (+)-THP (2.2).298 Chiral aminosulfoxide 2.120 was condensed
with aldehyde to provide intermediate compound 2.12, which was subjected to an intramolecular
Pummerer reaction to grant a single diastereomer 2.122. Reductive desulfurization in compound
2.122 provided (+)-THP (2.2).
Very recently, Mhaske et al. synthesized various THPB and 8-oxoprotoberberine alkaloids
via a unique intramolecular Pd-catalyzed tandem oxidative olefin amidation/C−H activation. 299
The corresponding amide 2.123 for (±)-THP (2.2), (derived after coupling of primary
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amine and dimethoxy benzoic acid) was iodinated using iodine and silver triflate to afford
iodoamide 2.124. A vinyl unit was inserted into compound 2.124 via Stille coupling to yield
vinylamide 2.125. After optimizing reaction conditions, C−N and C−C bonds were formed in a
single step by intramolecular tandem amidation/C−H activation sequence to produce 8oxoprtoberberine 2.32 which was reduced to (±)-THP (2.2).
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Owing to their widespread occurrence in nature, diverse biological activity, and unique chemical
properties, THPB alkaloids have become interesting targets for organic synthesis. In the past two
decades a large number of chiral and racemic synthetic methods have been reported for the
synthesis of THPB scaffold. General approaches adopted to synthesize THPB alkaloids include,
Bischler-Napieralski cyclization/simple reduction or catalytic hydrogenation (for enantioselective
methodologies) followed by either Mannich type condensation or ipso directing strategies to close
the second ring. Newer trends have been based on diastereoselective syntheses using chiral
auxiliaries, annexed either to or around the nitrogen atom. In this context, the addition of carbon
nucleophile from a tetrasubstituted benzyl moiety to the isoquinoline C=N double bond has been
the most often explored strategy.
Although THPB compounds are readily synthesized in a racemic manner, still there is a
demand to develop simple and efficient methods that would be applicable to the preparation of
enantiopure compounds. Generally the available methodologies bear various limitations such as:
e.g., multistep procedures, lack of diversity, moderate to poor yields, unsatisfactory regio- and
stereo-selectivity, etc. Therefore, exploration of more efficient and simpler synthetic strategies still
need to be undertaken.

2.4

Biological activities of tetrahydroprotoberberine alkaloids
Plants containing THPBs alkaloids have long been used traditionally in China, India, Japan

and other Eastern Asian countries as analgesics, anti-inflammatory, anti-infectious, anti-allergic,
anxiolytic, anti-venom, anti-arrhythmic, and in the treatment of rheumatism, gastric issues, and
duodenal ulcers.267, 269, 271, 300 Major attention has been developed towards the pharmacological
importance of THPB alkaloids (-)-SPD (2.1), (-)-THP (2.2), and (-)-govadine (2.11) have been
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studied for schizophrenia and psychostimulant drug abuse because of their dopamine receptor
pharmacological profiles.

2.4.1

CNS activities of THPB alkaloids
In functional assays, (-)-SPD (2.1) has been identified as an agonist at the dopamine D1

receptor and as an antagonist at the dopamine D2 and D3 receptor. 301, 302 Also, the online database
of the National Institute of Mental Health (NIMH), Psychoactive Drug Screening Program (PDSP)
revealed (-)-SPD (2.1) to have high affinity mostly for dopaminergic receptors (K i value for D1 =
5.9, D2 = 974.3, D3 = 30.1, D4 = 3748, D5 = 4.4 nM). (-)-SPD (2.1) significantly potentiated the
therapeutic effects of typical antipsychotic drugs (phenothiazenes or butyrophenones) and
markedly reduced the EPS induced by these drugs. Additionally, (-)-SPD (2.1) alone also exhibited
a significant antipsychotic effect.303 (-)-SPD (2.1) was demonstrated to be superior to perphenazine
(2.1) in antipsychotic efficacy and treating the negative symptoms, and, unlike perphenazine, (-)SPD induced no extrapyramidal symptoms.304 The effects of (-)-SPD (2.1) in increasing forelimb
and hindlimb retraction time (FRT and HRT) in the paw test and in reversing the apomorphine
induced disruption of prepulse inhibition was investigated. 305 In the paw test, all antipsychotics
increase the HRT and only the typical antipsychotics affect the FRT allowing a differentiation
between typical and atypical antipsychotics. The data show that (-)-SPD (2.1) behaved like an
antipsychotic with more similarity to clozapine. In the paw test, (-)-SPD (2.1) dose dependently
increased the HRT, while it only increased the FRT at the highest dose tested. 305 Since
theoretically, an agent with partial D1 receptor agonistic and D3 antagonistic properties may
reduce drug abuse liability, the potential role of THPBs in the treatment of drug abuse has recently
received greater attention. Clinical trial and animal studies demonstrated that THPBs including (-
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)- SPD (2.1), (-)-ICP (2.3), and (-)-THP (2.2) are potential candidates for the treatment of drug
abuse. A study in animals showed that (-)-SPD (2.1) inhibits acquisition, maintenance, and reacquisition of morphine conditioned place preference (CPP).306 The effect of pretreatment with ()-SPD (2.1) on heroin-seeking behavior induced by heroin priming was investigated. Pretreatment
with (-)-SPD (2.1) inhibited the heroin-induced reinstatement of heroin-seeking behavior.
Importantly, (-)-SPD (2.1) did not affect locomotion, indicating that the observed effects of (-)SPD (2.1) on reinstatement are not the result of motor impairments. 307 In a pharmacological study
in mice, (-)-SPD (2.1) was shown to increase dose-dependently c-Fos gene expression in neurons
of the ventrolateral preoptic area, a sleep center in the anterior hypothalamus. That indicates, (-)SPD initiates and maintains non rapid eye movement sleep with activation of the sleep center,
suggesting its potential application for the treatment of insomnia. 308 In Parkinson’s disease rat
model, (-)-SPD (2.1) was demonstrated to attenuate the development and expression of L-DOPA
induced dyskinesia.309
In various investigations, the effects of (-)-THP (2.2) on cocaine self-administration and
cocaine-induced reinstatement have exhibited promising results towards the treatment of cocaine
addiction.310, 311 (±)-THP (2.2) possesses anxiolytic effects avoiding sedation and myorelaxation
when administrated orally to mice at low dose regime. Results from the elevated plus-maze show
that (±)-THP (2.2) increases the percentage of entries and time spent by rats in open arms to basal
levels in this model for anxiety.312 The antinociceptive effect of (±)-THP (2.2) was evaluated using
different pain models including formalin-induced nociception, writhing test and bee venominduced hyperalgesia. Results suggested that (±)-THP (2.2) more effectively inhibited visceral
nociception and hyperalgesia than persistent nociception. 313, 314
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Effect of (-)-ICP (2.3) on cocaine addiction was evaluated using animal models.
Administration of (-)-ICP (2.3) before cocaine reduced cocaine-induced locomotor sensitization
and conditioned place preference (CPP).315 Pseudo-THPB alkaloid (-)-govadine (2.11) exhibited
antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2
receptors.316 (-)-govadine (2.11) demonstrated its ability to improve performance of the
dizocilpine-induced impairment in the paired associate learning task. This behavioral effect
correlates the ability of (-)-govadine to its antipsychotic potential.317

2.4.2

Non-CNS activities of THPB alkaloids
Investigations also suggest that (-)-SPD (2.1) possesses pronounced hypotensive effect

mediated through α1-adrenoceptor inhibition.318 In vitro, (-)-SPD (2.1) inhibited lipid peroxidation
and scavenged hydroxyl free radicals due to its free hydroxyl group as well as other properties. 319
(-)-SPD (2.1) improved cell differentiation, contact suppression, and expression of the tumour
suppressor gene protein (p53), and it inhibited cell growth, colony formation, and expression of
proto-oncogenes (C-myc bcl-2).320 Lin and group members studied the anti-hypertensive effects
of (±)-THP (2.2) and found it to act via 5-HT2A and/or D2 receptor antagonism.321 In a similar
study, (-)-THP (2.2), (-)-THB (2.4) and (-)-SPD (2.1) showed anti-ischemia and cardio-protective
property, acting directly on cardiomyocytes.322 The anti-inflammatory effect of (-)-THP (2.2) was
studied in vitro using human monocytic cell line. It was found that (-)-THP (2.2) inhibited
lipopolysaccharide (LPS) induced interleukin-8 (IL-8) production in a dose-dependent manner via
mitogen activated protein kinase (MAPK) inhibition. 323
Significant inhibition of spore germination was seen against several phytopathogenic fungi
by (-)-ICP (2.3) and (-)-corydalmine (2.12).324 Recently, corydalmine (2.12), and other THPB
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alkaloids were demonstrated to have antibacterial activity toward methicillin-resistant
Staphylococcus aureus.325 Lee and co-workers isolated various THPB alkaloids from C.
turtschaninovii and studied their inhibition activity against low density lipoprotein oxidation. (-)demethylcorydalmine (2.27) and (+)-stylopine (2.6) were the most active alkaloids with IC50
values of 2.1 and 2.0 µM.326 Antiplasmodial activity of (-)-SCL (2.5) was studied along with other
alkaloids isolated from C. dubia and it has shown remarkable activity against TM4/8.2 (transgenic
plasmodium) strain with IC50 values of 1.78 µg ml-1.327 In a similar manner coraximine (2.85)
exhibited antimalarial activity against P.falciparum.328 Experimental results obtained in a study
demonstrate that (±)-canadine (2.4) is effective in anti-lipid peroxide production and acts as an
antioxidant agent.329 (-)-canadine (2.4) also showed more than 80% inhibition in platelet
aggregation induced by different platelet aggregating agents. 330 Many different THPB alkaloids
including (-)-THP (2.2), (-)-ICP (2.3), (-)-canadine (2.4), and (-)-stylopine (2.6) have displayed
chemopreventive and anti-tumor activity.331

2.5

Structure-activity relationship studies at dopamine receptors
Since THPBs and dopamine share some structural similarities, various natural and

synthetic derivatives of THPBs have been studied for their binding affinity at dopamine receptors,
more specifically at DA D1 and DA D2 receptors.
In one study, the influence of the trisubstitution with methoxy, hydroxyl or chloro at the 2,
3- and 9 or 11 positions in THPB was evaluated for dopaminergic activity. Eleven trisubstituted
analogues of THPB (2.72–2.82, shown in Figure 2.7) were synthesized and tested for their binding
affinity (Table 2.3) at DA D1 and D2 receptors.332 Results of this SAR study indicate that protected
phenolic hydroxyls showed a lower affinity for DA D1 and D2 receptors than their corresponding
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homologues with free hydroxyl groups (see 2.72 vs 2.73, 2.74 vs 2.75, 2.77 vs 2.79, 2.78 vs 2.80
in Table 2.3). Introduction of the chlorine atom in to ring A of THPBs increases affinity for both
D1 and D2 receptors (2.73 vs 2.79, Table 2.3). A decrease in affinity

Table 2.3: Binding affinity data of 2,3,9 and 2,3,11 substituted THPBs
Ki (µM)
Compound

Substitution

D2/D1
D1

D2

2.72

3-Cl-2,11-diMeO

1.80

2.05

1.1

2.73

3-Cl-2,11-diOH

0.10

0.19

1.9

2.74

2,3-diBnO-11-MeO

40.60

40.87

1.0

2.75

2,3-diOH-11-MeO

1.10

0.08

0.07

2.76

2,3-OCH2O-11-MeO

2.40

1.33

0.5

2.77

2,3,11-triMeO

4.31

8.54

2.0

2.78

2,3,9-triMeO

3.923

0.39

0.1

2.79

2,3,11-triOH

2.96

0.40

0.1

2.80

2,3,9-triOH

3.78

0.09

0.02

2.81

2,3-OCH2O-11-OH

33.00

7.51

0.2

2.82

2,3-OCH2O-9-OH

0.34

0.04

1.1

at the D2 receptor was observed in 2.76c and 2.81e after the introduction of a methylenedioxy
group at 2, 3 positions. Compounds 2.73b and 2.82f in this series displayed the highest affinity for
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both DA D1 and D2 receptors. This study demonstrated that affinity for DA receptors was higher
with analogues having hydroxyl group in position 9 than in position 11 (2.82 versus 2.81).
In two sets of SAR studies, Hong Liu and group members designed and synthesized a series
of novel as well as known tetrahydroprotoberberine compounds (representative novel analogues
2.83-2.89 are shown in Figure 2.8) by introducing various substituents (such as methyl, methoxy,
hydroxymethyl,

and

methylenedioxy

groups)

at

different

positions

of

the

THPB

pharmacophore.333, 334. The binding affinity data for these analogues at dopamine D1 and D2
receptors is summarized in Table 2.4.

Tetra-alkoxy analogues ((-)- THP 2.2 and (-)-canadine 2.4) exhibited reduced binding
affinity for both DA D1 (Ki = 231 nM and 66 nM respectively) and D2 receptors (Ki = >5000 nM
and 119 nM respectively). Monohydroxy compound 2.3 ((-)-ICP) shows higher selectivity than
parent compound (-)-SPD (2.1) at D1 receptor over D2. Changing the C9, C10 di-methoxy
substitution in ring D of (-)-ICP (2.3) to C9, C11 di-methoxy produced highly D1 receptor selective
and potent compound 2.83. In addition, a congener of 2.83, compound 2.84 with C10-C11
methylenedioxy substitution possess similar high binding affinity at the D1 and D2 receptors (4.2
nM for D1 receptor and 32.1 nM for D2 receptor) with (-)-ICP (2.3). However, analogue 2.84
shows functional antagonism at DA D1 receptor in contrast to (-)-ICP (2.3), which is a D1 partial
agonist.
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Table 2.4: Structures of and binding affinity data for THPB analogues

No.

R1

R2

R3

2.1
2.2
2.4
2.3
2.83
2.84
2.34
2.85
2.18
2.86
2.17
2.87

H
H
H
H
H
H
H
H
H
H
H
H

OH
CH3O
OCH2O
OH
OH
OH
OCH2O
OCH2CH2
CH3O
OCH2O
CH3O
CH3O

CH3O
CH3O

2.88 CH3O

H

2.89 CH3O

CH3O

R4

R5

R6

Ki (nM)
D1
D2
3.4
11
231
>5000
66
119
4.5
91
2.5
4.2
32
6.3
145
7.5
443
60
>5000
310
530
>5000

D2/D1

CH3O
OH
CH3O CH3O
CH3O CH3O
CH3O CH3O
CH3O
H
H
OCH2O
CH3O
OH
CH3O
OH
OH
CH3O
OH
CH3O
CH3O CH3O
OH
CH3O

H
H
H
H
CH3O

CH3O

CH3O

H

CH3O

8.0

82%
Inhib.

-

CH3O

CH3O

H

CH3O

23.8

52%
Inhib.

-

CH3O
CH3O
CH3O

CH3O
OH
OH

H
H
H
H
H
H

3.2
>21.6
1.8
20.2
7.6
23.0
>83
>9.4

These results suggest that the hydroxyl group at C2 may be essential to maintain potency
at the D1 and D2 receptors. Compounds 2.34 and 2.85 showed a similar high binding affinity (K i
= 6.3 and 7.5 nM) and selectivity to the D1 receptor, indicating that apart from the C2 hydroxyl,
the C10 hydroxyl group is also crucial for D1 receptor activity. Compounds 2.18 and 2.86
containing only a hydroxyl group at C9 showed reduced binding affinity for the D1 receptor with
Ki values of 334 and 60 nM. Compound 2.17 having a hydroxyl group at C3 retained a moderate
affinity for the D1 receptor, with a K i value of 310 nM. On the contrary, 2.87 containing two
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hydroxyl groups at C3 and C9 with a K i value of 530 nM were less potent than 2.17 at the D1
receptor. Compound 2.88 and 2.89 in which two phenolic hydroxy groups on the A- and D-rings
were removed, exhibited high D1 receptor binding affinity (K i = 8.0 nM and 23 nM) and
selectivity. Functional assays revealed that both these analogues were full D1 receptor antagonists.
Similar to the naturally derived alkaloids, R enantiomer of all these compounds showed
remarkably weakened binding affinity to the dopamine receptors, indicating that the C14-S
configuration in THPBs is an important determinant of receptor binding affinity.
As shown in Figure 2.9 and explained below, the previous SAR study of THPB scaffold at
DA receptor can be summarized as below;

•

Either C2 or C10 hydroxyl group is necessary for dopamine D1 receptor activity (example
2.3, 2.34, and 2.85). This indicates, the hydrogen bonding donor (OH) at C2 and C10 is a
determining factor to D1 receptor binding.

•

Antagonist activity shown by compound 2.83, 2.88 and 2.89 reveals that 2, 3, 9, 10
tetrasubstituted pattern is crucial for D1 agonistic activity

•

Reduced affinity of compound 2.17, 2.18, 2.86, and 2.87 signifies the importance of C3
and C9 alkoxy group for the dopamine receptor activity

•

S configuration of the C14 position in the THPB skeleton is a critical factor determining
receptor binding affinity
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Chapter 3: Synthesis and evaluation of stepholidine and its analogues at
dopamine receptors
3.1

Background
(-)-SPD (2.1) shows a strong preference for binding to dopamine receptors as revealed by

data from the Psychoactive Drug Screening Program (PDSP) and by many previous studies
(discussed in chapter 2). (-)-SPD (2.1) has high affinity for D1 and D3 receptors (Ki = 5.9 and 30
nM respectively) and moderate affinity for the D2 receptor (K i = 974 nM).335 (-)-SPD (2.1) has
been studied primarily due to its multi-receptor targeted profile.302,

336-338

In this regard, its

interesting pharmacological profile has led to a number of animal studies where it has shown
potential as an antipsychotic and as an anti-drug abuse agent.
The THPB scaffold of (-)-SPD (2.1), which is characterized by a 2,3,9,10 tetra-substituted
pattern and the presence of two phenol groups, makes it a distinct THPB scaffold. 339 Although
several syntheses of THPBs have been reported (discussed in chapter 2, section 2.3), an efficient,
high yielding, and concise synthesis of (-)-SPD (2.1) is yet to emerge. Moreover, the extremely
low content (~0.1%) of this compound in natural sources 265 and the need for large amounts of the
compound for further pharmacological research necessitate its total synthesis.
Though having an interesting novel, pharmacological profile, there is a need to further
optimize the potency of (-)-SPD (2.1) at dopamine receptors. In that regard compounds with <10
nM affinity at D1 and D3 receptors and with higher degrees of selectivity versus D2 receptor, will
be valuable to study in vivo.
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Until now, limited SAR data is available for this THPB scaffold332-334, 337 and it is restricted to
structural modifications in the core pharmacore including:
I.

Switching the position of phenolic hydroxyl group and methoxy moiety in aromatic
rings

II.

Introducing methoxy, methylenedioxy and benzyloxy substituents

III.

Insertion of a halogen atom in the ring A

IV.

Effect of mono, di and tri hydroxy substitution on binding affinity

Additionally, all SAR studies have been performed (discussed in chapter 2, section 2.5) at DA
D1 and D2 receptors, no SAR data is available at the D3 receptor. Deficiency of enough structure
activity relationship (SAR) data at DA D1 and D3 receptor for this THPB scaffold has to be filled.
The pharmacokinetics of (-)-SPD (2.1) and its delivery to the brain was studied in rats. 340 Key
findings in this study reveal that although (-)-SPD (2.1) exhibits good brain penetration, it has a
very poor oral bioavailability (< 2%) because of extensive pre-systemic metabolism. Findings
suggest that rapid and extensive pre-systemic metabolism of (-)-SPD (2.1), predominantly by Oglucuronidation and O-sulphation of phenolic hydroxyl groups restricts its favorable biological
profile.341
Our work addresses the above mentioned shortcomings via;
I.

Developing a practical and versatile synthetic methodology which can provide SPD
(2.1) and its analogues in larger amount for further pharmacological studies

II.

Synthesizing and studying binding affinity at dopamine receptors of diversely
substituted C3 and C10 THPB analogues

III.

Studying the effect of various substitutions on THPB scaffold on metabolic stability
against hepatic enzymes
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Our efforts and the results we have obtained are discussed in this chapter.
3.2

Synthesis of (±)-SPD

3.2.1

Retrosynthesis
For the synthesis of (±)-SPD (2.1), late stage construction of the berberine bridge (ring C)

via a Mannich-type reaction is challenging because there is a substituent ortho (i.e. the methoxy
group) to the site of ring closure. In our retrosynthetic analysis (as shown in Figure 3.1), we
visualized constructing the berberine bridge in the final stage of synthesis. We planned to
synthesize (±)-SPD (2.1) from compound 3.1, which has previously established berberine bridge
carbon on ring D that can be utilized to close ring C. We envisaged that the tetrahydroisoquinoline
moiety in compound 3.1 could be prepared from amide intermediate 3.2 via Bischler-Napieralski
cyclization/reduction conditions. Amide intermediate 3.2 is derivable from acid 3.3 (via amide
coupling with the corresponding amine). Compound 3.3, we reasoned would serve as an easily
reachable synthetic surrogate for the ring D of SPD (2.1). The acid 3.3 would be prepared from
aryl bromide 3.4.
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3.2.2

Synthesis
Commercially available bromo cresol 3.5 was protected as the ethoxymethyl ether by

reaction with chloromethoxyethane affording 3.6. Thereafter reaction of 3.6 with Lithium
diisoproylamide in the presence of dimethylmalonate gave diester 3.7.342,

343

This reaction

presumably proceeds via nucleophilic attack of malonate anion on benzyne intermediate generated
from dehydrobromination of 3.6.344 Selective hydrolysis of the aliphatic ester group was
accomplished with K2CO3 in refluxing H2O/MeOH to give acid 3.8. This acid was coupled to
readily available amine 3.9 with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) to
provide key amide precursor 3.10. Bischler-Napieralski cyclization on amide 3.10 proved to be
successful with POCl3 as dehydrating agent and acetonitrile as solvent.
This cyclization was accompanied by simultaneous removal of the ethoxymethyl
protecting group. Other dehydrating conditions (shown in Table 3.1) and solvents
(dichloromethane or toluene) were tried but gave inferior yields of imine product. BischlerNapieralski cyclization was followed by immediate reduction (due to instability of the intermediate
imines of this type) with NaBH4 to afford the 8-oxotetrahydroprotoberberine 3.11. Reduction of
the 8- oxo group of 3.11 with LAH provided an intermediate tertiary amine, which was
subsequently heated with concentrated HCl, thus effecting debenzylation to give (±)-SPD (2.1).
Thus we accomplished synthesis of (±)-SPD (2.1) with overall yield of 30% over 8 synthetic steps
starting from bromocresol 3.5.
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Table 3.1: Bischler-Napieralski conditions (step e, Scheme 3.1)
Reagent

Conditions

Yield

Solvent

Time

Temperature

PCl5 (1.5 eq.)

DCM

10 h

0 ̊ C – rt

No reaction

P2O5 (10 eq.)

DCM

10 h

rt

No reaction

POCl3 (neat)

POCl3

10 min

POCl3 (6 eq.)

Toluene

2h

100 ̊ C

58%

POCl3 (6 eq.)

CH3CN

3h

60 ̊ C

82%

3.3

Enantioselective synthesis of (-)-SPD

3.3.1

Retrosynthesis

80 ̊ C
(MW-150W)

63%

In this section we describe our attempt to develop a practical route to synthesize (-)-SPD
(2.1). It is not restricted to only synthesis of (-)-SPD (2.1); the main consideration behind our aim
is to develop a versatile synthetic method that can be extended to synthesize optically pure C3
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analogues of (-)-SPD (2.1). Following a similar approach employed in our racemic synthesis of
(±)-SPD (2.1) (section 3.2), we planned to synthesize (-)-SPD (2.1) from compound 3.11, which
has a previously established berberine bridge carbon on ring D (Figure 3.2). Compound 3.11 can
be synthesized from amide ester 3.10 via Bischler-Napieralski cyclization followed by Noyori’s
asymmetric hydrogenation of the intermediate imine. 345 Amide ester 3.10 can be synthesized from
acid 3.8 and amine 3.9 as shown in Scheme 3.1.

3.3.2

Synthesis

3.3.2.1 Unsuccessful attempts via ester 3.10
Bischler-Napieralski cyclization of amide 3.10 was achieved using POCl3 to give
intermediate imine 3.12 (shown in Scheme 3.2). The imine formed was then subjected to Noyori’s
asymmetric hydrogenation conditions. To our surprise this did not yield the desired chiral
tetrahydroisoquinoline 3.13. Instead the 8-oxoprotoberberine 3.14 was produced. One possible
cause for failure of the reduction is due to formation (and subsequent isomerization) of an acyl
iminium ion formed from reaction of the imine nitrogen (from Bischler-Napieralski reaction) with
the aryl ester group. Another possibility is that when the imine derived from 3.10 (i.e., compound
3.12) is subjected to Noyori’s reduction conditions, isomerization of the imine to an enamine
precedes the cyclization of ring C. We found that treatment of 3.12 with triethylamine (the base
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used in the Noyori’s reduction) gives 3.14. Presumably, the isomerization/cyclization steps occur
at a faster rate than Noyori’s reduction.

Nevertheless, through this attempt to achieve an enantioselective synthesis of (-)-SPD
(2.1), it was recognized that naturally occurring 8-oxoprotoberberines could be synthesized by
variations of this method. Previous syntheses of the 8-oxoprotoberberine skeleton have required
several synthetic steps and/or suffer from low yielding steps. 346-349 Thus to demonstrate the
pliability of the route, compound 3.14 was transformed to the natural product oxypalmatine (3.15,
Scheme 3.3) by removal of the C2 benzyl group followed by Williamson ether methylation. Insofar
as synthesis of oxypalmatine is concerned, this method is comparable to published methods in both
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yield and number of steps (seven steps and 22% overall yield for the present synthesis; nine steps
10% yield for the previous synthesis).350
It was postulated that the reason for formation of 3.14 was due to nucleophilic attack by
the imine nitrogen on the methyl ester in intermediate 3.12. This would form an acyl iminium
intermediate that later isomerized to form 3.14. To avert this transformation, we planned to make
t-butyl ester 3.17 which can provide steric hindrance against approaching nitrogen. To synthesize
t-butyl ester 3.17, we attempted transesterification using t-BuOH and ester 3.10 in presence of
sulfuric acid but this was unsuccessful. In another attempt at synthesizing 3.17 (shown in Scheme
3.4), the ester 3.10 was hydrolyzed to acid 3.16 and then various conditions for esterification
(shown in Table 3.2) were applied on acid 3.16. However, none of the conditions that were tried
worked and we recovered starting material. Steric hindrance might be the factor at play here.

Table 3.2: Unsuccessful esterification conditions for compound 3.16 (step b, Scheme 3.4)
Entry

Reagents

Solvent

1

DCC, DMAP

t-BuOH

2

H2SO4, MgSO4

t-BuOH

3

(t-BuO)2O

DCM

After unsuccessfully attempting to synthesize 3.17, our efforts were directed towards
synthesis of di-amide 3.18. It was envisaged that the aromatic amide group in 3.18 would not be
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as susceptible to ring closure via the intermediate imine (akin to compound 3.12). Thus 3.18 was
synthesized as shown in Scheme 3.5. Bischler-Napieralski cyclization of diamide 3.18 followed
by Noyori’s catalytic hydrogenation produced enamine 3.19. This result tends to suggest that
imine 3.12 first isomerizes to an enamine which then cyclizes to form the enamide 3.14, contrary
to our initial postulate that cyclization preceded isomerization.

After unsuccessful attempts to stop the formation of enamine 3.14, we planned to reduce
ester 3.10 to primary alcohol 3.20 and the resultant alcohol could then be advanced to synthesize
(-)-SPD (2.1). We tried various conditions to reduce ester 3.10 (as shown in Table 3.3); in which
DIBAL (at -78 ̊ C) and NaBH4 (in refluxing THF) produced a complex TLC profile, while treating
with LAH at 0 ̊ C gave cyclic imide 3.21. Formation of imide 3.21 after the reaction with LAH
and NaBH4 revealed that cyclization of ring C occurs before ester reduction.
Reduction with LiBH4 at 0 ̊ C to room temperature did not furnish the desired alcohol 3.20,
but we received unexpected primary alcohol 3.22. We found similar literature precedence wherein
cyclic imide 3.23 was shown to transform to an opened ring aliphatic alcohol 3.24 in the presence
of excess NaBH4 (Scheme 3.7).351 We tried to cyclize imide 3.21 using POCl3, having thought that
cyclization would occur at aliphatic carbonyl and further advancing the intermediate iminium ion
to (-)-SPD (2.1) synthesis. But we observed a complex TLC profile after cyclization of imide 3.23.
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Table 3.3: Reduction of compound 3.10 (Scheme 3.6)
Reducing agent

Temperature

Solvent

Product

Yield

NaBH4

rt to reflux

THF/MeOH

NA

NA

DIBAL

-78 ̊ C

THF

NA

NA

LAH

0 ̊C

THF

3.21

46%

NaBH4

0 ̊ C to rt

MeOH

3.21

54%

LiBH4

0 ̊ C to rt

THF

3.22

52%

Finally, we planned to reduce enamide 3.14 (derived from ester 3.10) via enantioselective
hydrogenation using ruthenium catalyst as per the reported procedure (Scheme 3.8), wherein
enamide 3.25 was reduced to formamide 3.26.352 As shown in Scheme 3.9, enamide 3.14 was
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Table 3.4: Hydrogenation conditions (step a, Scheme 3.9)
Hydrogen
Pressure (atm)

Temperature ( ̊ C)

1

rt

5

rt

10

rt

20

rt

40

rt

50

rt

20

50

40
50

50
50

a.

All conditions were unsuccessful

treated with (S)- Ru(OAc)2(BINAP) under hydrogen pressure in a stainless steel high pressure
reactor. We applied different hydrogen pressure ranging from 1atm to 50 atm at different
temperature (shown in Table 3.4); however none of the conditions furnished the expected product
87

(-)-3.11. As per our assumption the cyclic conjugation between two aromatic rings makes this
enamide double bond quite inert against hydrogenation.

3.3.2.2 Synthesis via lactone 2.62
After all ineffective efforts to reduce ester 3.10 to primary alcohol 3.20 as well as
asymmetric hydrogenation of enamide 3.14, we redesigned our route (shown in Figure 3.4) to
synthesize (-)-SPD (2.1) via lactone 2.102, which can be synthesized from diester 3.7 via selective
reduction of aromatic ester.

As depicted in Scheme 3.10, our synthesis of (-)-SPD (2.1) commenced with compound
3.7 which was synthesized as per Scheme 3.1 from 4-bromoguaiacol (3.5). The ethoxymethyl
group of 3.7 was exchanged for a benzyl protecting group in two high yielding steps. Here, 3.7
was refluxed in acidic methanol to effect deprotection of the ethoxymethyl group and this was
followed by protection of resulting phenol as the benzyl ether to give 3.27. Global hydrolysis of
the ester functionalities of 3.27 and subsequent selective esterification of the aliphatic acid
functionality, generated acid 3.28. The acid 3.28 was converted to an intermediate activated ester
via reaction with EDCI/HOBt. This ester group was selectively reduced with NaBH 4 to provide an
alcohol which was then cyclized to the lactone 2.62. Thereafter the route developed by Yang was
implemented to prepare (-)-SPD (2.1).293
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To provide unequivocal stereostructural proof, we determined the 3-dimensional structure
of 2.1 by single crystal X-ray diffraction. Figure 3.5 shows a representation of the x-ray structure,
in which a water molecule co-crytallizes with 2.1. The synthesis of 2.1 was accomplished in 23%
overall yield from compound 3.5 in a fourteen step sequence. This route involves an alternative
preparation of the vital intermediate compound 2.102. The synthetic manipulations to afford 2.102
are straightforward, scalable ( > 5 g) and generally high yielding.

Figure 3.5: Crystal structure of (-)-SPD monohydrate
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3.3.2.3 Discussion
Herein, a new synthesis of (±)-SPD (2.1) is delineated, which features the use of the easily
obtainable diester intermediate 3.7. (±)-SPD (2.1) was prepared in eight steps from a readily
available precursor 4-bromoguaiacol in 30% overall yield. The route is attractive due to its
efficiency and practical ease; no chromatographic purification was necessary for a number of steps.
The present approach has the advantages of brevity, ease of synthetic manipulations and superior
overall yield as compared to previous reported syntheses of (±)-SPD (2.1). This method has
addressed a solution to the key problem in synthesis of THPBs, to set up the 2,3,9,10
tetrasubstituted pattern, by employing diester 3.7. The key amide intermediate (3.10), that is, used
for (±)-SPD (2.1) synthesis can also be used to prepare a 9,10-oxygenated-8-oxoprotoberberine
core, and we adapted this method to prepare oxypalmatine (3.15). Hence, the route examined here
is a versatile one for the preparation of 9,10-oxygenated THPBs as well as their 8oxoprotoberberine analogues.353
The enantioselective synthesis of (-)-SPD (2.1) was accomplished in 23% overall yield
from compound 3.5 in a fourteen step sequence. The crystal structure of (-)-SPD (2.1) was
determined by single crystal X-ray diffraction, and validated the success of this method. This is
comparable to Yang’s first synthesis where a 24% yield of (-)-SPD (2.1) was obtained in eleven
steps (from a 4-benzyloxy-3-hydroxy phenylacetic acid precursor).293 This, route involves an
alternative, reliable preparation293 of the vital intermediate compound 2.102. The synthetic
manipulations to afford 2.102 are straightforward, scalable and generally high yielding. This
synthetic pathway was applied to generate of C3 chiral analogues of (-)-SPD (2.1) for bioactivity
studies.
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3.4

Synthesis and evaluation of (±)-C10 analogues

3.4.1

Rationale

As mentioned previously in section 3.1, others have investigated the replacement of the C2
and C10 hydroxyl groups of (±)-SPD (2.1) with methoxy, methylenedioxy and benzyloxy motifs.
Based on the results obtained in previous studies, either C2 or C10 hydroxyl group are prerequisites for dopamine D1 activity. Base to this premise, in this project, we planned to probe the
tolerance of larger lipophilic substituents and steric bulk as well as hydroxyl group homologs at
C10 position while keeping the C2 hydroxyl group free. The rationale behind this study was to get
an insight about optimum size of the alkoxy group required at C10 position for dopamine D1 and
D3 receptor affinity and selectivity. To this end, molecules 3.29a-3.29h (Figure 3.6) were designed
to test the effect of extended alkyl chain, three carbon cyclic ring and hydroxyl homologs on the
affinity and activity at D1, D2 and D3 receptors.

3.4.2

Results and discussion

3.4.2.1 Synthesis
Using our newly developed synthetic method (Scheme 3.1), we synthesized amide 3.11 in
large amount from diester 3.7, and it was reduced to tertiary amine 3.30 using LAH. Compound
3.30 was deployed to synthesize C10 analogues (3.29a-3.29h) of (±)-SPD (2.1) via alkylation with
91

appropriate alkyl halide followed by debenzylation using concentrated HCl (as shown in Scheme
3.11).

3.4.2.2 Structure-activity correlations
This series of analogues along with (±)-SPD (2.1) were assayed for binding affinity to
human dopamine D1, D2 and D3 receptors by the Psychoactive Drug Screening Program (PDSP).
This data is presented in Table 3.5. (±)-SPD (2.1) displayed approximately 20-fold stronger
affinity for the D1 receptor as compared to the D2 and D3 receptors (Ki of 5.6, 115.5 and 101 nM
at D1, D2 and D3 respectively). Alkylation tends to reduce D1 affinity, with the analogues showing
a 1.2 to 7-fold decrease in affinity as compared to (±)-SPD (2.1). The C10 phenol plays role but is
not absolutely required for D1 affinity, given the relatively small drop in affinity seen for some
analogues (for example 3.29c and 3.29g). This result is in accordance with observations from
previous SAR work on the THPB framework by others.19
Methyl and ethyl substituents resulted in an approximately 2-fold decrease in affinity
(compounds 3.29a and 3.29b respectively). In the n-propyl (3.29c) to n-hexyl (3.29f) homologous
series, a progressive decrease in affinity was observed. The D1 receptor affinity seen for the
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hydroxypropyl analogue 3.29g was comparable to that observed for (±)-SPD (2.1) and the n-butyl
analogue 3.29d (6.7, 5.6 and 11 nM respectively). This suggests that the hydroxyl group in 3.29g
plays a relatively minor role in binding to the D1 receptor. The presence of the hydroxypropyl
substituent in 3.29d restores the D1 affinity of (±)-SPD (2.1), improves the selectivity versus the
D2 receptor (20.6 versus 31.5 for D2/D1 selectivity for (±)-SPD (2.1) and 3.29d respectively) and
retains the selectivity versus the D3 receptor (18 versus 16-fold for D3/D1 selectivity). Among the
alkylated analogues, a 3 carbon chain length seems to be optimal for D1 affinity (consider 3.29c
and 3.29g). The cyclopropylmethyl analogue (3.29h) had similar affinity to the n-butyl analogue
3.29d and ethyl analogue 3.29b. Thus some degree of branching on the alkyl chain may be
tolerated for D1 affinity. On a whole, the D2 affinity of the analogues was lower than their D1
affinities. Thus the compounds retained selective affinity for the D1 receptor, as was observed in
the lead molecule (±)-SPD (2.1). However, most compounds had lower than the 20-fold D1
selectivity seen for (±)-SPD (2.1) (except for compounds 3.29f and 3.29g).
Compounds in the homologous series from a methyl group to an n-butyl chain (3.29a3.29d), had D2 affinities that are similar to (±)-SPD (2.1), ranging from 99 to 159 nM. However,
compounds with the larger n-pentyl and n-hexyl chains had reduced affinities; in fact, the n-hexyl
analogue (3.29f) did not show any appreciable affinity for the D2 receptor (<50% inhibition) in
the primary assay. The cyclopropylmethyl analogue (3.29h) was the only compound in this series
that displayed a significantly higher affinity for the D2 receptor than (±)-SPD (2.1).
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Table 3.5: Binding affinity data (Ki nM) for C10 analogues at dopamine receptors

Compound

R

(±)-2.1

Ki (nM)a

Selectivity

D1b

D2c

D3d

D2/D1

D3/D1

D2/D3

H

5.6e

115.5e

101e

20.6

18.0

1.1

3.29a

Me

15

102

37

6.8

2.5

2.8

3.29b

Et

12.4

159

44

12.8

3.5

3.6

3.29c

n-Pr

7.8

99

53

12.7

6.8

1.9

3.29d

n-Bu

11

121

65

11

5.9

1.9

3.29e

n-Pent

19

283

101

14.9

5.3

2.8

3.29f

n-Hex

40

NAf

220

NDg

5.5

NDg

3.29g

Hydroxypropyl

6.7

211

110

31.5

16.4

1.9

3.29h

Cyclopropylmethyl

12

54

54

4.5

4.5

1

aExperiments

carried out in triplicate - SEM values are within 13% of reported Ki; b[3H]SCH2390 used as radioligand/(+)-butaclamol

used as reference compound - Ki = 2.3 nM; c[3H]N-methylspiperone used as radioligand/haloperidol used as reference compound Ki = 9.6 nM; d[3H]N-methylspiperone used as radioligand/chlorpromazine used as reference compound - Ki = 11.0 nM; eexperiments
carried out in duplicate; f NA- not active (<50% in primary assay); g ND-not determined.

There was a clear trend in the methyl to n-hexyl series at the D3 receptor, where an increase
in the alkyl chain length was associated with a progressive decrease in affinity for the receptor.
However, methyl to n-butyl analogues demonstrated improved binding affinity at the D3 receptor
as compared to the lead compound (±)-SPD (2.1) (37 to 65 nM versus 101 nM). The hydroxypropyl
analogue had similar affinity for the D3 receptor as compared to (±)-SPD (2.1). In the case of the
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cyclopropylmethyl analogue, D3 receptor affinity was improved two-fold as compared to (±)-SPD
(2.1) (54 nM vs 101 nM).

3.4.3

Molecular docking study at D3 receptor
The phenolic group at C10 of SPD (2.1) does not seem to play a major role in its binding

to dopamine D1 and D2 receptors (given the similarity in D1 and D2 affinities of the analogues as
compared to SPD (2.1)). In the case of the D3 receptor, a number of analogues had moderately
improved affinity as compared to SPD (2.1). Therefore it seems that the C10 phenolic group is not
an absolute necessity for affinity of SPD (2.1) to the D3 receptor. Based on the SAR trend observed
(increasing alkyl chain length decreases D3 affinity), it is apparent that the C10 alkoxy substituents
of the analogues might project into a shallow hydrophobic pocket in the receptor. To get further
clarity into this possibility and to aid in rationalizing the D3 affinity trend observed, docking
evaluations were performed on SPD (2.1) and analogues 3.29a-3.29h at the D3 receptor.
Investigation of the docked ligand poses and recognition of key protein–ligand interactions
provides insights into the SAR outcomes of the series of C10 analogues and the de-rigidified
compounds with respect to D3. In this study, ligand docking was performed retrospectively in
order to elucidate and rationalize the measured D3 affinity data. Overall, the calculated binding
energies for SPD (2.1) and the C10 analogues are in reasonable agreement with activities derived
from the experimental data as shown in Table 3.6.
Compounds SPD (2.1) and 3.29a-3.29h were docked into a pre-prepared 3-dimensional
structure of the D3 receptor derived from the crystal structure with PDB code 3PBL. 354 A
representation of the docked poses for the ligands SPD (2.1), 3.29a-3.29f and 3.29h within the D3
receptor binding pocket is depicted in Figure 3.7. Each ligand generated multiple binding
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Table 3.6: Predicted binding affinity from Glidescore for C10 analogues in D3 receptor docking
study
Ki (nM) at D3

Compound

R

Glidescore

3.29h

Cyclopropylmethyl

-7.3

54

3.29f

n-Hex

-7.3

220

3.29b

Et

-7.4

44

3.29d

n-Bu

-7.4

65

3.29a

Me

-7.5

37

3.29c

n-Pr

-7.5

53

3.29e

n-Pent

-7.5

101

SPD (2.1)

H

-7.9

101

3.29g

Hydroxypropyl

-8.1

110

receptor

modes and the structures shown display the top ranked poses according to Glidescore (+ligand
strain). These poses maintain key receptor–ligand interactions, including the critical protonated
tertiary N—Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic
interactions to Phe106 and Phe345 (Figure 3.7). The analogues are positioned such that the aryl
substituents project into hydrophobic cavities in the receptor (depicted in Figure 3.7b for
compound 3.29a). The estimated binding energies according to Glidescore are very similar for this
series of C10 analogue ligands, covering a narrow range from -7.9 to -7.3 kcal/mol. Overall, the
relatively small decrease in the predicted binding energy as the length of the alkyl chain increases
for compounds 3.29a-3.29f qualitatively matches the decrease in the measured affinity for these
ligands. Quantitatively, the binding energy differences are very small compared to the wider, yet
still relatively low, variation in measured affinities. The Glidescore value for SPD (-7.9 kcal/ mol)
was found to be lower than that for the other C10 analogues, including the cyclopropylmethyl
analogue (-7.3 kcal/mol), in contrast to the experimental measurements.
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a)

b)
Figure 3.7: (a) Docked poses of the lead molecule SPD (2.1) and the C10 analogues 3.29a-3.29f
and 3.29h. Key hydrogen bonding interactions are given by the yellow dashed lines and
hydrophobic interactions by the turquoise dashed lines (b) Compound 3.29a docked in binding
pocket.
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However, in a similar manner to the measured affinities, the hydroxypropyl analogue, with docked
pose illustrated in Figure 3.8, had a predicted binding energy that is close to that of SPD (2.1) (8.1 kcal/mol vs -7.9 kcal/mol, respectively). Examination of the D3 receptor binding site shows
that the alkyl, cyclopropylmethyl and hydroxypropyl groups of the C10 analogues fit into the
extracellular hydrophobic region of the binding pocket, consisting of the extracellular loops and
the junction of several helices, without incurring any significant clashes with the protein structure.
Hence, the small difference in predicted binding energies for these systems is unsurprising. The
hydroxyl group in compound 3.29g also forms an additional H-bond to Glu90 (Figure 3.8).

Figure 3.8: Docked pose of the hydroxypropyl analogue, compound 3.29g

Others have investigated docking of SPD (2.1) at the D3 receptor computationally.355 As
compared to prior work, we found similarities in the key residues that are important for affinity of
SPD (2.1) (and the C10 analogues), particularly Asp110, Ser192 and Phe345. Apart from the key
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protonated nitrogen- Asp110 salt bridge interaction, in both studies Ser192 interacts with an
aromatic hydroxyl group via a hydrogen bond and Phe345 interacts with an aromatic ring via
aromatic stacking (Figure 3.6a). The main difference is that the orientation of SPD (2.1) in our
Glide docking study is reversed compared to the AutoDock derived pose in the previous work.
Thus in our case Ser192 is H-bonded to the phenolic hydroxyl in ring A and Phe345 interacts with
ring A, whereas in prior work Ser192 and Phe345 have interactions with the ring D hydroxyl and
ring D respectively. Given the close to symmetric structure of the molecule and its high rigidity,
this reversal has little impact on the interactions with the receptor pocket, except for the formation
of an additional H-bonding interaction between the phenolic group in ring D of SPD (2.1) and the
backbone O of Cys181 in our docked pose.

3.4.4

Structure-activity relationship study at σ receptors

3.4.4.1 Background
There are two types of σ receptors - σ1 and σ2, as borne out by differential binding of
selective radioligands as well as other biochemical and pharmacological studies. 356-358 σ receptors
are distributed in the central nervous system (CNS) and in peripheral tissue. 359, 360 Within the CNS,
σ1 receptors are concentrated in the hippocampus and other limbic regions which control cognition
and emotion.361, 362 Thus these receptors have been implicated in a number of neuropsychiatric
disorders and have been targets for the development of treatment interventions for such
diseases.363-365 σ2 receptors are found predominantly in regions responsible for motor functions in
the CNS and are also highly expressed in the lung, liver and kidneys. 361, 362 The σ1 receptor has
been cloned but the σ2 receptor has not, and there is some debate about the identity of the σ2
receptor.366 Recent studies suggest that the σ2 receptor is Progesterone Receptor Membrane
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Component 1 (PGRMC1).367, 368 σ2 receptors are overexpressed in tumor cells and are upregulated
in rapidly proliferating cells and this receptor has attracted interest as a biomarker for cancer
proliferation.369,

370

Some σ2 ligands (particularly σ2 receptor agonists) display cytotoxic

activity.371 Thus, σ2 ligands have been of interest for the development of "stand alone" antitumor
drugs, targeted drug delivery agents and Positron Emission Tomography (PET) tools for imaging
the proliferative status of various cancers.367, 372-374 σ2 receptor ligands have been predominantly
from four structural classes: 6,7-dimethoxytetrahydroisoquinolines, indoles, tropanes and
cyclohexylpiperazines (Figure 3.9). Many of these compounds lack sufficient selectivity or are
otherwise hampered by unfavorable pharmacokinetic drawbacks that limit their usefulness as
drugs, anticancer drug delivery vehicles or tools. New, potent and selective σ2 receptor ligands are
sought after to fully exploit the potential of the σ2 receptor as a target for cancer diagnosis and
therapy.
(-)-SPD (2.1) also shows good affinity for σ2 (Ki = 54 nM), as revealed by data from the
Psychoactive Drug Screening Program (PDSP) database. 335 Given the comparatively high σ2
affinity of (-)-SPD (2.1), we considered that the C10 THPB analogues we made are also exploitable
towards the development of novel potent and selective σ2 receptor ligands. Since, no SAR studies
have been performed on THPBs in relation to their σ2 receptor affinity, such studies could propel
our understanding of the potential utility of this scaffold towards obtaining novel, selective σ2
receptor ligands.
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3.4.4.2 Structure-activity correlations
All C10 THPB analogues assayed for binding affinity to human σ1 and σ2 receptors by the
Psychoactive Drug Screening Program (PDSP). Binding affinity data is shown in Table 3.7. At the
σ1 receptor, all analogues tested showed increased affinity as compared to (±)-SPD (2.1) (ranging
from approximately 2-fold to 22-fold increase in σ1 affinity). Therefore, the C10 phenol
functionality is not required for σ1 receptor affinity. No clear SAR trend could be discerned in the
homologous series 3.29a-3.29f. The n-butyl analogue 3.29d had the highest affinity of the
compounds in this series (Ki = 13 nM for 3.29d vs 269 nM for (±)-SPD (2.1)). The hydroxypropyl
analogue 3.29g had lower affinity than 3.29d (53 vs 13 nM) which suggests that the hydroxyl
group in 3.29g does not have any significant binding interactions with the σ1 receptor (akin to
observations at the D1 receptor). The cyclopropylmethyl and n-butyl analogues had similar σ1
affinities- approximately 12 nM (a situation that mirrors results for 3.29h at the D1 receptor). It
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thus appears that the cyclopropylmethyl group may function as a less hydrophobic bioisostere of
the n-butyl group in this series at σ1 receptors. A clear trend was seen at the σ2 receptor for
analogues 3.29a-3.29f, wherein there was a progressive decrease in σ2 receptor affinity as the alkyl
chain was extended. Compounds 3.29a and 3.29b had the highest affinity of all compounds
assayed (1 nM and 1.3 nM respectively), representing an approximately 7- to 9-fold higher σ2
receptor affinity than (±)-SPD (2.1). With respect to

Table 3.7: Ki data for C10 analogues at dopamine and σ receptors

Compound

R

(±)-2.1

Ki (nM)

σ1/ σ2

σ1a

σ2b

H

269

9

30

3.29a

Me

106

1

106

3.29b

Et

124

1.3

95

3.29c

n-Pr

57

6.7

8.5

3.29d

n-Bu

13

49

0.27

3.29e

n-Pent

119

97

1.22

3.29f

n-Hex

37

107

0.35

3.29g

hydroxypropyl

53

3.8

13.9

3.29h

cyclopropylmethyl

12

2.4

5

a[3H](+)-pentazocine

used as radioligand/haloperidol used as reference compound - Ki = 1.1

nM; b[3H]DTG used as radioligand/haloperidol used as reference compound - Ki = 10.0 nM;
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binding at σ receptors, both 3.29a and 3.29b exhibited higher σ2 receptor selectivity than
compound (±)-SPD (2.1) (approximately 100-fold for 3.29a and 3.29b versus 30-fold for
compound (±)-SPD (2.1). All other analogues had decreased selective affinity for the σ2 receptor
as compared to the σ1 receptor. In fact, this σ receptor selectivity was reversed for compounds
3.29d and 3.29f which both showed approximately 3-fold higher selectivity for σ1 versus σ2
receptors. Analogues 3.29a-3.29c had higher affinity than (±)-SPD (2.1), indicating that small C10
alkoxy groups are better tolerated than the C10 phenolic group at the σ2 receptor. Compounds
3.29g and 3.29h displayed very high σ2 receptor affinity, comparable to 3.29a and 3.29b; thus
there is some tolerance for small polar or hydrophobic groups at C10 for σ2 affinity.
As alluded to before, some compounds have shown cytotoxic actions that are attributable to their
interaction with σ receptors. We were curious to determine the extent to which our newly identified
high affinity σ2 receptor ligands displayed cytotoxicity. Therefore, 3.29a, the most potent and
selective σ2 ligand identified in this study, was selected for cytotoxicity evaluation in an Alamar
Blue assay.375 Compound 3.29a lacked significant cytotoxic activity in this assay, with an IC 50 of
178 μM. Since σ2 receptor agonists are generally cytotoxic, 376-378 this result tends to imply that
compound 3.29a is a σ2 receptor antagonist (although this needs to be ratified with further assays).

3.5

Synthesis and evaluation of (-)-C3 analogues

3.5.1

Rationale and analogue design
Substituent pattern investigated at the C3 position in previous SAR studies was limited to

methoxy, methylenedioxy or hydroxy functionalities (discussed in chapter 2, section 2.5). These
SAR studies indicate that having hydroxyl group at C3 position diminishes the activity at
dopamine receptors and an alkoxy group is necessary for the activity. Still much chemi9cal
diversity space is present to explore this site using various alkoxy chains having different carbon
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length. Filling this deficient element, our project was aimed to design, synthesize and evaluate C3
alkoxy analogues of (-)-SPD (2.1) at dopamine receptors. Examining the binding affinity of these
variant bulk analogues would provide some idea about the size of the binding pocket in the vicinity
of C3 at the various receptors.. Compounds 3.35a-3.35f (Figure 3.10) have been designed to test
the effect of extended alkyl chain and fluorine-containing homologs on the affinity and activity at
D1, D2 and D3 receptors.

3.5.2

Results and discussion

3.5.2.1 Synthesis
Compounds 3.35a-3.35f were synthesized using the procedure developed for (-)-SPD (2.1)
as shown in Scheme 3.12. Commercially availably dihydroxy benzaldehyde (3.36) was selectively
protected with benzyl group as per the reported procedure to give compound 3.37.379 The phenolic
group of aldehyde 3.37 was protected with silyl group and the intermediate was subjected to
Henry’s condensation reaction to give nitrostyrene 3.38. Reduction of nitro compound 3.38 using
LiBH4 yielded primary amine 3.39. Aminolysis of lactone 2.102 with primary amine 3.39 was
carried out to give amide alcohol 3.40, which was acetylated to afford 3.41. Ring B of the THPB
scaffold was formed via Bischler-Napieralski cyclization followed by asymmetric hydrogenation
using Noyori’s catalyst and formic acid/triethylamine mixture to generate 3.42 with good yield
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(88%).345 Hydrolysis of acetyl group and subsequent chlorination endowed the tetracyclic scaffold
of THPB in compound 3.43. The enantiomeric excess of this precursor was found to be 90.2%
(chiral HPLC) and it was used for further analogue generation. Alkylation of compound 3.43
followed by debenzylation provided the C3 analogues 3.35a-3.35f.

3.5.2.2 Structure-activity correlations
All C3 analogues were assayed for binding affinity to human dopamine D1, D2 and D3
receptors by the PDSP. This data is presented in Table 3.8. The highest activity at D1 receptor was
demonstrated by compounds 3.35b and 3.35a, which were 2.5 and 3-fold lower than parent
compound (-)-SPD (2.1) respectively. This result suggests that an increase in the alkyl chain length
at C3 position decreases affinity at D1 receptor, the same trend also exhibited by other compounds.
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In comparison to other analogues, compound 3.35b showed 2.3 to 3.5 times higher binding affinity
at the D1 receptor. D1 receptor affinity was increased 1.2 to 1.7 fold while moving from four
carbon chain to five and six carbon chain (3.35c vs 3.35d and 3.35e). As displayed by compound
3.35f, terminal introduction of the fluoro group to the ethyl chain decreases the affinity 2 times
when compared with 3.35a. The selectivity for D1 versus D2 receptor was slightly improved for
compound 3.35b when compared with (-)-SPD (2.1). Though 3.35f and 3.35a have slightly
decreased selectivity at D1 receptor, they are comparable with (-)-SPD (2.1).
Table 3.8: Binding affinity (Ki nM) for C3 analogues at dopamine receptors

Compound

R

3.35a

Ki (nM)a

Selectivity

D1b

D2c

D3d

D2/D1

D2/D3

D3/D1

Et

17.0

2089.0

40.0

122.9

52.2

2.4

3.35b

n-Pr

15.0

2682.0

46.0

178.8

58.3

3.1

3.35c

n-Bu

53.0

2739.0

51.0

51.7

59.5

1

3.35d

n-Pen

31.0

1433.0

33.0

46.2

43.4

1.1

3.35e

n-Hex

42.0

1491.0

26.0

35.5

57.4

0.6

3.35f

2-fluoroethyl

34.0

5045.0

86.0

148.4

58.7

2.5

(-)-SPD 2.1

Me

5.9

974.3

30.1

165.1

32.4

5.1

aExperiments

carried out in triplicate - SEM values are within 13% of reported Ki; b[3H]SCH2390 used as radioligand/(+)-

butaclamol used as reference compound - Ki = 2.3 nM; c[3H]Nmethylspiperone used as radioligand/haloperidol used as reference
compound - Ki = 9.6 nM; d[3H]N-methylspiperone used as radioligand/chlorpromazine used as reference compound - Ki = 11.0
nM.

D1 versus D2 receptor selectivity progressively decreases from four carbon alkoxy chain
to six carbon alkoxy chain (3.35c-3.35e). All C3 analogues displayed a reduced affinity at D2
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receptor from 1.47 to 5.2 fold as compared to (-)-SPD (2.1). This reveals the importance of these
substitutions in suppressing the dopamine D2 receptor activity. The affinity observed at D3
receptor was comparable between C3 analogues and (-)-SPD (2.1). Slightly improvement in
affinity was seen in 3.35e (26.0 nM vs 30.1 nM), while a 2.8 fold reduced activity was found in
compound 3.35f. At the same time, the selectivity at D3 receptor versus D2 receptor is enhanced
by 1.3 to 1.8 fold as measured against (-)-SPD for all C3 compounds. Compounds 3.35e (8.5
times), 3.35c (5.1 times) and 3.35d (4.6 times) have higher selectivity for D3 versus D1 receptor
than (-)-SPD (2.1). That confers that larger lipophilc chains are more tolerated at this site for D3
receptor activity. Other compounds (3.35a, 3.35b, 3.35f) have comparable selectivity between 1.62.1 fold for D3 receptor versus D1 receptor as (-)-SPD (2.1).

3.6

Metabolic stability study

3.6.1

Rationale
Although (-)-SPD (2.1) possesses favorable properties for delivery to the CNS, rapid and

extensive pre-systemic metabolism restricts its application. Previous pharmacokinetic and
metabolic stability study of (-)-SPD (2.1) suggests that the phenolic hydroxyl groups of (-)-SPD
(2.1) are molecular targets for the unwanted pre-systemic metabolism via O-glucuronidation and
O-sulfation.340
It is very crucial to evaluate the effect of substitutions at C3 and C10 position on metabolic
stability of phenolic hydroxyl groups of (-)-SPD (2.1). In this project we aimed to study the
metabolic stability of the representative C3 and C10 analogues that we have synthesized using rat
hepatocytes. Among the routinely used in vitro systems, such as microsomes and hepatocytes, 380
microsomes are usually used to determine cytochrome P450-mediated metabolism (phase I).
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Hepatocytes, having intact cell membranes and physiological concentrations of enzymes and
cofactors, are believed to be a model close to whole liver for drug clearance measurements. 381-384
Though human hepatocytes mimic the ideal environment of hepatic metabolism, 385 we chose rat
hepatocytes because of their cost effectiveness and because they are easily available as compared
to human hepatocytes. Our next goal in this context is to study metabolic stability study using
human hepatocytes.
This study would provide us a valuable comparison of metabolic stability pattern of (-)SPD (2.1) and its various analogues. It would add a significant piece of information while
searching for a metabolically stable THPB scaffold having superior biological activity at dopamine
receptors. As shown in Figure 11, compounds (-)-SPD (2.1), 3.29a, 3.29f, 3.35e, 3.35f, and 3.44
as representative analogues from C3 and C10 series were studied for in vitro metabolic stability
using rat hepatocytes. Analogue 3.44 was selected to serve as a member of tetra-alkoxy substituted
THPB scaffold.

3.6.2

Results
For tested compounds, the % AUC was calculated from the LC/MS peak abundance in

comparison with that total AUC. The % AUC data for each compound during the 36 h time course
is shown in Table 3.9 and the time versus % AUC graph is depicted in Figure 3.12.
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Table 3.9: Metabolic stability study data for representative compounds
% of total AUC at given time point
Time (h)

(-)-SPD
(2.1)

3.29a

3.29f

3.35e

3.35f

3.44

0

100

100

100

96

100

100

1

98

95

95

81

97

100

2

91

92

86

89

89

100

3

82

74

72

78

66

100

6

52

23

31

47

26

100

12

10

22

3

10

0

100

24

10

8

3

1

3

99

36

11

8

1

0

3

100
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% of total AUC at given time point

120

SPD

3.29a

3.29f

3.35f

3.35e

3.44

100

80
60
40
20
0
0

5

10

15

20
Time (h)

25

30

35

40

Figure 3.12: % of total AUC at given time period of incubation for representative analogues
According to % AUC derived at particular time point, it was found that within six hours,
all of the compounds were metabolized to more than 50% except tetrasubstituted analogue 3.44.
Mono glucuronidated metabolite was predominant for all the tested compounds (shown in Figure
3.13; 3.45 for 2.1, 3.46 for 3.29a, 3.47 for 3.29f, 3.48 for 3.35e, and 3.49 for 3.35f). Peak
abundance of sulfate metabolites for each compound was very minor (< 0.5% of total AUC), which
suggests that O-glucuronidation is the major pathway for THPB metabolism in liver. These results
are in accordance with the previous study in terms of the major metabolite observed i.e. Oglucuronidated.340
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No difference was demonstrated in the rate of metabolism between dihydroxy and
monohydroxy analogues (3.29a, 3.29f versus 2.1, 3.35e, 3.35f). As per our expectation, no
metabolism was observed during the whole course of experiment for tetrasubstituted analogue
3.44. Previous study has revealed that C10 hydroxyl group is the primary site for metabolism and
it get glucuronidated first in (-)-SPD (2.1).341 This trend can be applied to other C3 analogues
(3.35e and 3.35f) having C2 and C10 free phenolic hydroxyl group similar to (-)-SPD (2.1). C10
analogues 3.29a and 3.29f do not have a free C10 hydroxyl group, but those having the C2
hydroxyl group free, get glucuronidated at similar rates as (-)-SPD. This indicates that the C2
phenol is also susceptible to glucuronidation to a similar extent as the C10 phenolic hydroxyl.
Based on results of previous study and our results here, we surmise that having C2alkoxy/C10
hydroxyl pattern in the THPB scaffold affords a similar rate of metabolism as the C2, C10dihydroxy analogues (2.1, 3.35e, 3.35f).
Tetrasubstituted analogue (3.44) remained stable during the 36 hour time period of the
assay with same abundance (% AUC); no metabolism was observed during whole experiment. We
reasoned that the unavailability of free phenolic OH group is responsible for inertness of this
compound towards metabolism. Steric hindrance due to the bulkier benzyl moieties at C2 and C10
position is also another possibility for metabolic stability of compound 3.44, as this could slow
down oxidative dealkylation of the alkoxy groups. To examine this prospect, compounds having
smaller alkoxy tetrasubstitutions, for instance (-)-THP (2.2), need to be tested for stability in the
hepatic environment.
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3.7

Conclusions
In our work we have addressed prominent issues and missing gaps towards the synthesis

and SAR studies of THPBs at dopamine D1, D2 and D3 receptors. We have developed a novel
route to synthesize (±)-SPD (2.1) in eight synthetic steps with 30% overall yield via the
intermediacy of easily obtainable diester 3.7. Compared to previous reported syntheses, this
approach is advantageous in terms of conciseness, ease of synthetic manipulations and superior
overall yield. Additionally, this route is applicable to prepare 8-oxoprotoberberine analogues as
exemplified by oxypalmatine (3.15).
The enantioselective synthesis of (-)-SPD (2.1) was accomplished in 23% overall yield
from compound 3.5 in a fourteen step sequence. The crystal structure of (-)-SPD (2.1) was
determined by single crystal X-ray diffraction, which validated the success of this method. This is
comparable to Yang’s first synthesis where a 24% yield of (-)-SPD (2.1) was obtained in eleven
steps (from a 4-benzyloxy-3-hydroxy phenylacetic acid precursor).293 This, route involves an
alternative, reliable preparation of the vital intermediate compound 2.102. The synthetic
manipulations to afford 2.102 are straightforward, scalable and generally high yielding. This
synthetic pathway we applied to generate of C3 chiral analogues of (-)-SPD (2.1) for bioactivity
studies.
While searching for selective D1/D3 receptor ligands, we have designed and synthesized
C10 alkoxy THPB analogues 3.29a-3.29h. The C10 THPB analogues seem to exhibit a general
preference for the D1 receptor. The lowest D1 affinity seen for any analogue was 40 nM (for
compound 3.29f). Thus the C10 position seems to be fairly tolerant of alkoxy substituent groups
with respect to D1 affinity. Among the 3 dopamine receptors, affinity was generally highest for
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the D1 receptor and lowest for the D2 receptor. Overall, the general order of affinities for C10
analogues at the dopamine receptors evaluated is D1>D3>D2. The clear trend observed in the
methyl to n-hexyl series at the D3 receptor, where an increase in the alkyl chain length was
associated with a progressive decrease in affinity for the receptor, indicates tolerance of smaller
alkoxy substituents at C10 position of THPB core. Methyl to n-butyl analogues have demonstrated
improved binding affinity at D3 receptor as compared to lead compound (±)-SPD (2.1) (37 to 65
nM versus 101 nm).
The ligand binding energies from the D3 receptor docking studies show some similarities
and minor discrepancies compared to the experimentally derived affinities. This is not surprising
as empirical scoring functions, such as Glidescore used in this study, cannot rank order correctly
and quantitatively discriminate all protein-ligand complexes based on the predicted scores. Further
exploration of a significantly larger and structurally more diverse ligand library would be required
to provide deeper understanding and quantitative evaluation of the effectiveness of our in silico
modeling process.
Using our enantioselective method to synthesize (-)-SPD (2.1), we have produced optically
pure C3 analogues (3.35a-3.35f) of THPB. The results for binding affinity data suggest that
introducing the alkyl chain substitution at C3 position, somewhat decreases D1 affinity, maintains
or slightly decreases D3 receptor affinity while improving selectivity at D3 versus D2 receptor
when compared with (-)-SPD (2.1). All C3 analogues displayed a reduced affinity at the D2
receptor from 1.47 to 5.2 fold as compared to (-)-SPD (2.1). This reveals the significance of C3
alkoxy substituents to suppress the dopamine D2 receptor affinity. In contrast to the C10 analogue
series, larger lipophilic substituents are well tolerated at the C3 position for D3 receptor affinity as
demonstrated by n-hexyl (3.35e) and n-pentyl (3.35d) compounds.
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In our efforts to examine the effect of C10 and C3 alkoxy substituents on the metabolic
stability against hepatic enzymes, we studied representative analogues having di, tri and tetra
alkoxy substituents on the THPB scaffold. The results of this metabolic study indicate that having
phenolic hydroxyl group at C2 and/or C10 on THPB scaffold engenders susceptibility to hepatic
metabolism. Since this study was done using rat hepatocytes, further studies need to be done using
either fresh or cryopreserved human hepatocytes to mimic the actual human hepatic metabolism
environment.

3.8

Experimental

3.8.1

Chemistry

4-bromo-1-(ethoxymethoxy)-2-methoxybenzene (3.6)
Compound 3.5 (8.0 g, 39.4 mmol) and diisopropylethyl amine (13.7 mL, 78.8 mmol) were
stirred in DCM (100 mL) at 0 ̊ C for 15 min. Ethoxycholoromethyl ether (5.48 mL, 59.1 mmol)
was added dropwise to the solution at 0 ̊ C. The solution was allowed to stir at rt for 1 h. The
reaction mixture was washed with 0.1N HCl (120 mL). The organic layers were combined, dried
over sodium sulfate and evaporated to dryness to give 3.6 (11.1 g, quantitative) as a brownish oil.
This product was used in the subsequent reaction without any further purification: 1H NMR
(CDCl3, 500 MHz) δ 7.06-7.00 (m, 3H), 5.24 (s, 2H), 3.86 (s,3H), 3.76 (q, J = 7.1 Hz, 2H), 1.22
(t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 150.5, 145.9, 123.6, 117.7, 115.2, 114.4, 94.2,
64.5, 56.1, 15.1; HRMS (ESI) m/z calcd. for C10H13BrO3 ([M+Na]+), 282.9940, found 282.9942.

Methyl-3-(ethoxymethoxy)-2-methoxy-6-(2-methoxy-2-oxoethyl)benzoate (3.7)
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Diisopropylamine (11.49 mL, 84.3 mmol) was stirred in dry THF (100 mL) at -78 ºC in an
oven-dried round bottom flask for 15 min. n-butyllithium (2.5 M in hexane, 100 mL) was added
and the solution allowed to stir at -78 ºC for 30 min. Dimethylmalonate (18.85 mL, 164.7 mmol)
in 60 mL dry THF was added. After stirring the solution at -78 ºC for 1 h, a solution of 3.6 (10.0
g, 38.3 mmol) in 50 mL dry THF was added. After 45 min, the reaction mixture was quenched
with a saturated solution of ammonium chloride. THF was evaporated and the crude mixture was
extracted with dichloromethane (4 × 100 mL). The solvent was reduced in vacuo and the crude
product was purified via flash chromatography on silica gel (10% acetone/hexanes) to afford
compound 3.7 (6.7 g, 56%) as a yellowish oil: 1H NMR (CDCl3, 500 MHz) δ 7.20 (d, J = 8.5 Hz,
1H), 6.96 (d, J = 8.5 Hz, 1H), 5.26 (s, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.75 (q, J = 7.1 Hz, 2H),
3.68 (s, 3H), 3.62 (s, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 171.5, 167.6,
149.7, 147.6, 129.0, 126.4, 125.6, 118.0, 93.8, 64.6, 61.7, 52.2, 52.1, 38.4, 15.1; HRMS (ESI) m/z
calcd. for C15H20O7 ([M+Na]+), 335.1101, found 335.1104.
2-[4-(ethoxymethoxy)-3-methoxy-2-(methoxycarbonyl)phenyl]acetic acid (3.8)
Compound 3.7 (5.8 g, 18.4 mmol) and potassium carbonate (5.1 g, 36.8 mmol) were
refluxed in a 1:1 water/methanol mixture (150 mL) for 1 h. The methanol was evaporated and the
crude mixture was acidified with 0.1N HCl. The solution was extracted with ethyl acetate (3 × 100
mL) and dried over sodium sulfate. Filtration and evaporation of the ethyl acetate extract afforded
3.8 (5.4 g, 98%) as a yellowish oil. This was used in the next step without purification: 1H NMR
(CDCl3, 500 MHz) δ 7.21 (dd, J = 8.4, 2.7 Hz, 1H), 6.97 (dd, J = 8.4, 3.2 Hz , 1H), 5.26 (d, J =
1.8 Hz, 2H), 3.90 (d, J = 3.7 Hz, 3H), 3.88 (d, J = 2.0 Hz, 3H), 3.76 (q, J = 1.75 Hz, 2H), 3.64 (s,
2H), 1.27-1.21 (m, 3H);

13C

NMR (CDCl3, 125 MHz) δ 171.1, 168.8, 150.0, 147.9, 128.3, 126.6,
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125.4, 118.5, 93.7, 64.6, 61.7, 52.7, 38.9, 15.1; HRMS (ESI) m/z calcd. for C14H18O7 ([M+Na]+),
321.0945, found 321.0948.
Methyl-6-(2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-2-oxoethyl)-3-(ethoxymethoxy)-2methoxybenzoate (3.10)
Compound 3.8 (5.0 g, 16.8 mmol) was dissolved in 60 mL DCM and stirred at 0 ̊ C for 15
min. EDCI (3.2 g, 16.8 mmol) was added portion-wise to the solution at 0 ̊ C and the mixture
allowed to stir at rt for 1 h. A solution of 3.9 (4.3 g, 16.8 mmol) in 60 mL DCM was added to the
above reaction mixture at 0 ̊ C and allowed to stir overnight at rt. 50 mL DCM was added to the
reaction mixture and it was washed with sodium bicarbonate and 0.1N HCl consecutively. The
organic layer was dried, filtered and concentrated in vacuo to afford 3.10 (7.3 g, 81%) as a brown
oil : 1H NMR (CDCl3, 500 MHz) δ 7.43 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.3 Hz , 2H), 7.30 (d, J =
7.4 Hz, 1H), 7.17 (d, J = 8.5, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 6.68 (d, J =
1.9 Hz, 1H), 6.51 (dd, J = 8.1, 1.9 Hz, 1H), 5.25 (s, 2H), 5.11 (s, 2H), 3.88 (s, 6H), 3.84 (s, 3H),
3.75 (q, J = 7.05 Hz, 2H), 3.43-3.39 (m, 4H), 2.67 (t, J = 7.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C
NMR (CDCl3, 125 MHz) δ 170.3, 168.4, 149.7, 149.6, 147.3, 146.7, 137.4, 132.1, 128.8, 128.5,
128.5, 127.8, 127.3, 127.3, 126.8, 126.1, 120.6, 118.5, 114.2, 112.4, 93.8, 71.1, 64.7, 61.6, 55.9,
52.6, 41.2, 40.9, 35.2, 15.1; HRMS (ESI) m/z calcd. for C30H35NO8 ([M+Na]+), 560.2255, found
560.2260.
2-(benzyloxy)-10-hydroxy-3,9-dimethoxy-5,6,13,13a-tetrahydro-8H-isoquinolino[3,2a]isoquinolin-8-one (3.11)
Compound 3.10 (5 g, 9.3 mmol) and POCl3 (5.2 mL, 55.8 mmol) were refluxed in 80 mL
acetonitrile for 2 h. The solvent was evaporated and the residue was dissolved in 120 mL DCM.
The resulting solution was washed with sodium bicarbonate and then dried over sodium sulfate.
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The organic solvent was removed in vacuo and methanol (100 mL) was added. Sodium
borohydride (0.7 g, 18.6 mmol) was added at 0 ̊ C and the mixture allowed to stir overnight. The
reaction was quenched with water and methanol was evaporated. The residue was extracted with
DCM (3 × 80 mL). The organic layer was dried, filtered and evaporated to dryness to afford 3.11
(3.3 g, 82% over two steps). It was used in the next step without further purification: 1H NMR
(CDCl3, 500 MHz) δ 7.44 (d, J = 7.2 Hz, 2H), 7.38 (t, J = 7.2 Hz , 2H), 7.33 (d, J = 7.3 Hz, 1H),
7.06 (d, J =8.1 Hz, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.71 (s, 1H), 6.68 (s, 1H), 5.15 (s, 2H), 5.00-4.98
(m,1H), 4.68 (dd, J = 13.0, 3.4, 1H), 4.00 (s, 3H), 3.90 (s, 3H), 2.95-2.71 (m, 5H);

13C

NMR

(CDCl3, 125 MHz) δ 162.5, 149.0, 148.8, 147.3, 147, 137.0, 130.7, 128.6, 128.6, 128.1, 127.9,
127.51, 127.4, 127.4, 121.5, 122.8, 118.1, 112.6, 111.9, 71.6, 62.4, 56.1, 54.9, 38.9, 38.3, 29.4;
HRMS (ESI) m/z calcd. for C26H25NO5 ([M+H]+), 432.1805, found 432.1809.
(±)-SPD (2.1)
Lithium aluminum hydride (40 mg, 1.1 mmol) was stirred in THF at 0 ̊ C for 10 min.
Compound 3.11 (0.3 g, 0.7 mmol) in THF was added to the reaction mixture at 0 ̊ C and it was
allowed to reflux for 2 h. The reaction mixture was allowed to cool to rt and excess of lithium
aluminum hydride was quenched with water. THF was evaporated and crude mixture was
extracted with dichloromethane. The organic layer was dried over sodium sulfate, filtered and
evaporated to dryness. The crude product was refluxed in mixture of methanol (5 mL) and
concentrated hydrochloric acid (5 mL) for 3 h. The reaction mixture was basified by ammonia
solution and extracted with dichloromethane (20 mL × 2). The combined organic layer was dried
over sodium sulfate and concentrated to give the crude product, which was purified by flash
column chromatography on silica gel (2%-6% methanol/dichloromethane) to give compound 2.1
(0.29 g, 81% over two steps): Yellowish white crystals, mp 157 ̊ C;
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1H

NMR (CDCl3, 400MHz)

δ 6.83-6.78 (m, 3H), 6.60 (s, 1H), 4.20 (d, J = 15.8 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.58-3.53
(m, 2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 15.9, 11.4 Hz, 1H), 2.70-2.62 (m, 2H); 13C NMR (CDCl3,
400MHz) δ 146.4, 145.1, 144.0, 143.1, 130.4, 127.8, 127.3, 125.9, 125.0, 114.1, 111.3, 110.6,
60.7, 59.3, 55.9, 58.9, 51.7, 36.1, 29.1; HRMS (ESI) m/z calcd. for C19H21NO4 ([M+H]+),
328.1551, found 328.1543.
2-(benzyloxy)-10-hydroxy-3,9-dimethoxy-5,6-dihydro-8H-isoquinolino[3,2-a]isoquinolin-8one: (3.14)
Compound 3.10 (0.2 g, 0.37 mmol) and POCl3 (0.28 mL, 2.97 mmol) were refluxed in 10
mL acetonitrile for 3 h. The solvent was evaporated and the residue was dissolved in 25 mL DCM.
The resulting solution was washed with sodium bicarbonate and then organic layer was dried over
sodium sulfate. The organic solvent was removed in vacuo and the residues were dissolved in 10
mL dry DCM. Triethylamine (1.6 mL, 0.103 mmol) was added to the solution and allowed to stir
at rt for 2 h. Reaction mixture was washed with 0.1N HCl and extracted with DCM (3 × 15 mL).
The combined organic layer was evaporated and concentrated to give the crude product, which
was purified by flash column chromatography on silica gel (1.5%-3% methanol/dichloromethane)
to give compound 3.14 (0.11 g, 70% over two steps):

1H

NMR (CDCl3, 500MHz) δ 7.49 (d, J

=7.4 Hz, 2H), 7.40 (t, J = 7.3 Hz , 2H), 7.35-7.30 (m,2H), 7.27 (s, 1H), 7.20 (d, J = 8.6 Hz, 1H),
6.75 (s, 1H), 6.60 (s, 1H), 5.21 (s, 2H), 4.31 (t, J = 6.1 Hz, 2H), 4.04 (s, 3H), 3.93 (s, 3H), 2.92 (t,
J = 6.1 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 159.7, 151.0, 147.7, 147.6, 145.5, 136.9, 135.3,
132.2, 129.0, 128.5, 128.5, 127.9, 127.4, 127.4, 122.9, 122.3, 121.1, 118.1, 111.3, 111.0, 101.4,
71.9, 62.6, 56.0, 39.4, 28.2; HRMS (ESI) m/z calcd. for C26H23NO5 ([M+H]+), 430.1649, found
430.1652.
Oxypalmatine (3.15)
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Compound 3.14 (0.1 g, 0.23 mmol) was refluxed in a mixture of methanol (5 mL) and
concentrated hydrochloric acid (3 mL) for 3h. Methanol was evaporated and the resultant mixture
was basified with ammonia solution and extracted with dichloromethane (3 × 10 mL). The
combined organic layer was dried and concentrated to give a crude product, which was used in the
next step without further purification. Crude residues were dissolved in 5 mL DMF. Potassium
carbonate (63 mg, 0.46 mmol) and methyl iodide (0.04 mL, 0.7 mmol) were added and reaction
mixture was stirred at rt for 6 h. DMF was evaporated and 0.1 N HCl (10 mL) was added in it. The
crude mixture was extracted with dichloromethane (3 × 10 mL). The combined organic layer was
dried over sodium sulfate the crude product was purified by flash column chromatography on silica
gel (1% - 3% methanol/dichloromethane) to yield oxypalmatine (3.15) (0.07 g, 79%) as yellowish
solid. mp: 178-185 ̊ C. 1H NMR (CDCl3, 500 MHz) δ 7.33 (d, J =8.8 Hz, 1H), 7.3 (d, J = 8.7 Hz
, 1H), 7.23 (s, 1H), 6.76 (s, 1H), 6.73 (s, 1H), 4.32 (t, J = 6.1 Hz, 2H), 4.02 (s, 3H), 3.98 (s, 3H),
3.96 (s, 3H), 3.94 (s, 3H), 2.93 (t, J = 6.1 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 160.3, 151.4,
150.1, 149.6, 148.4, 135.6, 132.4, 128.5, 122.3, 122.1, 119.4, 118.9, 110.5, 107.5, 100.9, 61.6,
56.9, 56.24, 56.0, 39.4, 28.2; HRMS (ESI) m/z calcd. for C21H21NO5 ([M+H]+), 368.1492, found
368.1497.
2-(4-(benzyloxy)-3-methoxyphenethyl)-7-(ethoxymethoxy)-8-methoxyisoquinoline1,3(2H,4H)-dione (3.21)
Compound 3.10 (0.1 g, 0.18 mmol) was dissolved in MeOH (5 mL) and reaction mixture
was allowed to cool at 0 ̊C. NaBH4 (14 mg, 0.36 mmol) was added slowly in to reaction mixture
and it was stirred for 1 hr at rt. Excess NaBH 4 was quenched with water and then solvent was
evaporated. Crude mixture was extracted with DCM (2 X 10 mL), combined organic layer was
dried over Na2SO4, and concentrated under reduced pressure to obtain crude residue, which was
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purified by column chromatography on silica gel using 1:99 MeOH:DCM as eluent to afford
compound 3.21 (0.05 g, 54%); 1H NMR (500 MHz, CDCl3) δ 7.44 (m, 3H), 7.37 (t, J = 5.0 Hz,
2H), 7.29 (t, J = 7.3 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 1.2 Hz, 1H), 6.81-6.77 (m,
2H), 5.29 (s, 2H), 5.12 9s, 2H), 4.17-4.14 (m, 2H), 3.94-3.88 (m, 8H), 3.78 (q, J = 7.1 Hz, 2H),
2.86-2.83 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (500 MHz, CDCl3) δ 169.6, 162.6, 151.9,
150.7, 149.5, 146.7, 137.3, 131.9, 128.5 X 2, 128.3, 127.7, 127.3, 122.9, 122.4, 121.0, 119.6,
114.2, 114.1, 112.6, 94.2, 71.1, 64.7, 61.5, 56.0, 41.6, 36.4, 33.7, 15.1; HRMS (ESI) m/z calcd for
C29H31NO7 ([M+H]+), 506.2179, found 506.2168.
2-(4-(benzyloxy)-3-methoxyphenethyl)-7-(ethoxymethoxy)-8-methoxyisoquinoline1,3(2H,4H)-dione (3.22)
Solution of compound 3.10 (0.1 g, 0.18 mmol) in THF (5 mL) was added to the suspension
of LiBH4 (8 mg, 0.36 mmol) in THF at 0 ̊C and reaction mixture was allowed to stir for 2 hr at rt.
Excess LiBH4 was quenched with water and then solvent was evaporated. Crude mixture was
extracted with DCM (2 X 10 mL), combined organic layer was dried over Na2SO4, and
concentrated under reduced pressure to obtain crude residue, which was purified by column
chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound 3.22 (0.05 g,
52%); 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 7.3 Hz, 2H), 7.3 (t, J = 7.7 Hz, 2H), 7.30-7.27
(m, 1H), 7.17 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 6.82-6.81 (m, 2H), 6.72 (dd, J = 8.2,
2.0 Hz, 1H), 6.29 (s, 1H), 5.24 (s, 2H), 5.13 (s, 2H), 3.90-3.84 (m, 4H), 3.80-3.71 (m, 8H), 2.87
(t, J = 7.0, 2H), 2.73 (t, J = 6.0, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (500 MHz, CDCl3): δ
167.7, 149.8, 148.7, 146.9, 146.3, 137.3, 131.9, 131.8, 128.5, 127.8, 127.3, 126.0, 120.7, 118.0,
114.4, 112.5, 93.8, 71.1, 64.5, 63.8, 61.8, 56.0, 41.0, 35.5, 35.2, 15.1; HRMS (ESI) m/z calcd for
C29H35NO7 ([M+H]+), 510.2486, found 510.2489.
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methyl 3-(benzyloxy)-2-methoxy-6-(2-methoxy-2-oxoethyl)benzoate (3.27):
Compound 3.7 (2 g, 6.4mmol) was refluxed in methanol with conc. HCl (1 mL) for 2 hr.
Solvent was evaporated and the residues were dissolved in acetonitrile (50 mL). K 2CO3 (1.7g, 12.8
mmol) and benzyl bromide (0.77 mL, 6.5 ) were added. Reaction mixture was refluxed for 3 hrs.
Solvent was evaporated and residues were extraced with water (30 mL) and ethyl acetate (20 mL
x3). Ethyl acetate layer was dried over sodium sulfate and evaporated to dryness to give compound
3.27 ( 2.2 g, quant.) as brown oily liquid. This product was used in the subsequent reaction without
any further purification: 1H NMR (CDCl3, 400 MHz) δ 7.44-7.33 (m, 5H), 6.98-6.92 (m, 2H), 5.12
(s, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.67 (s, 3H), 3.62 (s, 3H) 13C NMR (CDCl3, 100 MHz) δ 171.56,
167.67, 151.11, 147.42, 136.65, 129.06, 128.64 x 2, 128.05, 127.24 x 2, 126.27, 124.79, 115.81,
70.95, 61.62, 52.25, 52.06, 38.34; (ESI) m/z calcd. for C19H20O6 ([M+Na]+), 367.1152, found
367.1161.
3-(benzyloxy)-2-methoxy-6-(2-methoxy-2-oxoethyl)benzoic acid (3.28):
Compound 3.27 (2.1 g, 6.1 mmol) was relfuxed with 10% NaOH (10 mL ) in ethanol (20 mL ) for
1 hr. Solvent was evaporated and the residues were acidified with 3 N HCl and it was extraced
with ethyl acetate (20 mL x 3). Organic layer was dried over sodium sulfate and evaporated to
dryness. Residues were dissolved in to methanol and SOCl2 (0.11 mL, 1.5 mmol) was added and
allowed it to stir overnight at rt. Mehanol was evaporated and residues were washed with water
(50 mL) and ethyl acetate (20 mL x 3). Ethyl acetate layer was dried over sodium sulfate and
evaporated to dryness to give compund 3.28 (1.97 g, 98%) as yellowish viscous liquid. This
product was used in the subsequent reaction without any further purification: 1H NMR (CDCl3,
400 MHz) δ 7.45-7.34 (m, 5H), 7.08 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 5.15 (s, 2H),
4.04 (s, 3H), 3.88 (s, 2H), 3.71 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 172.20, 166.79, 150.88,
148.53, 136.16, 128.75, 128.41 x 2, 128.31, 128.15, 127.35 x 2, 124.50, 117.09, 71.16, 62.28,
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52.03, 39.78; (ESI) m/z calcd. for C18H18O6 ([M+Na]+), 335.0996, found 335.1003. 2-(benzyloxy)3,9,10-trimethoxy-5,8,13,13a-tetrahydro-6H- isoquinolino[3,2-a]isoquinoline (3.30)
Compound 3.11 (3.3 g, 7.6 mmol) in 50 mL THF was added to a suspension of lithium
aluminum hydride (0.6 g, 15.2 mmol) at 0 ̊C and the reaction mixture allowed to come down at
room temperature and then it was refluxed for 1 h. The reaction mixture was allowed to cool to rt
and excess of lithium aluminum hydride was quenched with water. THF was evaporated and the
crude mixture was extracted with dichloromethane (4 × 50 mL). Combined organic layers were
dried over sodium sulfate and concentrated in vacuo and the crude product was purified via flash
chromatography on silica gel (2% MeOH/DCM) to afford compound 3.30 (2.7 g, 84%) 1H NMR
(CDCl3, 500 MHz ) δ 7.46 (d, J = 7.4 Hz , 2H), 7.39-7.35 (m, 2H), 7.31 (t, J = 7.4 Hz, 1H), 6.78
(dd, J = 10.3, 8.3 Hz, 2H), 6.74 (s, 1H), 6.64 (s, 1H), 5.14 (s, 2H), 4.19 (d, J = 15.3 Hz, 1H), 3.88
(s, 3H), 3.80 (s, 3H), 3.56-3.49 (m, 2H), 3.20-3.06 (m, 3H), 2.73-2.61 (m, 3H); 13C NMR (CDCl3,
125 MHz) δ 148.3, 146.5, 146.5, 143.1, 137.3, 129.6, 128.5, 128.5, 128.0, 127.8, 127.5, 127.5,
127.4, 127.3, 125.0, 114.0. 112.2, 111.9, 71.6, 60.7, 59.3, 56.0, 53.9, 51.5, 36.2, 29.1 HRMS (ESI)
m/z calcd. for C26H27NO4 ([M+H]+), 418.2013, found 418.2007.

General procedure for synthesis of compounds 3.29a-3.29h (as described for compound
3.29a):
3,9,10-trimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol (3.29a)
Compound 3.30 (0.1 g, 0.24 mmol) was dissolved in DMF. Potassium carbonate (0.07 g,
0.48 mmol) and methyl iodide (0.02 mL, 0.36 mmol) were added and the reaction mixture was
stirred overnight at rt. The crude reaction solution was filtered and the filtrate was evaporated to
dryness. The residue was refluxed in a mixture of MeOH (5 mL) and concentrated HCl (3 mL) for
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3 h. The MeOH was evaporated and the crude mixture was basified with ammonia solution and
extracted with DCM (3 × 15 mL). The combined organic layer was dried over anhydrous Na2SO4
and concentrated to give the crude product, which was purified by flash column chromatography
on silica gel (2% MeOH/DCM) to give compound 3.29a (0.052 g, 64%) as an off-white solid; mp
208-210 ̊ C; 1H NMR (CDCl3, 400 MHz) δ 6.87-6.77 (m, 3H), 6.60 (s, 1H), 5.56 (s, 1H), 4.24
(d, J = 15.7 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 6H), 3.54-3.50 (m, 2H), 3.26-3.11 (m, 3H), 2.81 (dd, J
= 16, 11.5 Hz, 1H), 2.68-2.61 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 150.2, 145.1, 143.9, 143.9,
130.6, 128.7, 127.9, 126.1, 124.0, 111.3, 111.0, 110.6, 60.2, 59.3, 59.3, 55.9, 54.0, 51.7, 36.3, 29.2;
HRMS (ESI) m/z calcd. for C20H23NO4 [M+H]+, 342.1700, found 342.1704.
10-ethoxy-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol
(3.29b)
Yield 67%; off-white powder, mp 186-188 ̊ C ; 1H NMR (CDCl3, 400 MHz) δ 6.85-6.77
(m, 3H), 6.60 (s, 1H), 4.24 (d, J = 15.8 Hz, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.88 (s, 3H), 3.87 (s,
3H), 3.52 (d, J = 15.3 Hz, 2H), 3.27-3.10 (m, 3H), 2.84-2.61 (m, 3H), 1.44 (t, J = 7.0 Hz, 3H); 13C
NMR (CDCl3, 100 MHz) δ 147.5, 143.5 143.2, 142.0, 128.7, 126.7, 125.9, 124.2, 122.0, 110.5,
109.5, 108.7, 62.5, 58.2, 57.4, 54.0, 52.2, 49.8, 34.4, 27.3, 13.1; HRMS (ESI) m/z calcd. for
C21H25NO4 [M+H]+, 356.1856, found 356.1861.
3,9-dimethoxy-10-propoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol
(3.29c)
Yield 68%; brown solid, mp 87-90 ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.84-6.78 (m, 3H),
6.60 (s, 1H), 4.23 (d, J = 15.8 Hz, 1H), 3.94 (dt, J = 6.7, 1.8 Hz, 2H), 3.87 (s, 6H), 3.51 (d, J =
15.3 Hz, 2H), 3.25-3.10 (m, 3H), 2.80 (dd, J = 15.6, 11.4 Hz, 1H), 2.68-2.60 (m, 2H), 1.84 (sex, J
= 7.1 Hz, 2H), 1.06 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 149.6, 145.3, 145.1, 144.0,
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130.6, 128.6, 127.8, 126.0, 123.8 112.3, 111.3, 110.6, 70.4, 60.2, 59.2, 55.9, 54.1, 51.7, 36.3, 29.2,
22.8, 10.7; HRMS (ESI) m/z calcd. for C22H27NO4 [M+H]+, 370.2013, found 370.2020.
10-butoxy-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol
(3.29d)
Yield 73%; orange oil; 1H NMR (CDCl3, 400 MHz) δ 6.84-6.77 (m, 3H), 6.60 (s, 1H), 4.24
(d, J = 15.7 Hz, 1H) 3.98 (dt, J =1.0, 6.45 Hz, 2H), 3.86 (s, 6H), 3.52 (d J = 15.0 Hz, 2H), 3.253.10 (m, 3H), 2.80 (dd, J = 15.2, 11.3 Hz, 1H), 2.67-2.60 (m, 2H), 1.80 (quin, J = 6.9 Hz, 2H),
1.52 (sex, J = 7.6 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 149.6, 145.3,
145.1, 143.9, 130.5, 128.5, 127.7, 126.0, 123.8, 112.2, 111.3, 110.6, 68.5, 60.1, 59.2, 55.9, 54.0,
51.6, 36.2, 31.5, 29.2, 19.4, 13.9; HRMS (ESI) m/z calcd. for C23H29NO4 [M+H]+, 384.2169, found
384.2173.
3,9-dimethoxy-10-(pentyloxy)-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol
(3.29e)
Yield 65%; brown oil; 1H NMR (CDCl3, 400 MHz ) δ 6.84-6.76 (m, 3H), 6.60 (s, 1H), 4.23
(d, J = 15.8 Hz, 1H), 3.97 (dt, J =1.5, 6.55 Hz, 2H), 3.87 (s, 6H), 3.51 (d, J = 15.2 Hz, 2H), 3.263.10 (m, 3H), 2.80 (dd, J = 15.7, 11.5 Hz, 1H), 2.68-2.60 (m, 2H), 1.82 (quin, J = 6.7 Hz, 2H),
1.49-1.36 (m, 4H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 149.6, 145.3, 145.0,
143.9, 130.6, 128.6, 127.7, 126.1, 123.8, 112.3, 111.3, 110.6, 68.9, 60.2, 59.2, 55.9, 54.6, 51.6,
36.3, 29.2, 29.1, 28.3, 22.5, 14.0; HRMS (ESI) m/z calcd. for C24H31NO4 [M+H]+, 398.2326, found
398.2326.
10-(hexyloxy)-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol
(3.29f)
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Yield 70%; dark brown oil; 1H NMR (CDCl3, 500MHz ) δ 6.84-6.76 (m, 3H), 6.60 (s, 1H),
4.23 (d, J = 15.7 Hz, 1H), 3.97 (t, J = 6.6 Hz , 2H), 3.86 (s, 6H), 3.53-3.50 (m, 2H), 3.26-3.10 (m,
3H), 2.80 (dd, J = 15.8, 11.6 Hz, 1H), 2.68-2.60 (m, 2H), 1.81 (quin, J = 6.7 Hz, 2H), 1.48 (quin,
J= 7.2, 2H), 1.34 (sex, J = 3.8 Hz, 4H), 0.91 (t, J= 7.0 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ
149.6, 145.3, 145.0, 143.9, 130.6, 128.6, 127.7, 126.1, 123.8, 112.3, 111.4, 110.6, 68.9, 60.2, 59.2,
55.9, 54.1, 51.7, 36.3, 31.6, 29.4, 29.2, 25.8, 22.6, 14.0; HRMS (ESI) m/z calcd. for C25H33NO4
[M+H]+, 412.2482, found 412.2429.
10-(3-hydroxypropoxy)-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2a]isoquinolin-2-ol (3.29g)
Yield 76%; reddish-brown solid, mp 73-78 ̊ C; 1H NMR (CDCl3, 500MHz ) 6.87-6.80 (m,
3H), 6.60 (s, 1H), 4.22 (d, J = 15.7 Hz, 1H), 4.16 (td, J = 6.1, 1.5 Hz, 2H), 3.91-3.84 (m, 8H),
3.52 (d, J = 15.4 Hz, 2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 15.7, 11.6 Hz, 1H), 2.68-2.61 (m, 2H),
2.07 (quin, J = 5.8 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 149.4, 145.4, 145.1, 143.9, 130.5,
128.8, 128.4, 126.1, 124.1, 112.5, 111.3, 110.6, 67.5, 61.0, 60.3, 59.2, 55.9, 54.0, 51.6, 36.3, 32.1,
29.2; HRMS (ESI) m/z calcd. for C22H27NO5 [M+H]+, 386.1884, found 386.1897.
10-(cyclopropylmethoxy)-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2a]isoquinolin-2-ol (3.29h)
Yield 81%; yellow oil; 1H NMR (CDCl3, 500 MHz ) δ 6.83-6.76 (m,3H), 6.60 (s, 1H),
4.23 (d, J = 15.7 Hz, 1H), 3.90- 3.83 (m, 8H), 3.51 (d, J = 15.1 Hz, 2H), 3.26-3.11 (m, 3H), 2.80
(dd, J = 15.0, 12.0 Hz, 1H), 2.68-2.62 (m, 2H), 1.31-1.27 (m, 1H), 0.61 (q, J = 5.7 Hz, 2H), 0.36
(q, J = 4.85 Hz, 2H);

13C

NMR (CDCl3, 125 MHz) δ 149.5, 145.7, 145.0, 143.9, 130.6, 128.6,

128.1, 126.1, 123.8, 113.1, 111.3, 110.6, 73.9, 60.2, 59.2, 55.9, 54.1, 51.6, 36.3, 29.2, 10.5, 3.2,
3.2; HRMS (ESI) m/z calcd. for C23H27NO4 [M+H]+, 382.2013, found 382.2019.
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4-(benzyloxy)-3-hydroxybenzaldehyde (3.37)
To a stirring solution of 3,4-dihydroxybenzaldehyde, 3.36 (2.5 g, 18.1 mmol) in anhydrous
Acetonitrile (50 mL), was added K2CO3 (2.5 g, 18.1 mmol) followed by benzyl bromide (3.2 mL,
27.15 mmol) slowly, at room temperature, under an inert atmosphere. Resulting reaction mass was
heated to reflux temperature and stirring was continued for 2 h. The reaction solvent was removed
by evaporation under reduced pressure and to the resulted residue was added cold 10% NaOH
solution and stirred for 10 min. and added the ethyl acetate (2 x 50 mL). Resulted biphasic mixture
was separated and aqueous layer was acidified using 4N HCl and extracted with DCM (3 x 30
mL), combined organic layer was washed with brine solution, water, dried on Na2SO4, and
concentrated under reduced pressure to obtain the residue, which was purified by crystallization
using ethylacetate to afford, 3.37 (2.7 g, 65%); 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H), 7.467.38 (m, 7H), 7.03 (d, J = 8.2 Hz, 1H), 5.81 (s, 1H), 5.20 (s, 2H); 13C NMR (400 MHz, CDCl3) δ
190.9, 150.9, 146.3, 135.2, 130.8, 128.9 X 2, 128.8, 127.9 X 2, 124.3, 114.4, 111.5, 71.2; HRMS
(ESI) m/z calcd for C14H12O3 ([M+H]+), 229.0859, found 229.0863.

2-(benzyloxy)-5-(2-nitrovinyl)phenoxy)(tert-butyl)diphenylsilane (3.38)
Compound 3.37 (2.7 g, 11.8 mmol) was dissolved in anhydrous DCM (50 mL). Imidazole
(1.6 g, 23.6 mmol) and DMAP (0.1 g, 0.12 mmol) were added in to reaction mixture and allowed
it to stir at 0 ̊C for 10 minute. To the reaction mixture, TBDPSCl (4.6 mL 17.7 mmol) was added
and the reaction was allowed to stir overnight at rt. Reaction mixture was acidified with 2N HCl
and extracted with (2 x 40 mL) DCM. Combined organic layer was washed with brine solution,
water, dried on Na2SO4, and concentrated under reduced pressure to obtain the crude residue,
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which was used in the next step without further purification. Residues were dissolved in 50 mL
acetic acid, NH4OAc (1.0 , 12.98 mmol) and CH3NO2 (2.5, 47.2 mmol) were added in it and
allowed it to reflux for 8 hr. Solvent was evaporated and the residues were basified using 10%
NaOH and extracted with DCM (2 x 50 mL). Combined organic layer was dried over Na2SO4, and
concentrated under reduced pressure to obtain a crude residue, which was purified by column
chromatography on silica gel using 10:90 EtOAC:Hexanes as eluent to afford compound 3.38 (5.1
g, 85% over two steps); 1H NMR (400 MHz, CDCl3) δ 7.73-7.63 (m, 5H), 7.46-7.27 (m, 11H),
7.05-7.00 (m, 2H), 6.86-6.77 (m, 2H), 4.97 (s, 2H), 1.10 (s, 9H); 13C NMR (400 MHz, CDCl3) δ
153.5, 145.8, 139.1, 136.1 X 2, 135.4 X 2 , 135.3 X 2, 135.0, 134.8, 132.8, 130.1, 129.7, 128.5 X
3, 128.0 X 2, 127.8 X 4, 127.4 X 2, 124.8, 122.7, 119.5, 113.5, 70.5, 26.6; HRMS (ESI) m/z calcd
for C31H31NO4Si ([M+H]+), 510.2101, found 510.2098.
2-(4-(benzyloxy)-3-((tert-butyldiphenylsilyl)oxy)phenyl)ethan-1-amine (3.39)
In a dry round bottom flask, LiBH4 (1.8 g, 82.4 mmol), was suspended in THF (30 mL)
and TMSCl (5.3 mL, 41.2 mmol) was added slowly. Solution of compound 3.38 (5.1 g, 10.3 mmol)
in THF (30 mL) was added slowly in to reaction mixture and allowed to reflux overnight. Reaction
was allowed to cool at rt and excess LiBH4 was quenched with MeOH. 10% NaOH (20 mL) was
added to the reaction and it was filtered through celite. Solvent was evaporated and the crude
mixture was extracted with DCM (2 x 50 mL). Combined organic layer was dried over Na2SO4,
and concentrated under reduced pressure to obtain compound 3.39; 1H NMR (400 MHz, CDCl3)
δ 7.72-7.68 (m, 5H), 7.41-7.27 (m, 10H), 6.74 (d, J = 6.6 Hz, 1H) 6.62 (dd, J = 1.4, 6.5 Hz, 1H),
6.4 (d, J = 1.5 Hz, 1H), 4.88 (s, 2H), 2.72 (t, J = 5.8 Hz, 2H), 2.59 (t, J = 5.8 Hz, 2H), 1.08 (s, 9H);
13C

NMR (400 MHz, CDCl3) δ 147.5, 144.4, 136.1, 134.4 X 2 , 135.3 X 2, 133.7, 132.2, 129.1,
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128.7 X 3, 128.6, 127.2 X 4, 126.8 X 2, 126.7, 126.4 X 2, 120.7, 119.7, 113.2 X 2, 69.6, 40.9,
34.5, 25.5; HRMS (ESI) m/z calcd for C31H35NO2Si ([M+H]+), 482.2515, found 482.2509.
2-(4-(benzyloxy)-2-(hydroxymethyl)-3-methoxyphenyl)-N-(4-(benzyloxy)-3-((tertbutyldiphenylsilyl) oxy)phenethyl)acetamide (3.40)
Compound 2.102 (1.5 g, 5.3 mmol) and primary amine 3.39 (2.5g, 5.3 mmol) were refluxed
in to ethanol (20 mL) for 16 h. Solvent was evaporated and the residues were purified by column
chromatography (2 % MeOH/DCM) to yield 3.40 (3.2g, 78%). 1H NMR (CDCl3, 600 MHz) δ 7.69
(dd, J = 8.1, 1.3 Hz, 4H), 7.43-7.36 (m, 6H), 7.33-7.28 (m, 10H), 6.82 (d, J = 8.4 Hz, 1H), 6.72 (d,
J = 8.4 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.42-6.38 (m, 2H), 5.56 (s, 1H), 5.10 (s, 2H), 4.93 (s,
2H), 4.64 (d, J = 6.2 Hz, 2H), 3.93 (s, 3H), 3.55 (t, J = 6.2 Hz, 1H), 3.35 (s, 2H), 3.11 (q, J = 6.4
Hz, 2H), 2.41 (t, J = 6.6 Hz, 2H), 1.09 (s, 9H); 13C NMR (CDCl3, 150 MHz) δ 171.4, 151.1, 148.7,
145.5, 137.3, 137.0, 135.5 X 3, 134.2, 133.4, 131.4, 129.8 X 3, 128.6 X 3, 128.3 X 3, 128.0 X 3,
127.7 X 2, 127.6 X 2, 127.4 X 2, 127.2 X 2, 125.6, 121.8, 120.6, 114.3, 114.1, 70.8 X 2, 61.8,
56.6, 40.7, 40.6, 34.3, 26.6 X 3, 19.7; (ESI) m/z calcd. for C48H51NO6Si ([M+Na]+), 788.3378,
found 788.3416.
3-(benzyloxy)-6-(2-((4-(benzyloxy)-3-((tert-butyldiphenylsilyl)oxy)phenethyl)amino)-2oxoethyl)-2-methoxybenzyl acetate (3.41)
To the solution of compound 3.40 (3.1 g, 4.1 mmol) in DCM (20 mL) was added pyridine
(0.6 mL, 8.2 mmol) and DMAP (10 mg, 0.08 mmol). The mixture was cooled to 0 ̊ C and acetic
anhydride (0.8 mL, 8.2 mmol) was added dropwise. The solution was allowed to stir for 1.5 h at
room temperature, the reaction mixture was diluted with DCM (20 mL), washed with 1 N HCl and
dried over sodium sulfate and concentrated. The residue was purified by flash chromatography
(1.5% MeOH/DCM) to afford 3.41 (3.1 g, 92%). 1H NMR (CDCl3, 500 MHz) δ 7.66 (dd, J = 8.1,
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1.3 Hz, 4H), 7.41-7.36 (m, 6H), 7.33-7.27 (m, 10H), 6.88 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 8.4 Hz,
1H), 6.68 (d, J = 8.4 Hz, 1H), 6.40-6.38 (m, 2H), 5.14 (s, 2H), 5.08 (s, 2H), 4.88 (s, 2H), 3.88 (s,
3H), 3.45 (s, 2H), 3.10 (q, J = 6.7 Hz, 2H), 2.40 (t, J = 6.8 Hz, 2H), 1.97 (s, 3H), 1.07 (s, 9H););
13C

NMR (CDCl3, 125 MHz) δ 170.8, 170.5, 151.1, 149.2, 148.3, 145.4, 137.2, 136.6, 135.4 X 3,

133.3, 131.2, 129.7 X 3, 128.6 X 3, 128.3 X 3, 128.0 X 3, 127.6 X 4, 127.4 X 2, 127.2 X 2, 126.2,
121.6, 120.5, 114.8, 114.1, 70.7 X 2, 61.4, 58.4, 40.5, 40.4, 34.5, 26.6 X 3, 20.9, 19.7; (ESI) m/z
calcd. for C50H53NO7Si ([M+Na]+), 830.3489, found 830.3491.
(S)-3-(benzyloxy)-6-((7-(benzyloxy)-6-hydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)2-methoxybenzyl acetate (3.42)
To the solution of 3.41 (3.0 g, 3.7mmol) in dry acetonitrile (20 mL) was added POCl3 (2.1
mL, 22.3 mmol) and the mixture was refluxed for 1 h. The reaction mixture was cooled to room
temperature and the solvent was evaporated. The residue was dissolved in DCM (30 mL) and
washed with saturated NaHCO3 (15 mL). The organic layer was dried over sodium sulfate and
evaporated to dryness. The yellow solid residue was dissolved in DMF (15 mL) and RuCl[(R,R)TsDPEN(P-cymene)] (20 mg, 0.03 mmol) was added under nitrogen. The solution was purged
Nitrogen gas for 15 minutes. The mixture of formic acid (0.8 mL, 20.7 mmol ) and triethyl amine
(0.3 mL 2.21 mmol) was added in to the reaction mixture and allowed it to stir overnight at rt. The
reaction mixture was adjusted pH to 8 with saturated NaHCO 3 and extracted with ethyl acetate (3
X 35 mL). The combined organic layer was washed with brine, dried over Na2SO4 and
concentrated. The crude product was purified by column chromatography on silica gel using 3:97
to 5:95 MeOH:DCM as eluent to afford compound, 3.42 (1.4 g, 67% from two steps).
(S)-2,10-bis(benzyloxy)-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2a]isoquinolin-3-ol (3.43)
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Compound 3.42 (1.4 g, 2.5 mmol) was dissolved in ethanol (20 mL) and added 10% NaOH
(10 mL) to the solution then the mixture was refluxed for 1 h. The mixture was cooled and ethanol
was evaporated. The residue was extracted with ehylacetate (2 X 30 mL) and the combined organic
layer was washed dried over Na2SO4 and evaporated to dryness. The residues were dissolved in
dry DCM (15 mL) and the solution was cooled 0 ̊ C. Thionyl chloride (0.9 mL, 12.5 mmol) was
added dropwise to the reaction mixture and allowed it to stir for 1 hr. Reaction solution was cooled
to 0 ̊ C and saturated NaHCO3 (30 mL) was added to it and allowed it stir for 1 h. Reaction
mixture was extracted with DCM (2 X 50 mL), combined organic layer was dried over sodium
sulfate and evaporated to dryness. The crude product was purified by column chromatography on
silica gel using 1:99 MeOH:DCM as eluent to afford compound, 3.43 (1.1 g, 88% over two
steps).1H NMR (CDCl3, 500 MHz) δ 7.45-7.37 (m, 10H), 6.83 (s, 2H), 6.78 (s, 1H), 6.71 (s, 1H),
5.58 (s, 1H), 5.14-5.06 (m, 4H), 4.25 (d, J = 15.8 Hz, 1H), 3.90 (s, 3H), 3.55-3.52 (m, 2H), 3.203.08 (m, 3H), 2.80 (dd, J = 11.5, 15.4 Hz, 1H), 2.67-2.60 (m, 2H); 13C NMR (CDCl3, 120 MHz) δ
149.3, 145.6, 144.3, 144.2, 137.2, 136.4, 129.2, 128.9, 128.7 X 2, 128.5 X 2, 128.4, 128.2, 128.0,
127.9, 127.8 X 2, 127.3 X 2, 123.7, 114.4, 113.1, 109.4, 71.4, 70.9, 60.3, 59.3, 54.0, 51.5, 36.5,
28.9; (ESI) m/z calcd. for C32H31NO4 ([M+H]+), 494.2326, found 494.2330.
General synthetic procedure for the compounds 3.35a-3.35f as demonstrated for 3.35a
(S)-3-ethoxy-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10-diol
(3.35a)
Compound, 3.43 (1.0 eq) was dissolved in anhydrous DMF and added K 2CO3 (2.0 eq)
followed by ethyl bromide (1.2 eq). Resulted reaction mass was allowed to stir at rt for 5 h. The
reaction mass was quenched with cold water and extracted with ethyl acetate (3 x 50 mL).
Combined organic layer was washed with brine solution, dried over Na2SO4 and concentrated to
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obtain a residue, which was used in the next step without further purification. Residues were
dissolved in ethanol (10 mL) and refluxed with conc. HCl (4 mL) for 3 hr. The reaction mixture
was concentrated in vacuo and residue was basified using aqueous ammonia solution and extracted
with ethyl acetate (2 X 20 mL). Combined organic layer was washed with brine solution, dried
over Na2SO4 and concentrated under reduced pressure to obtain a residue, which was purified by
column chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound 3.35a.
Yield 71 %, white solid, Mp 104 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.84-6.79 (m, 3H), 6.59 (s,
1H), 4.20 (d, J = 15.4 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 3.81 (s, 3H), 3.58-3.53 (m, 2H), 3.27-3.09
(m, 3H), 2.80 (dd, J = 11.4, 15.9 Hz, 1H), 2.67-2.62 (m, 2H), 1.45 (t, J = 7.0, 3H);

13C

NMR

(CDCl3, 125 MHz) δ 146.4, 144.3, 144.0, 143.1, 130.3, 127.9, 127.3, 125.8, 125.0, 114.0, 111.4,
111.2, 64.4, 60.7, 59.3, 53.9, 51.7, 36.2, 29.1, 14.0; (ESI) m/z calcd. for C20H23NO4 ([M+H]+),
342.1700, found 342.1697.
(S)-9-methoxy-3-propoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10diol (3.35b)
Yield 75%, dark brown solid, Mp 82 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.85-6.81 (m, 3H),
6.59 (s, 1H), 4.28 (d, J = 15.4 Hz, 1H), 3.99 (t, J = 6.6 Hz, 2H), 3.82 (s, 3H), 3.65-3.58 (m, 2H),
3.28-3.24 (m, 2H), 3.15 (td, J = 5.6, 16.7 Hz, 1H), 2.84 (dd, J = 11.8, 16.0 Hz, 1H), 2.70-2.66 (m,
2H), 1.84 (sext, J = 7.1 Hz, 2H), 1.05 (t, J = 7.5, 3H); 13C NMR (CDCl3, 125 MHz) δ 146.5, 144.5,
144.1, 143.2, 130.3, 127.9, 127.3, 125.8, 125.0, 114.2, 111.5, 111.2, 70.4, 60.7, 59.4, 53.9, 51.7,
36.1, 29.1, 22.6, 10.5; (ESI) m/z calcd. for C21H25NO4 ([M+H]+), 356.1856, found 356.1849.
(S)-3-butoxy-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10-diol
(3.35c)
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Yield 76%, yellowish powder, Mp 85 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.85-6.81 (m,
3H), 6.59 (s, 1H), 4.28 (d, J = 15.4 Hz, 1H), 3.99 (t, J = 6.6 Hz, 2H), 3.82 (s, 3H), 3.65-3.58 (m,
2H), 3.28-3.24 (m, 2H), 3.15 (td, J = 5.6, 16.7 Hz, 1H), 2.84 (dd, J = 11.8, 16.0 Hz, 1H), 2.70-2.66
(m, 2H), 1.84 (sext, J = 7.1 Hz, 2H), 1.05 (t, J = 7.5, 3H); 13C NMR (CDCl3, 125 MHz) δ 146.5,
144.5, 144.0, 143.1, 130.2, 127.8, 127.3, 125.8, 125.0, 114.2, 111.4, 111.1, 68.6, 60.7, 59.4, 53.9,
51.7, 36.1, 31.3, 29.1, 19.2, 13.8; (ESI) m/z calcd. for C22H27O4 ([M+H]+), 370.2013, found
370.2006.

(S)-9-methoxy-3-(pentyloxy)-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline2,10-diol (3.35d)
Yield 73%, brown solid, Mp 73 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.83-6.79 (m, 3H), 6.59
(s, 1H), 5.56 (s, 1H), 4.20(d, J = 15.3 Hz, 1H), 4.02 (t, J = 6.6 Hz, 2H), 3.81 (s, 3H), 3.58-3.55 (m,
2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 11.6, 15.8 Hz, 1H), 2.67-2.62 (m, 2H), 1.82 (pent, J = 6.6
Hz, 2H), 1.48-1.36 (m, 4H), 0.94 (t, J = 7.2, 3H); 13C NMR (CDCl3, 125 MHz) δ 146.4, 144.5,
144.1, 143.1, 130.2, 127.8, 127.3, 125.8, 125.0, 114.1, 111.4, 111.1, 68.9, 60.7, 59.4, 53.9, 51.7,
36.1, 29.0, 28.9, 28.2, 22.4, 14.0 ; (ESI) m/z calcd. for C23H29NO4 ([M+H]+), 384.2169, found
384.2165.
(S)-3-(hexyloxy)-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10diol (3.35e)
Yield 70%, dark brown powder, Mp 61 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.83-6.79 (m,
3H), 6.59 (s, 1H), 4.22 (d, J = 15.3 Hz, 1H), 4.02 (t, J = 6.6 Hz, 2H), 3.81 (s, 3H), 3.58(d, J = 14.7
Hz, 2H), 3.28-3.12 (m, 3H), 2.84-2.79 (m, 1H), 2.69-2.64 (m, 2H), 1.81 (pent, J = 6.7 Hz, 2H),
1.49-1.43 (m, 2H), 1.34 (sext, J = 3.7, 4H), 0.91 (t, J = 7.0, 3H); 13C NMR (CDCl3, 125 MHz) δ
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146.4, 144.5, 144.0, 143.1, 130.2, 127.9, 127.3, 125.8, 125.0, 114.1, 111.4, 111.1, 68.9, 60.7, 59.4,
53.9, 51.7, 36.2, 31.5, 29.2, 29.1, 25.7, 22.6, 14.0; (ESI) m/z calcd. for C24H31NO4 ([M+Na]+),
398.2326, found 398.2319.
(S)-3-(2-fluoroethoxy)-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2a]isoquinoline-2,10-diol (3.35f)
Yield 87%, yellow powder, Mp 95 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.85-6.79 (m, 3H),
6.61 (s, 1H), 4.82 (t, J = 3.9 Hz, 1H), 4.73 (t, J = 3.9 Hz, 1H), 4.32-4.19 (m, 3H), 3.81 (s, 3H),
3.58-3.54 (m, 2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 11.5, 15.7 Hz, 1H), 2.68-2.62 (m, 2H);

13C

NMR (CDCl3, 125 MHz) δ 146.4, 144.3, 143.8, 143.1, 131.5, 127.8, 127.2, 126.0, 125.0, 114.2,
112.4, 111.9, 82.4, 81.0, 68.5, 68.3, 60.7, 59.3, 53.8, 51.6, 36.0, 29.0; (ESI) m/z calcd. for
C20H22FNO4 ([M+Na]+), 360.1606, found 360.1599.

3.8.2

Biological evaluation: primary and secondary radioligand binding assays
Both the assays were done at the PDSP facility. In the primary binding assays, compounds

were tested at single concentrations (10 μM) in quadruplicate in 96-well plates. Compounds that
showed a minimum of 50% inhibition at 10 μM were tagged for secondary radioligand binding
assays to determine equilibrium binding affinity at specific targets. In the secondary binding
assays, selected compounds were usually tested at 11 concentrations (0.1, 0.3, 1, 3, 10, 30, 100,
300 nM, 1, 3, 10 μM) and in triplicate (3 sets of 96-well plates). Both primary and secondary
radioligand binding assays were carried out in a final of volume of 125 μl per well in appropriate
binding buffer. The hot ligand concentration was usually at a concentration close to the Kd (unless
otherwise indicated). Total binding and nonspecific binding were determined in the absence and
presence of 10 μM appropriate reference compound, respectively. In brief, plates were usually
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incubated at room temperature and in the dark for 90 min (unless otherwise indicated). Reactions
were stopped by vacuum filtration onto 0.3% polyethyleneimine (PEI) soaked 96-well filter mats
using a 96-well Filtermate harvester, followed by three washes with cold wash buffer. Scintillation
cocktail was then melted onto the microwave-dried filters on a hot plate and radioactivity was
counted in a Microbeta counter.For detailed experimental details please refer to the PDSP website
http://pdsp.med.unc.edu/ and click on ‘Binding Assay’ or ‘Functional Assay’ on the menu bar.

3.8.3

Metabolic stability study

The procedure is described below that was used for in vitro metabolic stability study.
A 48-well plate seeded with fresh Sprague Dawley rat hepatocytes, having cell density
0.75-1.5 X 105 cells/well was obtained from TRL, LLC (Durham, NC, USA). After receiving the
plated hepatocytes, the shipping media was aspirated and replaced with maintenance media and
the plate was incubated in 5% CO2 incubator at 37 ⁰C for 16 h to resume the cellular activity.
After 16 h, the maintenance media was replaced with 250 µL of fresh maintenance media.
2 µL of stock solution of each compound prepared in DMSO was diluted with cell culture media
(198 µL) to achieve the final incubation concentration 2 µM of compound and 0.4 % DMSO V/V.
Each of these solutions (200 µL) were added in to plate wells in duplicate and the plate was placed
into the 37 ⁰C incubator, set at 95% relative humidity and 5% CO2. The sample aliquots were taken
at the time point of 0h, 1h, 2h, 3h, 6h, 12h, 24h and 36h, and transferred in to microcentrifuge tube
preloaded with 100 µL of cold acetonitrile as stop solution. The microcentrifuge tubes were
centrifuged at 13,000 rpm for 6 min and the supernatant layer was separated and each sample was
analyzed via LC/MS in duplicate.

3.8.4

Alamar Blue Cytotoxicity Assay
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Pre-assay optimization protocol
Cells (MDA MB 231) were plated in a range from (105-102) per well in triplicates in 96
well plate and they are incubated at 37 oC for 24 h. 25 µl of Alamar blue [10% v/v of 440µM
solution of resazurin (Sigma #R7017)] was added to each well and incubated at 37 oC for 5 h.
Fluorescence intensity was measured (Alamar blue, 561 dichroic mirror from bottom). A standard
graph between log (fluorescence intensity) and log (number of cells) was plotted and the optimal
number of cells required for the assay was determined from the linear range of the standard graph.

Cytotoxicity assay protocol
10000 cells were plated (optimal cell number obtained from the standard graph) in 100 µL
wells in 96 well plate and were incubated at 37 oC for 24 h. Serial dilutions of the compound (30
mM - 300 nM) were made in the cell growth media. The media in each well was replaced with
media containing the compound, with triplicates for each dilution. The cells were then incubated
at 37 oC for 24 h. Subsequently, 25 µl of Alamar blue (10%v/v of 440 µM solution of resazurin)
was added to each well and incubated at 37 oC for 5 h. Fluorescence intensity was measured
(Alamar blue, 561 dichroic mirror from bottom). The number of cells after treatment in each well
was determined from the standard graph and IC50 values were determined using GraphPad Prism
software.

135

Chapter 4: Synthesis and evaluation of de-rigidified THPB analogues at
dopamine receptors
4.1

Background and rationale
THPBs share the common structure consisting of a four-ring main structural backbone

(isoquinoline ring) with substituent methoxyl or hydroxyl groups at the two benzene rings. The
dopaminergic activity of THPB scaffold resides in the structural alikeness between dopamine and
THPB (as shown in Figure 4.1). Based on previous SAR studies it was found that C2 or C10
hydroxyl groups of THPB play key roles in determining the intrinsic activities and affinity at DA
receptors (Chapter 2, Section 2.5).332-334 The, rigid THPB pharmacophore is devoid of flexibility
of the free ethtylamine chain of dopamine. It is quite interesting to know the results of derigidifying this rigid scaffold on dopaminergic affinity and activity. We hypothesized that the rigid
tetracyclic THPB core is not required for affinity and activity at the dopamine receptors and that
de-rigidification would engender increased affinity and selectivity for dopamine D3 receptors.
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To test this hypothesis, we planned to prepare compounds 4.1, 4.2a-4.2c and 4.3a-4.3d
(shown in Figure 4.2) having a flexible core structure and which do not have an intact THPB
scaffold. Compound 4.1 has broken ring C although having similar carbon skeleton as of SPD
(2.1). Analogues 4.2a-4.2c posses complete flexibility and are devoid of an intact ring B and ring
C of the THPB core. While having complete THIQ portion of THPB scaffold, analogues 4.3a4.3d carry rest of the segment of THPB impaired. These molecules will test the necessity of the
rigid core structure of THPB for the dopaminergic receptor activity. This approach is attractive
because if it is found that rigidity is not required, compound library synthesis and hence ligand
optimization would be more efficient since the synthesis of these molecules would be shorter and
simpler.
In the design and development of novel D3 receptor ligands, a primary challenge is
achieving a high degree of selectivity for D3 receptor over the highly homologous D2 receptor for
ligands with druglike characteristics. These issues, as well as the progress made in the development
of D3 receptor selective ligands, have been the subject of several reviews. 75, 142, 386-389 A typical
pharmacophore for dopamine D3 receptor ligands, possess a general pattern, which is divided into
three subunits (as shown in Figure 4.2): an aryl moiety, which is connected to an amide (first
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subunit) and further linked via an alkyl or aryl spacer (second subunit) to a basic residue with aryl
substituent (third subunit).390 For example, as shown in Figure 4.3, SB-277011A or BP-897 contain
arylpiperazine or tetrahydroisoquinoline basic subunit and n-butyl or cyclohexyl ethyl spacer
attached to arylamide group.233, 238, 391

In our efforts towards the discovery of novel, selective and potent D3 receptor ligands, we
planned to incorporate the THIQ portion of the THPB scaffold into typical pharmacophore of D3
ligands to generate a hybridized D3 receptor ligand as shown in Figure 4.3. This hybrid moiety is
different from previously made analogues in having a mono-protected catechol moiety on the
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THIQ ring and we presumed that this would add potency and preference for the D3 receptor. 392
Based on this hybridization pattern, we planned to synthesize series of compounds 4.4a-4.4l
(Figure 4.4) with variant arylamide functionalities.

4.2

Results and discussion

4.2.1

Synthesis
As shown in the Scheme 4.1, we deployed secondary amine 4.4 to synthesize de-rigidified

analogues 4.1 and 4.2a-4.2c. Starting with primary amine 3.9, it was subjected to reductive
amination with 3-benzyloxy-2-methoxy benzaldehyde derived from 2, 3-dihydroxybenzaldehyde
to give secondary amine 4.5.393 Pictet-Spengler reaction with 1,1, diethoxyethane followed by
debenzylation produced compound 4.1 from secondary amine 4.5.394, 395 Reductive amination of
an appropriate aldehyde and amine 4.5 and subsequent debenzylation gave the desired tertiary
amine analogues 4.2a-4.2c.
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THIQ based flexible analogues 4.3a-4.3d were synthesized from primary amine 3.9 via
tetrahydroisoquinoline derivative 4.6 (Scheme 4.2). Primary amine 3.9 was subjected to PictetSpengler reaction with paraformaldehyde in presence of formic acid to afford THIQ derivative
4.6.396 Reductive amination with appropriate aldehyde followed by acid catalyzed debenzylation
gave analogues 4.3a-4.3d from compound 4.6.
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Synthesis of tetrahydroisoquinoline-arylamide hybrid analogues was carried out as
depicted in Scheme 4.3. Compound 4.7 was prepared from compound 4.6 via four carbon chain
elongation with 4-bromobutyronitrile followed by reduction of the intermediate nitrile group to
primary amine 4.7 using LAH.237 Appropriate acids were coupled with primary amine 4.7 and the
final analogues 4.4a-4.4l were synthesized after debenzylation of intermediate amide compounds.

4.2.2

Structure-activity correlations
The data for binding affinity to human dopamine D1, D2 and D3 receptors is presented in

Table 4.1. Dismantling the THPB scaffold via truncation of ring B and ring C (in compounds 4.2a4.2c) results in significantly lower affinity for all dopamine receptors. Thus, intact THPB core
seems to be very important for affinity to dopamine receptors. Compounds 4.2a-4.2c which lacked
a tetrahydroisoquinoline motif had lower affinities for the dopamine receptor than compounds 4.1
and 4.3a-4.3d possess such motif. THIQ derivatives 4.3a, 4.3c and 4.3d have shown good affinity
and selectivity at D3 receptor, specifically compound 4.3c has notable selectivity at D3 versus D1
receptor (286.9) and D2 receptors (33.3). Therefore it would appear that the presence of an intact
THIQ moiety contributes significantly to better D3 receptor affinity and selectivity.
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Compounds 4.4a-4.4l were submitted to the PDSP for evaluation of D1, D2 and D3
receptor affinity and activity. The binding affinity data is shown in Table 4.2. The primary binding
assay data suggest that the % inhibition at D3 receptor is very high when compared with %
inhibition at D1 and D2 receptor. Many compounds including 4.4d-4.4g, 4.4k and 4.4l have
exhibited less than 50% inhibition (10 µM concentration) at D1 and D2 receptor in the primary
binding assay so they could not carried further for secondary binding assay as per PDSP protocol.
In the secondary binding assay analogues 4.4a and 4.4b having bulkier aryl substituents
have shown high and similar potency (2.7 nM) at D3 receptor while retaining some affinity at D1
and D2 receptors. Higher binding affinity for these compounds suggests the possibility of presence
of hydrophobic pocket at this position of the D3 binding site. Very similar binding profile was
demonstrated by p-chlorobenzyl analogue 4.4h, which possess the highest binding affinity in the
series at D3 receptor (2.1 nM) and having low affinity at D1 (683 nM) and D2 (1060 nM)
receptors. Compound 4.4c retain heteroatom in the ring showed 8 fold reduced affinity at D3
receptor as compare to similar analogue (4.4b) without heteroatom. In a similar manner, 4.4d
having pyridine heteroaromatic ring, displayed the least D3 receptor affinity (24
nM) among all analogues tested. Surprisingly, 4-methoxybenzyl analogue 4.4k presented higher
affinity at D3 receptor as compared to 4-hydroxybenzyl analogue 4.4e (Ki value of 5.9 nM for 4.4k
versus 8.7 nM for 4.4e) and both these analogues were inactive at D1 and D2 receptors. Compound
4.4f with 3-methoxy substitution exhibited 2 fold reduced affinity as compared to 4-methoxy
analogue 4.4k (12 nM for 4.4f versus 5.9 nM for 4.4k).
Table 4.1: Binding affinity data (Ki nM) for de-rigidified analogues at dopamine receptors
Compound
4.1

Ki (nM)a

Selectivity

D1b

D2c

D3d

D2/D3

D1/D3

833

1095

1367

1.2

0.6
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4.2a

>10,000

>10,000

1811.0

5.5

5.5

4.2b

3111.0

>10,000

2680.0

3.7

1.1

4.2c

>10,000

>10,000

>10,000

1

1

4.3a

6479.0

1593.0

92.0

17.3

70.4

4.3b

3318.0

3450.0

191.0

18.1

17.4

4.3c

4590.0

533.0

16.0

33.3

286.9

4.3d

3255.0

1972.0

41.0

48.1

79.4

aExperiments

carried out in triplicate - SEM values are within 13% of reported Ki;

butaclamol used as reference compound - Ki = 2.3 nM;

c[3H]Nmethylspiperone

b

[3H]SCH2390 used as radioligand/(+)-

used as radioligand/haloperidol used as reference

d

compound - Ki = 9.6 nM; [3H]N-methylspiperone used as radioligand/chlorpromazine used as reference compound - Ki = 11.0
nM.

Analogues 4.4g, 4.4k, and 4.4l bearing 4-fluoro, 4-methoxy and 4-cayno benzyloxy
substituent possess similar range of binding affinity at D3 receptor (K i value 4.4 nM, 5.9 nM and
6.3 nM respectively). Additionally, none of 4.4g, 4.4k, and 4.4l is active at dopamine D1 and D2
receptors. Amongst all 4-halogenated analogues, fluoro compound 4.4g have shown the highest
selectivity for D3 receptor while, its chloro congener 4.4h expressed highest potency (2.1 nM) at
D3 receptor with some retention of affinity at D1 and D2 receptors (683 nM and 1060 nM). The
general order of affinities for halogenated analogues evaluated at the D3 receptors was
chloro>bromo>fluoro>iodo. Compound 4.4i with bromo substitution have shown noticeable
selectivity (20 fold) at D1 receptor over D2 receptor apart from D3 receptor selectivity (2941 fold).
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Table 4.2: Binding affinity (Ki nM) data for THIQ-arylamide hybridized D3 receptor ligands

Compound

R

4.4a

Ki (nM)a
D1b

D2c

D3d

1-Biphenyl

788.0

787.0

2.7

4.4b

2-Naphthyl

809.0

668.0

2.7

4.4c

4-Quinolyl

1808.0

NAe

22.0

4.4d

4-Pyridyl

NAe

NAe

24.0

4.4e

4-Hydroxybenzyl

NAe

NAe

8.7

4.4f

3-methoxybenzyl

NAe

NAe

12.0

4.4g

4-Fluorobenzyl

NAe

NAe

4.4

4.4h

4-Chlorobenzyl

683.0

1060.0

2.1

4.4i

4-Bromobenzyl

495.0

>10,000

3.4

4.4j

4-Iodobenzyl

1573.0

NAe

10.0

4.4k

4-Methoxybenzyl

NAe

NAe

5.9

4.4l

4-Cyanobenzyl

NAe

NAe

6.3

aExperiments

carried out in triplicate - SEM values are within 13% of reported Ki;

butaclamol used as reference compound - Ki = 2.3 nM;
compound - Ki = 9.6 nM;

d[3H]N-methylspiperone

nM. ND = not determined;

eNA-

c[3H]Nmethylspiperone

b

[3H]SCH2390 used as radioligand/(+)-

used as radioligand/haloperidol used as reference

used as radioligand/chlorpromazine used as reference compound - Ki = 11.0

not active (<50% in primary assay).

Overall, all of the para substituted benzyl amide analogues (4.4e-4.4l) endowed with <10
nM D3 receptor binding affinity and most of them were only active at D3 receptor except 4.4h,
4.4i, and 4.4j. In general, this series of analogues have demonstrated very high potency and
selectivity at D3 receptors amongst all dopamine receptor subtypes.
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4.3

Molecular docking study at D3 receptor
Molecular docking evaluations were performed on analogues 4.1, 4.2a, and 4.2b at the D3

receptor. Investigation of the docked ligand poses and recognition of key protein-ligand
interactions provides insights into the SAR outcomes of the series the de-rigidified compounds
with respect to D3. In this study, ligand docking was performed retrospectively in order to
elucidate and rationalize the measured D3 affinity data. The docked posses maintain key receptor–
ligand interactions, including the critical protonated tertiary N—Asp110 salt bridge motif and Hbonds to Ser192 in flexible compound 4.1 (Figure 4.5a). As shown in Figure 4.5b, hydrophobic
interaction was observed between compounds 4.2a and 4.2b and imidazole ring of His349 as well
as phenyl ring of Tyr373.
In order to assess the binding stability of flexible compounds 4.1, 4.2a, and 4.2b the ligands
were simulated in complex with D3 (crystal structure 3pbl).354 Ligand parameters were generated
in Generalized Amber Force Field (GAFF),397 protein parameters were assigned from
AMBERFF14SB,398 and the system was solvated in a 10 Å buffer of Tip4pew (~12000 water
molecules). Ligands were allowed to move freely, however, protein heavy atoms were restrained
with 2.5 kcal/Å2 harmonic restraints to maintain model accuracy (in the absence of lipids). The
starting configuration utilized for these simulations was the top ranked docked poses discussed
above. These configurations were minimized and heated to 300 K, then equilibrated for 20 ns in
NPT, and finally run in a 100 ns production NVT molecular dynamics simulation sampling every
1 ps. The results of these simulations show that the docking poses are stable within this D3
configuration. Two metrics were utilized to assess ligand stability throughout the production
simulations: ligand RMSD and the distance between the ligand’s center of mass and Asp110
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a)

b)
Figure 4.5: Docked pose of the flexible analogues, a) compound 4.1 and b) compound 4.2a
and 4.2b

146

(critical for binding shown in Figure 4.5). Ligand RMSD was computed for each frame of the
production trajectories compared to the ligand configuration in the original docked pose. This
analysis shows that while ligand positions fluctuated over the course of the simulation, however,
this did not differ greatly from their starting poses (Figure 4.6). The distance between ligand center
of mass and Asp110 was utilized to determine whether the ligand maintained this key contact over
the course of the simulation. Though the distance does change by a small amount in compounds
4.1 and 4.2b, all three ligands maintain a bound state during the simulation (Figure 4.7).

a)

b)

c)
Figure 4.6: RMSD between all atom coordinates at each frame, compared to the coordinates of
the docked pose of flexible compounds a) 4.1, b) 4.2a, and c) 4.2b

These data suggest that compounds 4.1, 4.2a, and 4.2b maintain a configuration similar to
the predicted docked pose during a molecular dynamics simulation and that these predicted poses
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are stable with respect to the crystal D3 configuration. This supports the assertion that the
difference in binding affinity is not likely due to destabilized binding, but rather the added ligand
flexibility and decreased lipophilic interactivity.

a)

b)

c)
Figure 4.7: Distance between flexible compounds a) 4.1, b) 4.2a, and c) 4.2b center of mass and
the key aspartate Asp110 over the course of a 100 ns simulation.

4.4

Metabolic stability study
As discussed in Chapter 3 (Section 3.6b), metabolic susceptibility of (-)-SPD (2.1) against

hepatic enzyme needs to be resolved to make it orally bioavailable. It is very crucial to evaluate
the metabolic stability of synthesized analogues in order to get a comparative idea between
metabolism of rigid scaffold of (-)-SPD (2.1) and flexible conformation of these analogues. To test
the effect of structural flexibility in the metabolism we have studied the in vitro metabolic stability
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of representative flexible and THIQ/arylamide analogues (4.3c and 4.4l) along with C-3 and C-10
analogues of THPB (Chapter 3, Section 3.6).
Table 4.3: Metabolic stability study data for representative compounds

% of total AUC at given time point

Time (h)

% of total AUC at given time point
(-)-SPD (2.1)

4.3c

4.4l

0

100

100

100

1

98

99

93

2

91

98

96

3

82

94

92

6

52

73

48

12

10

25

46

24

10

2

2

36

11

4

2

120
l-SPD

100

4.3c
80

4.6l

60
40
20
0

0

5

10

15

20

25

30

35

40

Time (h)

Figure 4.8: % of total AUC at given time period of incubation for representative analogues
For tested compounds, the % AUC was calculated from the LC/MS peak abundance in
comparison with that total AUC. The % AUC data for each compound during the 36 h time course
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is shown in Table 4.3 and the time versus % AUC graph is depicted in Figure 4.8. In this study the
major metabolite observed was O-glucuronidated one as similar to (-)-SPD (2.1) and other rigid
THPB analogues. Results of the metabolic stability study show that flexible compounds have
slightly slower rate of metabolism than parent compound (-)-SPD (2.1). At 6 hr time point, 52 %
of active (-)-SPD (2.1) was present in the sample aliquot while 73% of compound 4.3c was present
in active form at the same time point. In a same manner, 46% of active analogue 4.4l was present
as compare to 10% of (-)-SPD (2.1) at 12 hr time point. These results indicate that, though it does
not affect drastically, conformational flexibility has some impact on metabolic stability of THPB
scaffold against hepatocyte enzymatic environment. Further study needs to be done to evaluate
this fact using more diversely flexible analogues of (-)-SPD (2.1).

4.5

Conclusion
In conclusion, we have completed structure–activity relationship studies on various

conformationally flexible analogues of (-)-SPD (2.1) with the goal of identifying a potential and
selective DA D1 and D3 receptor ligand. Two categories of analogues were synthesized and
assayed for binding affinity at DA receptors, one group (4.1, 4.2a-c and 4.3a-4.3d) having
flexibility in (-)-SPD scaffold and second one (4.4a-4.4l) based on THIQ/arylamide hybridization
concept.
The results of this study revealed that intact THPB scaffold of (-)-SPD is necessary for all
dopamine receptor activity and de-rigidification is detrimental to DA receptor activity. On the
other hand, having THIQ moiety annexed with flexible arylamide subunit, generates high potency
for and preference at DA D3 receptor. Analogue 4.4h was identified as the most potent compound
in this series with Ki value of 2.1 nM. All compounds in this series (4.4a-4.4l) displayed high
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selectivity at D3 along with very little affinities at other DA receptors (D1, D2, D4, and D5),
however, compound 4.4l was found to be active solely at D3 receptor. To the best our knowledge,
this is the first ever selective D3 ligand which does not have affinity at other DA receptors at all.
Results from docking study (4.1, 4.2a, 4.2b) at D3 receptor revealed the key receptor–ligand
interactions, including the protonated tertiary N—Asp110 salt bridge motif, H-bonds to Ser192,
and hydrophobic interaction with imidazole ring of His349 as well as with phenyl ring of Tyr373.
Overall, structure-activity relationship study of de-rigidified and THIQ/arylamide
analogues revealed potent and selective D3 receptor ligands. Still more diverse analogues need to
be synthesized and tested for D3 receptor affinity in order to retrieve compounds having
subnanomolar potency. Also, compounds having metabolic stability against hepatic metabolism
need to be discover as a potential candidate for the treatment of drug addiction. There is plenty of
room for exploration to modify THIQ-arylamide hybrid ligands, for instance, replacement of the
n-butyl spacer link with ethyl cyclohexane and replacing the catechol moiety with its bioisosteres.
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4.6

Experimental

4.6.1

Chemistry

N-(3-(benzyloxy)-2-methoxybenzyl)-2-(4-(benzyloxy)-3-methoxyphenyl)ethan-1-amine (4.5)
Amine 3.9 (0.25 g, 0.97 mmol) and 3-(benzyloxy)-2-methoxybenzaldehyde (0.24 g ,0.97
mmol) were dissolved in 10mL DCM and allowed to stir the solution at 0 ⁰C for 10 minutes.
Sodium triacetoxy borohydride (0.31 g, 1.5 mmol) was added in to the reaction mixture at 0 ⁰C
and allowed it to stir for 3 h at room temperature. Reaction mixture was washed with saturated
NaHCO3 and organic layer was dried over sodium sulfate and concentrated to give the compound
4.5 (0.4 g, 83%)%) as brown oil; 1H NMR (CDCl3, 500MHz ) δ 7.40-7.27 (m, 10H), 6.98-6.95
(m, 1H), 6.89-6.6.85 (m, 2H), 6.79-6.74 (m, 2H), 6.66 (dd, J = 1.6, 8.1 Hz, 1H), 5.12 (s, 2H), 5.10
(s, 2H), 3.85-3.79 (m, 8H), 2.86 (t, J = 7.3, 2H), 2.77 (t, J = 7.3 Hz, 2H);

13C

NMR (CDCl3,

500MHz) δ 151.6, 149.5, 147.7, 146.5, 137.3, 137.0, 133.5, 133.0, 128.6, 128.5, 128.0, 127.7,
127.3, 127.2, 123.8, 122.2, 122.1, 121.3, 120.6, 114.7, 114.1, 113.3, 112.4, 111.9, 71.1, 70.1, 60.7,
55.9, 50.3, 48.8, 35.7 ; HRMS (ESI) m/z calcd. for C31H33NO4 ([M+H]+), 484.2488, found
484.2475.
7-(benzyloxy)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (4.6)
Mixture of primary amine 3.9 (4 g, 15.6 mmol) and formic acid (20 mL) was stirred at 0 ̊
C for 15 minutes. Paraformaldehyde (0.47 g) was added into the reaction mixture and allowed it
stir at 50 ̊ C for 12 h. reaction mixture was concentrated in vacuo and residues were washed with
saturated NaHCO3 and extracted with ethyl acetate (4 X 50 mL). Organic layer was combined,
dried over sodium sulfate and concentrated. Crude product was purified by flash column
chromatography on silica gel (3% methanol/dichloromethane) to give the compound 4.6 (3.65 g,
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87%) as brown oil; 1H NMR (CDCl3, 500 MHz) δ 7.41 (d, J = 7.1 Hz, 2H), 7.37 (t, J = 7.6 Hz,
2H), 7.31 (t, J = 7.1 Hz, 1H), 6.62 (s, 1H, 6.57 (s, 1H), 5.09 (s, 2H), 4.15 (s, 2H), 3.85 (s, 3H),
3.65 (t, J = 6.2 Hz, 2H), 3.05 (t, J = 6.0 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 149.3, 147.4,
136.7, 128.6 X 2, 128.0, 127.3 X 2, 124.2, 119.6, 111.9, 111.6, 71.1, 56.0, 44.0, 41.6, 25.2; (ESI)
m/z calcd. for C17H19NO2 ([M+H]+), 270.1489, found 270.1485.
2-(3-hydroxy-2-methoxybenzyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol
(4.1)
Compound 4.5 (0.3 g, 0.6 mmol) was dissolved in 10 mL DCM. 1,1 diethoxyethane (0.13
mL, 0.9 mmol) and TFA (0.14 mL, 1.8 mmol) were added in to the reaction mixture and allowed
it to stir overnight. The reaction mixture was washed with 10 mL saturated NaHCO 3 and organic
layer was dried over sodium sulfate and evaporated to dryness. The residues were refluxed in to
the mixture of methanol (5 mL) and concentrated HCl (3 mL) for 3 h. Methanol was evaporated
and the crude mixture was basified with ammonia solution, and extracted with dichloromethane
(10 mL × 3). The combined organic layers were dried over sodium sulfate and concentrated to
give the crude product, which was purified by flash column chromatography on silica gel (3%
methanol/dichloromethane) to give the compound 4.1 (0.12 g, 60%) as yellow powder, mp 56-58
̊ C; 1H NMR (CDCl3, 500MHz) δ 7.00-6.98 (m, 2H), 6.88 (dd, J =6.85, 2.8 Hz, 1H), 6.64 (s, 1H),
6.55 (s, 1H), 3.85-3.79 (m, 8H), 3.67 (d, J = 13.6 Hz, 1H), 3.07-3.02 (m, 1H), 2.83-2.77 (m, 1H),
2.68 (dt, J = 12.5, 4.5 Hz, 1H), 2.58 (dt, J = 13, 4.5 Hz, 1H), 1.37 (d, J = 6.6 Hz, 3H); 13C NMR
(CDCl3, 500MHz) δ 149.0, 145.9, 144.9, 143.6, 133.0, 132.7, 125.6, 124.6, 122.1, 114.3, 113.0,
110.6, 61.8, 56.3, 55.9, 52.2, 44.0, 27.0, 20.0; HRMS (ESI) m/z calcd. for C19H23NO4 ([M+H]+),
330.1700, found 330.1707.
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General procedure to synthesize compounds 4.2a-4.2c and 4.3a-4.3d is described for 4.2a:
3-(((4-hydroxy-3-methoxyphenethyl)(methyl)amino)methyl)-2-methoxyphenol (4.2a)
Amine 4.5 (0.2 g, 0.41 mmol) and formaldehyde (0.06 mL, 1.64 mmol) were dissolved in
10 mL DCM and allowed to stir the solution at 0 ⁰C for 10 minutes. Sodium triacetoxy borohydride
(0.13 g, 0.62 mmol) was added in to the reaction mixture at ⁰C and allowed it to stir for 3 h at
room temperature. Reaction mixture was washed with saturated NaHCO 3 and organic layer was
dried over sodium sulfate and concentrated. The residues were refluxed in to the mixture of
methanol (5 mL) and concentrated HCl (3 mL) for 3 h. Methanol was evaporated and the crude
mixture was basified with ammonia solution, and extracted with dichloromethane (10 mL × 3).
The combined organic layers were dried over sodium sulfate and concentrated to give the crude
product, which was purified by flash column chromatography on silica gel (3%
methanol/dichloromethane)

to give the compound 4.2a (0.1 g, 74%) as yellow oil; 1H NMR

(CDCl3, 500MHz) δ 7.0-6.89 (m, 3H), 6.82 (d, J = 8.1 Hz, 1H), 6.68-6.66 (m, 2H), 3.86 (s, 3H),
3.80 (s, 3H), 3.64 (s, 2H), 2.79 (s, 2H), 2.70 (s, 2H), 2.33 (s, 3H); 13C NMR (CDCl3, 500MHz) δ
149.0, 146.3, 145.9, 143.8, 124.7, 122.5, 121.2, 121.2, 114.2, 114.1, 114.0, 111.2, 61.7, 55.9, 55.7,
52.2, 42.0, 33.3; HRMS (ESI) m/z calcd. for C18H23NO4 ([M+H]+), 318.1700, found 318.1693
3-((ethyl(4-hydroxy-3-methoxyphenethyl)amino)methyl)-2-methoxyphenol (4.2b)
Yield 68%, brown oil; 1H NMR (CDCl3, 500MHz ) δ 6.98-6.93 (m, 2H), 6.87 (dd, J = 2.0,
7.5 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 6.65-6.64 (m, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.67 (s, 2H),
2.71 (s, 4H), 2.62 (q, J = 6.8 Hz, 2H), 1.1 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 500MHz) δ 149.0,
146.3, 145.7, 143.7, 124.6, 122.3, 121.3, 121.3, 114.3, 114.1, 114.1, 111.2, 61.7, 55.8, 55.3, 51.9,
47.5, 33.0, 11.8; HRMS (ESI) m/z calcd. for C19H25NO4 ([M+H]+), 332.1856, found 332.1851.
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3,3'-(((4-hydroxy-3-methoxyphenethyl)azanediyl)bis(methylene))bis(2-methoxyphenol)
(4.2c)
Yield 67%, dark brown solid, mp 61 ̊ C; 1H NMR (CDCl3, 500 MHz) δ 7.00-6.95 (m, 4H),
6.85 (dd, J = 2.1, 7.4 Hz, 2H), 6.72-6.68 (m, 2H), 6.56 (dd, J = 2.0, 8.2 Hz, 1H), 3.84 (s, 3H), 3.76
(s, 6H), 3.70 (s, 4H), 2.74 (q, J = 6.0 Hz, 2H), 2.67 (q, J = 4.5 Hz, 2H); 13C NMR (CDCl3, 125
MHz) δ 148.8 X 2, 145.7, 145.3 X2, 144.8, 133.7, 132.5, 124.7, 121.9 X 4, 120.1, 115.0, 114.2 X
2, 110.5, 61.6 X 2, 56.0 X 2, 55.7, 52.2, 32.6; (ESI) m/z calcd. for C25H29NO6 ([M+H]+), 440.2068,
found 440.2063.
6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol (4.3a)
Yield 72%, white powder, mp 164 ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.57 (s, 1H), 6.56
(s, 1H), 3.85 (s, 3H), 3.46 (s, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.65 (t, J = 7.4 Hz, 2H), 2.43 (s, 3); 13C
NMR (CDCl3, 125 MHz) δ 145.1, 143.6, 127.3, 125.0, 112.0, 110.6, 57.4, 55.9, 53.0, 46.1, 28.9;
(ESI) m/z calcd. for C11H15NO2 ([M+H]+), 194.1176, found 194.1172.
2-ethyl-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (4.3b)
Yield 65%, brown solid, mp 90 ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.59 (s, 1H), 6.7 (s,
1H), 3.85 (s, 3H), 3.59 (s, 2H), 2.87 (t, J = 5.7 Hz, 2H), 2.78 (t, J = 5.7 Hz, 2H), 2.63 (q, J = 7.1
Hz, 2H), 1.22 (t J = 7.2 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 147.8, 146.2, 129.8, 128.0, 114.9,
113.1, 58.4, 57.7, 54.7, 53.3, 31.3,14.9; (ESI) m/z calcd. for C12H17NO2 ([M+H]+), 208.1332,
found 208.1327.

2-(3-hydroxy-2-methoxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (4.3c)
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Yield 68%, yellow solid, mp 150 ̊ C; 1H NMR (CDCl3, 500 MHz) δ 7.01-6.97 (m, 2H),
6.91-6.89 (m, 1H), 6.57 (s, 2H), 3.85 (s, 6H), 3.69 (s, 2H), 3.57 (s, 2H), 2.79 (t, J = 5.7 Hz, 2H),
2.73 (t J = 5.6 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 149.0, 145.9, 145.1, 143.6, 131.5, 127.5,
125.6, 124.6, 122.3, 114.5, 112.2, 110.6, 61.9, 56.4, 55.9, 55.6, 50.6, 28.9; (ESI) m/z calcd. for
C18H21NO4 ([M+H]+), 316.1543, found 316.1538.
2-(4-hydroxy-3-methoxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (4.3d)
Yield 70%, light brown powder, mp 62 ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.97 (d, J = 1.6
Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.81 (d J = 8.2, 1H), 6.57 (s, 1H), 6.54 (s, 1H), 3.89 (s, 3H),
3.84 (s, 3H), 3.61 (s, 2H), 3.55 (s, 2H), 2.82 (t, J = 5.3 Hz, 2H), 2.74 (t J = 5.2 Hz, 2H); 13C NMR
(CDCl3, 125 MHz) δ 145.8, 145.4, 145.1, 143.6, 125.5, 120.8 X 2, 115.4, 112.2, 110.6, 110.6,
110.4, 62.0, 56.0 X 2, 55.3, 50.4, 28.5; (ESI) m/z calcd. for C18H21NO4 ([M+H]+), 316.1543, found
316.1537.
4-(7-(benzyloxy)-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butan-1-amine (4.7)
Compound 4.6 (3.0 g, 11.2 mmol), K2CO3 (3 g, 22.4 mmol) and 4-bromobutyronitrile (1.1
mL, 11.2 mmol) were refluxed in acetonitrile (30 mL) for 2 h. Reaction was cooled to room
temperature and it was filtered. The filtrate was concentrated in vacuo and the residue was washed
with sat. NaHCO3 and extracted with ethyl acetate (3 X 40 mL). Combined organic layer was dried
over sodium sulfate and evaporated to get the crude product which was used in next step without
further purification. The crude mass (3.4 g) was dissolved in THF and the solution was cooled to
0 ̊ C for 10 minutes. LAH (0.6 g, 16.8 mmol) was added portion wise in to the solution and allowed
it to sir for 2 h at rt. Excess LAH was quenched with water and 10 % aqueous NaOH was added.
Reaction mixture was filtered through celite, filtrate was evaporated to dryness and the residue
was extracted with ethyl acetate (3 X 40 mL). The combined organic layers were dried over sodium
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sulfate and concentrated to give the crude product, which was purified by flash column
chromatography on silica gel (5% methanol/dichloromethane) to give the compound 4.7 (2.9 g,
76%) as yellow oil. 1H NMR (CDCl3, 500MHz) δ 7.43 (d, J = 7.8 Hz, 2H), 7.36 (t, J = 7.8 Hz,
2H), 7.29 (t J = 7.1 Hz, 1H), 6.61 (s, 1H), 6.56 (s, 1H), 5.08 (s, 2H), 3.83 (s, 3H), 3.65 (s, 2H),
2.86-2.81 (m, 6H), 2.57 (t, J =5.8 Hz, 2H), 1.82-1.73 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ
148.5, 146.7, 137.1, 128.6 X 2, 127.8, 127.3, 125.9, 124.4, 124.4 X 2, 111.9, 71.1, 56.5, 56.0, 54.8,
49.7, 39.7, 27.2, 26.9, 24.9; (ESI) m/z calcd. for C21H28N2O2 ([M+H]+), 341.2224, found 341.2225.

General procedure to synthesize compounds 4.4a-4.4l is described for 4.4a:
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-[1,1'-biphenyl]-4carboxamide (4.4a)
Compound 4.7 (100 mg, 0.3 mmol), EDCI (86 mg, 0.45 mmol) and biphenyl-4-carboxylic
acid (89 mg, 0.45 mmol) were added in to DCM (5 mL). The reaction mixture was allowed to stir
overnight at rt. Extra 10 mL of DCM was added in to the reaction and it was washed with sat.
NaHCO3 (15 mL). Organic layer was dried over sodium sulfate and evaporated to dryness. The
crude mass was dissolved in EtOH (5 mL). Conc. HCl (2 mL) was added into the reaction mixture
and it was refluxed for 3 h. The solvent was evaporated and residue was basified with aqueous
ammonia solution and extracted with ethyl acetate (2 X 15 mL). Combined organic layer was dried
over sodium sulfate and evaporated to dryness. The crude product was purified using column
chromatography (1% MeOH/DCM) to give 4.4a as yellow solid (94 mg, 73 %) mp 85 ̊ C; 1H
NMR (CDCl3, 500MHz) δ 7.71 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 7.5 Hz, 2H), 7.46-7.35 (m, 5H),
6.58 (s, 1H), 6.52 (s, 1H), 3.78 (s, 3H), 3.57-3.51 (m, 4H), 2.77 (dd, J = 5.3, 22.1 Hz, 4H), 2.61 (s,
2H), 1.79 (d, J = 2.9 Hz, 4H); 13C NMR (CDCl3, 125 MHz) δ 167.2, 145.4, 143.9, 143.5, 140.0,
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133.3, 128.8 X 2, 127.8 X 2, 127.4 X 2, 127.1 X 2, 126.8 X 2, 125.3, 112.2, 110.5, 57.2, 56.0,
55.9, 50.0, 39.8, 28.3, 27.3, 24.8; (ESI) m/z calcd. for C27H30N2O3 ([M+H]+), 431.2329, found
431.2328.
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-naphthamide (4.4b)
Yield 76%, yellow solid, mp 82 ̊ C; 1H NMR (CDCl3, 500MHz) δ 8.21 (s, 1H), 7.81-7.66
(m, 5H), 7.49 (td, J = 7.9, 23.7 Hz, 2H), 6.52 (s, 1H), 6.41 (s, 1H), 3.77 (s, 3H), 3.56 (s, 4H), 2.75
(s, 4H), 2.62 (s, 2H), 1.81 (s, 4H);

13C

NMR (CDCl3, 125 MHz) δ 167.8, 145.3, 143.8, 134.5,

132.5, 132.0, 128.9 X 2, 128.1, 127.6 X 2, 127.3 X 2, 126.3, 123.7, 112.2, 110.4, 57.3, 55.8, 55.7,
50.2, 40.0, 28.1, 27.2, 24.7; (ESI) m/z calcd. for C25H28N2O3 ([M+H]+), 405.2173, found 405.2177.
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)quinoline-4carboxamide (4.4c)
Yield 66%, yellow powder, mp 89 ̊ C 1H NMR (CDCl3, 500MHz) δ 8.80 (s, 1H), 8.62 (d,
J = 4.3 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.70(t, J = 7.2 Hz, 1H), 7.54
(t, J = 7.8 Hz, 1H), 7.16 (d, J = 4.3 Hz, 1H), 6.27 (s, 1H), 6.13 (s, 1H), 3.78 (s, 3H), 3.56 (d, J =
5.5 Hz, 2H), 3.34 (s, 2H), 2.55 (pent, J = 7.3 Hz, 4H), 2.35(t, J = 5.6 Hz, 2H), 1.84-1.80 (m, 4H);
13C

NMR (CDCl3, 125 MHz) δ 167.4, 149.6, 148.3, 145.3, 143.7, 129.6, 129.5, 127.2 X 2, 125.5

125.3, 124.5, 124.3, 118.3, 111.8, 110.1, 57.8, 55.7, 55.3, 50.5, 40.1, 27.9, 27.8, 25.1; (ESI) m/z
calcd. for C24H27N3O3 ([M+H]+), 406.2125, found 406.2134.

N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)isonicotinamide (4.4d)
Yield 70%, brown solid, mp 104 ̊ C 1H NMR (CDCl3, 600MHz) δ 8.44 (dd, J = 1.6, 3.7
Hz, 2H), 8.29 (s, 1H), 7.46 (dd, J = 1.3, 3.8 Hz, 2H), 6.54 (s, 1H), 6.50 (s, 1H), 3.84 (s, 3H), 3.59
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(s, 2H), 3.50 (q, J = 5.4 Hz, 2H), 2.79 (s, 4H), 2.65 (t, J = 6.1 Hz, 2H), 1.83-1.76 (m, 4H); 13C
NMR (CDCl3, 150 MHz) δ 165.6, 150.1 X 2, 145.8, 144.3, 141.7, 124.6 X 2, 121.0 X 2, 112.3,
110.6, 56.8, 56.0, 55.6, 50.0, 39.7, 27.8, 27.0, 24.4; (ESI) m/z calcd. for C20H25N3O3 ([M+H]+),
356.1969, found 356.1976.
4-hydroxy-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide
(4.4e)
Yield 65%, yellow powder, mp 80 ̊ C 1H NMR (C5D5N, 500MHz) δ 9.03 (s, 1H), 8.42 (d,
J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 6.97 (s, 1H), 6.75 (s, 1H), 3.87 (s, 2H), 3.75-3.71 (m,
5H), 3.97 (s, 4H), 2.79 (s, 2H), 1.88-1.77 (m, 4H); 13C NMR (CD3OD, 125 MHz) δ 169.1, 161.1,
147.6, 145.4, 129.2 X 2, 125.3, 123.3, 123.1, 115.0 X 2, 112.8, 111.3, 57.0, 55.3, 54.2, 50.7, 39.2,
27.2, 26.5, 22.9; (ESI) m/z calcd. for C21H26N2O4 ([M+H]+), 371.1965, found 371.1969.
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methoxybenzamide
(4.4f)
Yield 80%, yellow solid, mp 68 ̊ C 1H NMR (CDCl3, 500MHz) δ 7.38 (s, 2H), 7.22 (d, J
=7.5 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 6.96 (dd, J = 2.3, 8.1 Hz, 1H), 6.53 (s, 2H), 3.83 (s, 3H),
3.81 (s, 3H), 3.67 (s, 2H), 3.49 (q, J = 6.0 Hz, 2H), 2.88 (dd, J = 4.0, 13.3 Hz, 4H), 2.73 (t, J =
6.6 Hz, 2H), 1.81 (pent, J = 6.9 Hz, 2H), 1.73 (pent, J = 6.3 Hz, 2H); 13C NMR (CDCl3, 125 MHz)
δ 167.5, 159.6, 145.9, 144.2, 136.0, 129.3 X 2, 124.2, 118.8, 117.6, 112.3, 112.1, 110.6, 56.4, 55.9,
55.4, 54.6, 50.1, 39.4, 27.2, 26.9, 23.6; (ESI) m/z calcd. for C22H28N2O4 ([M+H]+), 385.2122,
found 385.2126.
4-fluoro-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide
(4.4g)
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Yield 78%, yellow solid, mp 57 ̊ C 1H NMR (CDCl3, 500MHz) δ 7.75 (s, 1H), 7.61-7.58
(m, 2H), 6.81 (t, J = 8.7 Hz, 2H), 6.54 (s, 1H), 6.50 (s, 1H), 3.85 (s, 3H), 3.50-3.45 (m, 4H), 2.752.68 (m, 4H), 2.56 (t, J = 6.1 Hz, 2H), 1.76 (t, J = 5.8 Hz, 4H); 13C NMR (CDCl3, 125 MHz) δ
166.6, 164.3 (d, J = 249 Hz), 145.4, 143.9, 130.9 X 2, 129.2, 129.1, 126.8, 125.1, 115.2 (d, J =
21.8 Hz), 112.2, 110.5, 57.5, 56.2, 55.9, 50.2, 40.0, 28.5, 27.3, 24.9; (ESI) m/z calcd. for
C21H25FN2O3 ([M+H]+), 373.1922, found 373.1927.
4-chloro-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide
(4.4h)
Yield 76%, brown solid, mp 63 ̊ C 1H NMR (CDCl3, 500MHz) δ 7.93 (s, 1H), 7.53 (d, J =
8.4 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 6.51 (s, 1H), 6.48 (s, 1H), 3.84 (s, 3H), 3.50-3.46 (m, 4H),
2.70 (t, J = 3.0 Hz, 4H), 2.56 (s, 2H), 1.76 (s, 4H); 13C NMR (CDCl3, 125 MHz) δ 166.7, 145.5,
144.0, 137.0, 133.1 X 2, 128.4, 126.5 X 2, 125.1 X 2, 112.2, 110.5, 57.4, 56.1, 55.9, 50.1, 40.0,
28.3, 27.3, 24.; (ESI) m/z calcd. for C21H25ClN2O3 ([M+H]+), 389.1626, found 389.1624.
4-bromo-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide
(4.4i)
Yield 72%, yellow powder, mp 89 ̊ C 1H NMR (CDCl3, 500MHz) δ 7.98 (s, 1H), 7.48 (d,
J = 8.4 Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H), 6.53 (s, 1H), 6.48 (s, 1H), 3.84 (s, 3H), 3.53 (s, 2H), 3.46
(d, J = 5.3 Hz, 2H), 2.73 (s, 4H), 2.59 (t, J = 5.6 Hz, 2H), 1.77 (s, 4H); 13C NMR (CDCl3, 125
MHz) δ 166.7, 145.6, 144.0, 133.5, 131.3 X 2, 128.6, 126.1 X 2, 125.5, 125.0, 112.2, 110.5, 57.3,
55.9 X 2, 50.0, 39.9, 28.1, 27.2, 24.7; (ESI) m/z calcd. for C21H25BrN2O3 ([M+H]+), 433.1121,
found 433.1108.
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-4-iodobenzamide (4.4j)
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Yield 69%, brown solid, mp 95 ̊ C 1H NMR (CDCl3, 500MHz) δ 7.86 (s, 1H), 7.65 (dd, J
= 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 6.55 (s, 1H), 6.53 (s, 1H), 3.86 (s, 3H),
3.75 (s, 2H), 3.48 (q, J = 5.5 Hz, 2H), 2.96-2.95 (m, 2H), 2.86-2.84 (m, 2H), 2.80 (t, J = 6.9 Hz,
2H), 1.86 (pent, J = 6.7 Hz, 2H), 1.75 (pent, J = 6.3 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.9,
145.9, 144.4, 137.4, 137.2, 134.0, 131.3 X 2, 128.7 X 2, 124.0, 112.2, 110.5, 97.9, 56.0, 55.8, 54.5,
49.5, 39.1, 26.7, 23.4; (ESI) m/z calcd. for C21H25IN2O3 ([M+H]+), 481.0983, found 481.0986.
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-4-methoxybenzamide
(4.4k)
Yield 83%, brown powder, mp 62 ̊ C 1H NMR (CDCl3, 500MHz) δ 7.70 (d, J = 8.3 Hz,
2H), 7.41 (s, 1H), 6.75 (d, J = 8.3 Hz, 2H), 6.57 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.72 (s, 2H),
3.49 (q, J = 5.5 Hz, 2H), 2.93-2.89 (m, 4H), 2.76 (s, 2H), 1.84 (pent, J = 6.6 Hz, 2H), 1.74 (pent,
J = 6.2 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 167.1, 161.8, 145.8, 144.2, 128.8 X 2, 126.8 X 2,
124.2 X 2, 113.5, 112.3, 110.6, 56.1, 55.9, 55.3, 54.6, 49.7, 39.1, 29.5, 26.9, 23.5; (ESI) m/z calcd.
for C22H28N2O4 ([M+H]+), 385.2122, found 385.2122.
4-cyano-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide
(4.4l)
Yield 68%, yellow solid, mp 115 ̊ C 1H NMR (CDCl3, 500MHz) δ 8.43 (s, 1H), 7.80 (d,
J = 8.0 Hz, 2H), 6.45 (d, J = 8.2 Hz, 2H), 6.53 (s, 1H), 6.49 (s, 1H), 3.86 (s, 3H), 3.71 (s, 2H), 3.50
(d, J = 5.3 Hz, 2H), 2.93-2.75 (m, 6H), 1.88 (pent, J = 6.3 Hz, 2H), 1.79 (pent, J = 6.4 Hz, 2H);
13C

NMR (CDCl3, 125 MHz) δ 166.0, 146.1, 144.5, 138.5, 132.0 X 2, 127.8 X 2, 123.9 X 2, 118.2,

114.3, 112.1, 110.4, 56.2, 56.0, 54.9, 49.6, 39.3, 26.9, 26.6, 23.5; (ESI) m/z calcd. for C22H25N3O3
([M+H]+), 380.1969, found 380.1971.
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4.6.2

Biological evaluation
As per Section 3.8.2

4.6.3

Metabolic stability study
As per Section 3.8.3
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Appendix: NMR spectra of final compounds
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